<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001768.pub3" GROUP_ID="BREASTCA" ID="424099112511540721" MERGED_FROM="" MODIFIED="2016-05-29 02:26:48 +0100" MODIFIED_BY="Melina Willson" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2016-05-29 11:24:57 +1000" MODIFIED_BY="Melina L Willson">
<TITLE>Follow-up strategies for women treated for early breast cancer</TITLE>
<CONTACT>
<PERSON ID="12130" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ivan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moschetti</LAST_NAME>
<SUFFIX/>
<POSITION>General Practitioner</POSITION>
<EMAIL_1>ivan.moschetti@marionegri.it</EMAIL_1>
<EMAIL_2/>
<URL>www.cochrane.it</URL>
<MOBILE_PHONE>0039 345 5012918</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Mario Negri Institute for Pharmacological Research IRCCS</ORGANISATION>
<ADDRESS_1>Via La Masa, 19</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20156</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-05-29 11:23:39 +1000" MODIFIED_BY="Melina Willson">
<PERSON ID="12130" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ivan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moschetti</LAST_NAME>
<SUFFIX/>
<POSITION>General Practitioner</POSITION>
<EMAIL_1>ivan.moschetti@marionegri.it</EMAIL_1>
<EMAIL_2/>
<URL>www.cochrane.it</URL>
<MOBILE_PHONE>0039 345 5012918</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Mario Negri Institute for Pharmacological Research IRCCS</ORGANISATION>
<ADDRESS_1>Via La Masa, 19</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20156</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2428962382E26AA200DA2AF32E041B0D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Michela</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cinquini</LAST_NAME>
<SUFFIX/>
<POSITION>Statistician</POSITION>
<EMAIL_1>cinquini@marionegri.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Mario Negri Institute for Pharmacological Research IRCCS</ORGANISATION>
<ADDRESS_1>Via La Masa, 19</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20156</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1402170045571371561960244344501" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Matteo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lambertini</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Oncologist</POSITION>
<EMAIL_1>matteo.lambertini85@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>BrEAST Data Centre, Department of Medicine</DEPARTMENT>
<ORGANISATION>Institut Jules Bordet, and l'Université Libre de Bruxelles (U.L.B.)</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Brussels</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1402170048483457206398030585724" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alessia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Levaggi</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Oncologist</POSITION>
<EMAIL_1>alessia.levaggi@hsanmartino.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medical Oncology</DEPARTMENT>
<ORGANISATION>U.O. Oncologia Medica 2, IRCCS AOU San Martino &#8211; IST</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Genova</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39105600666</PHONE_1>
<PHONE_2/>
<FAX_1>+39105600850</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6387" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Alessandro</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Liberati</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL>www.cochrane.it</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Italian Cochrane Centre</DEPARTMENT>
<ORGANISATION>Mario Negri Institute for Pharmacological Research</ORGANISATION>
<ADDRESS_1>Via La Masa, 19</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20156</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 02 39014 327</PHONE_1>
<PHONE_2>+39 02 39014 517</PHONE_2>
<FAX_1>+39 02 3559048</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>'Deceased'</FOOTNOTE>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-05-26 09:46:32 +1000" MODIFIED_BY="Melina Willson">
<UP_TO_DATE>
<DATE DAY="4" MONTH="7" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="7" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="4" MONTH="7" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-05-29 11:24:57 +1000" MODIFIED_BY="Melina L Willson">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2016-05-29 11:24:57 +1000" MODIFIED_BY="Melina L Willson">
<DATE DAY="29" MONTH="5" YEAR="2016"/>
<DESCRIPTION>
<P>In the last decade, only one new study has been published and the review findings remain consistent. Therefore, the results of this review confined to trials of specialist- and physician-led follow-up programmes are unlikely to change and future updates of this review are not planned</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-05-29 11:24:05 +1000" MODIFIED_BY="Melina L Willson">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-05-29 11:24:05 +1000" MODIFIED_BY="Melina L Willson">
<DATE DAY="4" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>One new study was included, involving 968 patients (<LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK>). Full 'Risk of bias' tables were added. Conclusions remain unchanged</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-05-29 11:24:02 +1000" MODIFIED_BY="Melina L Willson">
<DATE DAY="4" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Performed search for new studies on 4 July 2014</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-03-25 11:48:40 +1100" MODIFIED_BY="Melina L Willson">
<DATE DAY="8" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Additional table linked to text</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-03-08 17:14:44 +1100" MODIFIED_BY="Melina Willson">
<DATE DAY="26" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="8" MONTH="8" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-11-13 08:43:40 +1100" MODIFIED_BY="Melina L Willson">
<INTERNAL_SOURCES MODIFIED="2015-11-13 08:43:40 +1100" MODIFIED_BY="Melina L Willson">
<SOURCE MODIFIED="2015-11-13 08:43:40 +1100" MODIFIED_BY="Melina L Willson">
<NAME>No specific funding was available for the original conduct and update</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-12-06 21:29:09 +1100" MODIFIED_BY="[Empty name]">
<NAME>Ivan Moschetti and Michela Cinquini: Mario Negri Institute for Pharmacological Research IRCCS</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION>
<P>The form of support is related to facilities and salary provided by Mario Negri Institute </P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-08-02 01:20:32 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-08-02 01:20:32 +1000" MODIFIED_BY="[Empty name]">
<NAME>No resources of external support were provided</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-05-23 11:47:06 +1000" MODIFIED_BY="Melina L Willson">
<SUMMARY MODIFIED="2016-05-13 22:59:04 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-07-31 07:15:48 +1000" MODIFIED_BY="[Empty name]">Different follow-up strategies for women after breast cancer treatment</TITLE>
<SUMMARY_BODY MODIFIED="2016-05-13 22:59:04 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Review question: </B>Whether an intensive follow-up decreases the number of recurrences or deaths and affects health-related quality of life (HRQoL) compared with a less intensive follow-up and whether a follow-up offered by specialists is different from that performed by family physicians.</P>
<P>
<B>Background:</B> Follow-up after breast cancer is performed in order to check whether breast cancer has returned to the breast or other part of the body and to monitor side effects related to treatment. Follow-up may be performed by specialists or family physicians, regularly or on demand, and may be based on routine clinical visits (physical examinations and yearly mammography), or on a more intensive surveillance (laboratory tests and imaging examinations). The first update of this Cochrane review published in 2004 has shown that having more tests does not improve the length or quality of life in breast cancer survivors and a comparable effectiveness of follow up by specialist to that by primary physician. Moreover, additional screening tests could increase anxiety related to false positive results, unnecessary radiation exposure and health-related costs.</P>
<P>
<B>Study Characteristics: </B>A literature search up to July 2014 found five trials (involving 4023 women with a median follow-up variable from 16 to 120 months). Since the previous version of this Cochrane review in 2004, one new study has been published.</P>
<P>
<B>Key results: </B>This review of trials found that follow-up programs based on a regular physical examination and a yearly mammogram appear to be as effective as the more intensive approaches and to have similar impact on HRQoL. No significant differences were found between follow-up performed by specialists or family physicians, regularly or on demand. These results should be interpreted with caution bearing in mind that these studies were conducted almost two decades ago; additional trials incorporating new biological knowledge and improved imaging technologies are needed.</P>
<P>
<B>Quality of the evidence: </B>Allocation concealment was adequate in all but one trial; two trials were judged to be at low risk of selection bias<I>;</I> the blinding of the outcome assessor was not described in two trials. For one trial it was not possible to judge risk of bias because it reported no methodological information.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-05-23 11:47:06 +1000" MODIFIED_BY="Melina L Willson">
<ABS_BACKGROUND MODIFIED="2016-01-16 00:02:58 +1100" MODIFIED_BY="[Empty name]">
<P>Follow-up examinations are commonly performed after primary treatment for women with breast cancer. They are used to detect recurrences at an early (asymptomatic) stage. This is an update of a Cochrane review first published in 2000.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-02-25 20:37:03 +1100" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness of different policies of follow-up for distant metastases on mortality, morbidity and quality of life in women treated for stage I, II or III breast cancer.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-05-23 11:46:29 +1000" MODIFIED_BY="Melina L Willson">
<P>For this 2014 review update, we searched the Cochrane Breast Cancer Group's Specialised Register (4 July 2014), MEDLINE (4 July 2014), Embase (4 July 2014), CENTRAL (2014, Issue 3), the World Health Organization (WHO) International Clinical Trials Registry Platform (4 July 2014) and ClinicalTrials.gov (4 July 2014). References from retrieved articles were also checked.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-08-10 16:49:52 +1000" MODIFIED_BY="Melina L Willson">
<P>All randomised controlled trials (RCTs) assessing the effectiveness of different policies of follow-up after primary treatment were reviewed for inclusion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-05-01 22:13:40 +1000" MODIFIED_BY="Heather Maxwell">
<P>Two review authors independently assessed trials for eligibility for inclusion in the review and risk of bias. Data were pooled in an individual patient data meta-analysis for the two RCTs testing the effectiveness of different follow-up schemes. Subgroup analyses were conducted by age, tumour size and lymph node status.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-05-23 11:47:06 +1000" MODIFIED_BY="Melina L Willson">
<P>Since 2000, one new trial has been published; the updated review now includes five RCTs involving 4023 women with breast cancer (clinical stage I, II or III).</P>
<P>Two trials involving 2563 women compared follow-up based on clinical visits and mammography with a more intensive scheme including radiological and laboratory tests. After pooling the data, no significant differences in overall survival (hazard ratio (HR) 0.98, 95% confidence interval (CI) 0.84 to 1.15, two studies, 2563 participants, <I>high-quality evidence</I>), or disease-free survival (HR 0.84, 95% CI 0.71 to 1.00, two studies, 2563 participants, <I>low-quality evidence</I>) emerged. No differences in overall survival and disease-free survival emerged in subgroup analyses according to patient age, tumour size and lymph node status before primary treatment. In 1999, 10-year follow-up data became available for one trial of these trials, and no significant differences in overall survival were found. No difference was noted in quality of life measures (one study, 639 participants, <I>high-quality evidence</I>).</P>
<P>The new included trial, together with a previously included trial involving 1264 women compared follow-up performed by a hospital-based specialist versus follow-up performed by general practitioners. No significant differences were noted in overall survival (HR 1.07, 95% CI 0.64 to 1.78, one study, 968 participants, <I>moderate-quality evidence</I>), time to detection of recurrence (HR 1.06, 95% CI 0.76 to 1.47, two studies, 1264 participants, <I>moderate-quality evidence</I>), and quality of life (one study, 356 participants, <I>high-quality evidence</I>). Patient satisfaction was greater among patients treated by general practitioners. One RCT involving 196 women compared regularly scheduled follow-up visits versus less frequent visits restricted to the time of mammography. No significant differences emerged in interim use of telephone and frequency of general practitioners's consultations.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-05-01 22:32:12 +1000" MODIFIED_BY="Heather Maxwell">
<P>This updated review of RCTs conducted almost 20 years ago suggests that follow-up programs based on regular physical examinations and yearly mammography alone are as effective as more intensive approaches based on regular performance of laboratory and instrumental tests in terms of timeliness of recurrence detection, overall survival and quality of life.</P>
<P>In two RCTs, follow-up care performed by trained and not trained general practitioners working in an organised practice setting had comparable effectiveness to that delivered by hospital-based specialists in terms of overall survival, recurrence detection, and quality of life.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-05-23 11:20:15 +1000" MODIFIED_BY="Melina L Willson">
<BACKGROUND MODIFIED="2016-05-01 23:00:01 +1000" MODIFIED_BY="Heather Maxwell">
<CONDITION MODIFIED="2016-05-01 22:42:25 +1000" MODIFIED_BY="Heather Maxwell">
<P>Breast cancer is the second most common cancer in the world and the most frequent cancer among women with an estimated 1.67 million new cancer cases diagnosed in 2012 (25% of all cancers) (<LINK REF="REF-Globocan-2012" TYPE="REFERENCE">Globocan 2012</LINK>). In Europe, the estimated age-adjusted annual incidence of breast cancer was 94.2/100,000 and the mortality was 23.1/100,000 in 2012 (<LINK REF="REF-Ferlay-2013" TYPE="REFERENCE">Ferlay 2013</LINK>). In the USA, according to the SEER database (2006 to 2010), the age-adjusted annual incidence of breast cancer was 124.6/100,000 and the mortality was 22.2/100,000. The median age at breast cancer diagnosis is 61 years. About 10% of breast cancers occur among women aged younger than 45 years, while 40% occur among women aged 65 years or older (<LINK REF="REF-SEER-database-2014" TYPE="REFERENCE">SEER database 2014</LINK>). Overall, 60% of breast cancers are diagnosed at a localised stage, 32% at a regional stage and 5% at an advanced stage. The five-year relative survival rate for women diagnosed with localised breast cancer is 98.5%; survival declines to 84.6% for regional stage and 25% for distant stage. Due to both early detection through screening programs and the improvement in the available treatment strategies, the percentage of women surviving at least five years after diagnosis and treatment has shifted from 74.8% in the early 1970s to 90.3% in the late 1990s. In the last few years, the increase in the number of women diagnosed with breast cancer each year and the improvement in the survival rates, have led to a significant increase in the number of breast cancer survivors (<LINK REF="REF-SEER-database-2014" TYPE="REFERENCE">SEER database 2014</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-07-31 07:20:31 +1000" MODIFIED_BY="[Empty name]">
<P>Follow-up (care after primary treatment) of women with breast cancer includes terms such as "routine testing", "follow-up" or "surveillance". These indicate the regular use of laboratory or instrumental tests in otherwise asymptomatic patients to detect distant metastases (that is, when the cancer has spread beyond the breast) earlier. The type of tests can vary by hospital or doctor or both and they typically include routine haematological tests, all biochemical first level test examinations, for example, liver function tests, kidney function test, C-reactive protein, erythrocyte sedimentation rate, tumour markers, chest X-rays, and bone and liver scans.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-07-31 07:20:39 +1000" MODIFIED_BY="[Empty name]">
<P>Follow-up care should have several aims. These include the provision of physical and psychosocial rehabilitation, monitoring of treatment effectiveness including short- and long-term toxicity, and detecting recurrence or new cancers.</P>
<P>Post-treatment survivors are at risk for physical and psychosocial sequelae. Women with breast cancer may experience early and late treatment-related side effects such as fatigue, arthralgia (joint pain), cardiotoxicity, reproductive system changes, osteoporosis and the development of second tumours. Other effects may include cognitive dysfunction and psychosocial issues such as anxiety and depression, disturbances in body image, and changes in sexual quality of life (<LINK REF="REF-Burstein-2000" TYPE="REFERENCE">Burstein 2000</LINK>). So, the post-treatment follow-up is essential to ensure detection and management of late or long-term effects and to provide psychological and supportive care.</P>
<P>In actual practice, however, follow-up care is offered with the main objective of detecting local or distant recurrences earlier, so that treatment for any relapse can be started. Conceptually, follow-up care can be considered as a screening program - i.e. screening for early detection of metastases. As such, it is quite difficult to evaluate its efficacy retrospectively, because survival of asymptomatic patients who have relapses detected by these screening tests can only be compared with survival of symptomatic patients who have relapses. This kind of comparison can be severely biased by lead time (early detection simply increases the period during which a metastasis is observed), and length time (cases with a long pre-clinical phase and, therefore, presumably less aggressive relapses are more likely to be detected by a screening program) (<LINK REF="REF-Duffy-2008" TYPE="REFERENCE">Duffy 2008</LINK>). A randomised design is thus the only valid way to get an unconfounded estimate of the effectiveness of different follow-up strategies. Despite the lack of convincing proof that this postoperative surveillance care improves outcomes in these patients, intensive follow-up is quite common in clinical practice and represents a significant workload for radiotherapy, surgical and oncologic departments (<LINK REF="REF-Grunfeld-2010" TYPE="REFERENCE">Grunfeld 2010</LINK>; <LINK REF="REF-Loprinzi-1994" TYPE="REFERENCE">Loprinzi 1994</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-05-01 23:00:01 +1000" MODIFIED_BY="Heather Maxwell">
<P>In the previous update of this review in 2004 of randomised clinical trials (RCTs) evaluating the different strategies of follow-up for stage I, II or III breast cancer patients, we concluded that, according to the RCTs available at that time, a follow-up based on routine clinical visits (physical examinations and yearly mammography) had the same effectiveness as a more intensive surveillance (laboratory tests and imaging examinations) in terms of overall survival and quality of life. Furthermore, a centralised approach (follow-up performed by a specialist at a multidisciplinary breast clinic) showed the same effectiveness as the decentralised approach (surveillance performed by a general practitioner); finally, no differences were found among a regularly scheduled surveillance and a follow-up strategy &#8220;on demand&#8221;.</P>
<P>Despite all the studies included in the systematic review concluding that new studies would have been necessary on this topic, only one new study has been published so far; moreover, to our knowledge, while cancer research is actively pushed in the field of anticancer treatments and drug development, no clinical trials evaluating the efficacy of the different follow-up strategies are ongoing in ClinicalTrials.gov (<LINK REF="REF-Clinical-trial-2014" TYPE="REFERENCE">Clinical trial 2014</LINK>) or the WHO ICTRP search portal (<LINK REF="REF-WHO-2014" TYPE="REFERENCE">WHO 2014</LINK>).</P>
<P>Updating this systematic review about follow-up strategies for women with breast cancer would allow us to understand better the state of the art on this clinically relevant topic, which could be the basis to focus future research in this field. In fact, due to the improvements in the understanding of the biology of breast cancer, the availability of advanced imaging technologies and the progress made in the treatment of breast cancer, new more personalised follow-up approaches should be studied. In particular, positron emission tomography (PET)-computed tomography (CT) showed to be more sensitive and specific in detecting distant metastatic lesion as compared to conventional imaging (<LINK REF="REF-Constantinidou-2011" TYPE="REFERENCE">Constantinidou 2011</LINK>). Furthermore, new biomarkers such as circulating tumour cells are promising markers to detect microscopic residual disease after primary treatment (<LINK REF="REF-Lucci-2012" TYPE="REFERENCE">Lucci 2012</LINK>). These new diagnostic tools should be studied for their ability to anticipate the clinical evidence of recurrence, and the subsequent impact on survival.</P>
<P>Breast cancer is no longer considered a single disease, but is classified into at least four different intrinsic molecular subtypes based on the immunohistochemical classification (Luminal A-like, Luminal B-like, HER2 positive, and triple negative (<LINK REF="REF-Goldhirsch-2013" TYPE="REFERENCE">Goldhirsch 2013</LINK>)). Nowadays, it is well-established that not only the stage at diagnosis, but also the biology of the disease influence the risk of breast cancer recurrence and death (<LINK REF="REF-Jatoi-2011" TYPE="REFERENCE">Jatoi 2011</LINK>). Moreover, a growing amount of evidence has shown that the different biological subtypes differ in terms of timing of disease recurrence (<LINK REF="REF-Jatoi-2011" TYPE="REFERENCE">Jatoi 2011</LINK>; <LINK REF="REF-Metzger_x002d_Filho-2013" TYPE="REFERENCE">Metzger-Filho 2013</LINK>) and pattern of metastatic spread (particularly, site of first recurrence) (<LINK REF="REF-Kennecke-2010" TYPE="REFERENCE">Kennecke 2010</LINK>). These observation could lead to the hypothesis that different schedules and different intensity of follow-up strategies should vary according to the different breast cancer subtypes.</P>
<P>Moreover, thanks to the improvement of breast cancer management and the availability of new effective treatments, metastatic breast cancer, at least for a small percentage of women, should not be considered a fatal condition anymore (<LINK REF="REF-Hortobagyi-2002" TYPE="REFERENCE">Hortobagyi 2002</LINK>): particularly, women with oligometastatic disease treated with a multidisciplinary aggressive approach can still be cured (<LINK REF="REF-Kobayashi-2012" TYPE="REFERENCE">Kobayashi 2012</LINK>). Based on this assumption, an early detection of metastatic disease could lead to the identification of patients with low burden of disease who can be still treated with curative intent.</P>
<P>Taking into account the improvement in the understanding of the biology of breast cancer, in the available imaging technologies and in the treatment of the disease, a better assessment of the state of the art about the follow-up strategies should be considered the basis for the design of new clinical trials in this setting towards a more &#8220;personalised follow-up approach&#8221;.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-05-01 23:00:22 +1000" MODIFIED_BY="Heather Maxwell">
<P>To assess the effectiveness of different policies of routine follow-up testing on morbidity, survival and quality of life in women with breast cancer after primary treatment.<BR/>
<BR/>Specifically, the effectiveness of the following types of routine follow-up policies were explored.<BR/>
</P>
<UL>
<LI>Follow-up based on routine clinical visits plus yearly mammogram compared to a more intensive surveillance where radiological and laboratory tests are regularly added to routine visits.</LI>
<LI>Centralised compared to decentralised follow-up (i.e. surveillance offered by a specialist at a multidisciplinary breast clinic compared to that delivered by a general practitioner).</LI>
<LI>Regular follow-up compared to surveillance on demand.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2016-05-02 00:58:43 +1000" MODIFIED_BY="Heather Maxwell">
<SELECTION_CRITERIA MODIFIED="2016-05-01 23:01:02 +1000" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES MODIFIED="2016-05-01 23:00:34 +1000" MODIFIED_BY="Heather Maxwell">
<P>All randomised controlled trials (RCTs) comparing different approaches to follow-up after completion of primary treatment.</P>
<P>We extracted and reviewed additional information from prospective non-randomised studies but the data were not used for quantitative pooling.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women who have had primary surgical treatment for breast cancer (clinical stage I, II or III), with no evidence of recurrence. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-05-01 23:00:50 +1000" MODIFIED_BY="Heather Maxwell">
<UL>
<LI>Follow-up based on routine clinical visits plus yearly mammogram compared to a more intensive surveillance including radiological and laboratory tests.</LI>
<LI>Centralised versus decentralised follow-up (i.e. surveillance offered by a specialist at a multidisciplinary breast clinic compared to that delivered by a general practitioner).</LI>
<LI>Regular follow-up compared to surveillance on demand.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-05-01 23:01:02 +1000" MODIFIED_BY="Heather Maxwell">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-05-01 23:00:57 +1000" MODIFIED_BY="Heather Maxwell">
<UL>
<LI>Overall survival, as estimated from the date of randomisation to the date of last contact or death from any cause.</LI>
<LI>Health-related quality of life (HRQoL), assessed using EORTC QLQ-C30, SF-36 and the "hospital anxiety and depression scale (HADS)"</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-05-01 23:01:02 +1000" MODIFIED_BY="Heather Maxwell">
<UL>
<LI>Disease-free survival (expression of the time to detect a recurrence). It is used in this context to compare the power of different follow-up strategies to detect recurrence earlier, possibly in an asymptomatic stage.</LI>
<LI>Occurrence of metastases detected in an asymptomatic status.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-05-01 23:01:16 +1000" MODIFIED_BY="Heather Maxwell">
<ELECTRONIC_SEARCHES MODIFIED="2016-05-01 23:01:16 +1000" MODIFIED_BY="Heather Maxwell">
<P>(a) The Cochrane Breast Cancer Group Specialised Register was searched on the 4 July 2014 (details of search strategies used by the group for the identification of studies and the procedure used to code references are outlined in the group's module at <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html">http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html</A>). Studies including the text words 'early breast cancer', 'locally advanced breast cancer', 'follow up', 'follow-up studies', 'follow-up care', 'centralised follow-up', 'decentralised follow-up', postoperative surveillance' and 'routine clinical visits' on the Specialised Register were retrieved for consideration.<BR/>(b) MEDLINE (via OvidSP) from 1950 until 4 July 2014. <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.<BR/>(c) Embase (via Embase.com) from 1966 until 4 July 2014. <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.<BR/>(d) CENTRAL, 2014, Issue 3. See <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.<BR/>(e) The WHO International Clinical Trials Registry Platform (ICTRP) search portal (<A HREF="http://apps.who.int/trialsearch/Default.aspx">http://apps.who.int/trialsearch/Default.aspx</A>) for all prospectively registered and ongoing trials on the 4 July 2014. See <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.<BR/>(f) ClinicalTrials.gov ( <A HREF="http://clinicaltrials.gov/ct2/home">http://clinicaltrials.gov/ct2/home</A> ) was searched until 4 July 2014. See <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-07-31 08:00:44 +1000" MODIFIED_BY="[Empty name]">
<P>No other sources were searched.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-05-02 00:58:43 +1000" MODIFIED_BY="Heather Maxwell">
<STUDY_SELECTION MODIFIED="2016-05-01 23:14:58 +1000" MODIFIED_BY="Heather Maxwell">
<P>For this 2014 review update and the previous update two review authors (2014 update: Ivan Moschetti (IM), Michela Cinquini (MC); 2004 update: IM, Laura Coe (LC)) independently inspected the search hits by reading the titles and abstracts. The full-text article of each potentially relevant study identified in the search was obtained and assessed for inclusion independently by the same two authors. No disagreements regarding eligibility occurred. Both review authors read and assessed 15 PDF documents. The other papers retrieved by the search strategy were not considered because they were not RCTs, or they clearly referred to follow-up managed by nurses. For this reason a "<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>" table was not completed.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-05-02 00:57:50 +1000" MODIFIED_BY="Heather Maxwell">
<P>Two review authors independently extracted data (2014 update: IM, MC; 2004 update: IM, LC) using a standardised data collection form.</P>
<P>We extracted the following characteristics from each included study: participants, setting, interventions, comparators and outcomes, <I>see</I> "<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>" table. When a meta-analysis was performed (i.e. for the GIVIO and Rosselli Del Turco trials), we used individual patient data. We did not contact any trial authors for the 2004 and 2014 updates.</P>
<P>For studies with more than one publication, we extracted data from all publications. However, we considered the final or updated version of each trial as the primary reference.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-05-01 23:32:32 +1000" MODIFIED_BY="Heather Maxwell">
<P>Two review authors (2014 review update: IM, MC) independently assessed the risk of bias in each trial using Cochrane's 'Risk of bias' tool. Any differences were resolved in a consensus meeting.</P>
<P>We classified the generation of allocation sequence, allocation concealment, blinding of outcome assessor, completeness of outcome data, and selective outcome reporting as low risk of bias, high risk of bias, or &#8217;unclear&#8217; following the criteria specified in the <I>Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>Given the nature of the interventions under investigation, only blinding of outcome assessor (avoidance of performance bias and detection bias) was considered for subjective outcomes (e.g. quality of life, disease-free survival and occurrence of metastases).</P>
<P>No sensitivity analyses depending on 'Risk of bias' criteria were performed.<BR/>
</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-05-02 00:58:43 +1000" MODIFIED_BY="Heather Maxwell">
<P>For each trial, the overall and disease-free survival hazard ratio (HR) was calculated using the log rank "O-E" and its variance (V). When the HR and the relative confidence interval (CI) were not reported in the article to permit a direct calculation of this two measures, we calculated them indirectly using the Mantel-Haenszel estimate of the HR and its CI reported in the paper, or we used the total number of events and the number of patients at risk in each arm. The individual HR estimates were combined into an overall HR using the Peto odds ratio method that allows for fixed-effect only.</P>
<P>We planned to report the occurrence of metastases detected in an asymptomatic state as risk ratio (RR) and its 95% CI.</P>
<P>Quality of life was considered as a continuous outcome and we planned to report the results as the mean difference (MD) and its standard error. However, none of the trials had information on health-related quality of life (HRQoL) that could be extracted and meta-analysed. These data have been described in a narrative way. For quality of life, we considered the "overall health perception", the "satisfaction of patients" and the "hospital anxiety and depression scale (HADS)".</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-07-31 07:59:22 +1000" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the study participant.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-05-01 23:47:47 +1000" MODIFIED_BY="Heather Maxwell">
<P>For this 2014 review update, we did not contact the authors of primary studies. All analyses were performed on an intention-to-treat basis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-05-01 23:48:02 +1000" MODIFIED_BY="Heather Maxwell">
<P>A formal statistical test for heterogeneity was done using the Chi<SUP>2</SUP> test and I<SUP>2</SUP> statistic. A P value of 0.10 for heterogeneity was considered as statistically significant. We planned to use a fixed-effect model or a random-effects model, depending on the evidence of statistical heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-09-21 19:21:09 +1000" MODIFIED_BY="[Empty name]">
<P>Publication bias was not evaluated given the type of intervention considered. We are confident that no relevant data on this type of intervention have been kept concealed.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-05-01 23:48:29 +1000" MODIFIED_BY="Heather Maxwell">
<P>For time-to-event outcomes, we used a fixed-effect analysis (O-E and Variance).<BR/>
<BR/>Because a certain degree of heterogeneity was not expected among trials for dichotomous outcomes, we used a fixed-effect analysis (Mantel-Haenszel).<BR/>
<BR/>For continuous outcomes, we planned to use a fixed-effect analysis (inverse-variance method).<BR/>
<BR/>
<LINK REF="REF-RevMan" TYPE="REFERENCE">RevMan</LINK> 5.3 software was used for all the analyses.</P>
<P>The overall quality of the evidence for all the outcome was judged using the GRADE system (<LINK REF="REF-GRADE-2004" TYPE="REFERENCE">GRADE 2004</LINK>), which takes into account the 'Risk of bias' assessment, imprecision and directness of results. The 'Summary of findings' tables present the main findings of the review.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-11-13 08:41:38 +1100" MODIFIED_BY="Melina L Willson">
<P>Subgroup analyses by age, tumour size and lymph node status before primary treatment were conducted based on the hypothesis that these may influence the biological behaviour of the disease and therefore lead to different benefits for the different follow-up strategies (<LINK REF="REF-De-Lena-1995" TYPE="REFERENCE">De Lena 1995</LINK>; <LINK REF="REF-Greco-1998" TYPE="REFERENCE">Greco 1998</LINK>).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-11-06 15:45:59 +1100" MODIFIED_BY="Melina L Willson">
<P>A sensitivity analysis was not carried out.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-05-23 11:20:15 +1000" MODIFIED_BY="Melina L Willson">
<STUDY_DESCRIPTION MODIFIED="2016-05-02 00:48:26 +1000" MODIFIED_BY="Heather Maxwell">
<SEARCH_RESULTS MODIFIED="2016-05-01 23:49:59 +1000" MODIFIED_BY="Heather Maxwell">
<P>In this 2014 review update, searching the Specialised Register, MEDLINE, Embase and CENTRAL yielded 1493 records while ClinicalTrials.gov and WHO ICTRP retrieved 669 ongoing trials. Two review authors (IM, MC) independently screened all records excluding 2102 of them by title and abstracts. For the remaining 15 records, after reading the full text, only one answered the review's question. No disagreement rose between review authors during the process of study selection.</P>
<P>This update includes information from one new report and provides the results of a study conducted in Ontario from 1997 to 2003 (<LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK>) comparing a follow-up structured in the cancer centre according to usual practice and a follow-up managed by family physicians (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-05-02 00:48:26 +1000" MODIFIED_BY="Heather Maxwell">
<P>Five studies met the inclusion criteria. All of the studies were multicentre randomised controlled trials (RCTs) comparing different types of follow-up in women with breast cancer. Overall, these studies included 4023 women (the number of patients ranged from 196 to 1320) with breast cancer (clinical stages I, II or III) with no evidence of recurrence after their primary surgical treatment. The median follow-up time available in the five trials varied from 16 to 120 months.</P>
<P>Data on overall and disease-free survival were available for four trials (<LINK REF="STD-GIVIO" TYPE="STUDY">GIVIO</LINK>; <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK>; <LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK>; <LINK REF="STD-Rosselli-Del-Turco-1994" TYPE="STUDY">Rosselli Del Turco 1994</LINK>). None of the trials had information on health-related quality of life (HRQoL) that could be extracted and meta-analysed. These data have been described in a narrative way. Only one trial (<LINK REF="STD-GIVIO" TYPE="STUDY">GIVIO</LINK>) reported information about metastases.</P>
<P>The trials included in this review explored three different follow-up strategies.<BR/>
</P>
<UL>
<LI>Two trials (<LINK REF="STD-GIVIO" TYPE="STUDY">GIVIO</LINK> and <LINK REF="STD-Rosselli-Del-Turco-1994" TYPE="STUDY">Rosselli Del Turco 1994</LINK>) compared follow-up based on clinical visits and mammography alone, with a more intensive surveillance scheme including radiological and laboratory tests. Combined, they included 2563 women. Their outcomes were overall survival, disease-free survival and, in one trial (<LINK REF="STD-GIVIO" TYPE="STUDY">GIVIO</LINK>), HRQoL.</LI>
<LI>Two trials (<LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK> and <LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK>) compared follow-up offered by a specialist at the hospital with follow-up offered by a general practitioner. The first trial included 296 women. Its outcomes were time to detection of recurrence and HRQoL. The second trial enrolled 968 women and evaluated overall survival, disease-free survival and quality of life.</LI>
<LI>One trial (<LINK REF="STD-Gulliford-1997" TYPE="STUDY">Gulliford 1997</LINK>) compared conventionally scheduled follow-up with follow-up limited to the time of mammography, but with telephone and GP consultation available on demand. It included 196 women and was a pilot study to evaluate feasibility of women's acceptance of symptom-driven follow-up. Outcomes included acceptability of less frequent follow-up, use of telephone and GP consultations and satisfaction with allocation to a particular follow-up strategy.</LI>
</UL>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-05-02 00:01:17 +1000" MODIFIED_BY="Heather Maxwell">
<P>There are no excluded studies.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-05-02 00:02:37 +1000" MODIFIED_BY="Heather Maxwell">
<P>An iconographic summary of the risk of bias is illustrated in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>. The <LINK REF="STD-Gulliford-1997" TYPE="STUDY">Gulliford 1997</LINK> trial was judged as having an unclear risk of bias on all domains because it reported no methodological information.</P>
<ALLOCATION MODIFIED="2016-05-02 00:01:29 +1000" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="4">Random sequence generation</HEADING>
<P>In the <LINK REF="STD-Gulliford-1997" TYPE="STUDY">Gulliford 1997</LINK>, <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK> and <LINK REF="STD-Rosselli-Del-Turco-1994" TYPE="STUDY">Rosselli Del Turco 1994</LINK> trials the method for generating the random sequence was not reported; in <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK>, the trial authors stated only that "random allocation was in blocks of eight". <LINK REF="STD-GIVIO" TYPE="STUDY">GIVIO</LINK> and <LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK> had an adequate random sequence generation using a computer-generated list.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Allocation concealment was adequate in all trials, except for <LINK REF="STD-Gulliford-1997" TYPE="STUDY">Gulliford 1997</LINK>.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2016-05-02 00:02:14 +1000" MODIFIED_BY="Heather Maxwell">
<P>Double-blinding was not considered as adequate for this kind of study, so only the blinding of the outcome assessor was judged.</P>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of outcome assessors</HEADING>
<P>In the <LINK REF="STD-GIVIO" TYPE="STUDY">GIVIO</LINK>, <LINK REF="STD-Gulliford-1997" TYPE="STUDY">Gulliford 1997</LINK> and <LINK REF="STD-Rosselli-Del-Turco-1994" TYPE="STUDY">Rosselli Del Turco 1994</LINK> trials, it was not described whether or not the outcome assessor was blinded. This can lead to a potential detection bias for disease-free survival. In <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK>, blinding of the outcome assessors was judged as adequate as they assessed recurrence independently even though the trial authors stated that "in some cases, the allocation group could have been deduced from the course of clinical events". A blinded committee adjudicated all events in <LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK>.</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-05-02 00:02:19 +1000" MODIFIED_BY="Heather Maxwell">
<P>The <LINK REF="STD-GIVIO" TYPE="STUDY">GIVIO</LINK> study lost 8% of its randomised patients, who could not be traced and were not included in the analyses. The overall loss to follow-up in <LINK REF="STD-Rosselli-Del-Turco-1994" TYPE="STUDY">Rosselli Del Turco 1994</LINK> was 0.8%. In both trials (<LINK REF="STD-GIVIO" TYPE="STUDY">GIVIO</LINK> and <LINK REF="STD-Rosselli-Del-Turco-1994" TYPE="STUDY">Rosselli Del Turco 1994</LINK>), approximately 10% of the patients discontinued follow-up care, with a similar distribution between intensive and clinical groups. Survival data were available for those lost to follow-up and were included in the analyses (intention-to-treat analysis). In <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK>, only one patient per group was lost to follow-up. <LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK> did not report any information.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-05-02 00:02:37 +1000" MODIFIED_BY="Heather Maxwell">
<P>
<LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK> and <LINK REF="STD-Gulliford-1997" TYPE="STUDY">Gulliford 1997</LINK> were not designed to assess overall survival. Their outcomes (quality of life, time to diagnosis of recurrence, interim use of telephone and GP consultations and patient satisfaction) were assessed to investigate differences within the first two years. For additional details see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>As all the studies have been conducted before protocol registration was mandatory, we did not search for additional information.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-11-06 20:28:51 +1100" MODIFIED_BY="[Empty name]">
<P>No other sources of bias identified.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-05-23 11:20:15 +1000" MODIFIED_BY="Melina L Willson">
<P>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Follow-up based on routine clinical visits (experimental group) compared to a more intensive surveillance (i.e. with radiological/laboratory tests) (control group)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Overall survival</HEADING>
<P>The meta-analysis for overall survival of the <LINK REF="STD-GIVIO" TYPE="STUDY">GIVIO</LINK> and <LINK REF="STD-Rosselli-Del-Turco-1994" TYPE="STUDY">Rosselli Del Turco 1994</LINK> trials found no significant survival advantage in the intensive surveillance group; hazard ratio (HR) 0.98 (95% confidence interval (CI) 0.84 to 1.15; two studies, 2563 participants; high-quality evidence; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). We found no significant differences in overall survival between the strategies in respect to the subgroup analyses by age (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), tumour size (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), nodal status (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), or at five years (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Health-related quality of life (HRQoL)</HEADING>
<P>Data regarding quality of life were available just for the <LINK REF="STD-GIVIO" TYPE="STUDY">GIVIO</LINK> trial. Questionnaires used were the Functional Living Index-Cancer Scale, the Sickness Impact Profile, the Profile of Mood States, and the Cancer Inventory of Problem Situation. The HRQoL scores were assessed at baseline, six,12, 24, and 60 months, and administered four times between six and 60 months with an average response rate of 73.5%; overall, no significant difference was found between the two follow-up strategies. The evidence was graded as high quality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Disease-free survival</HEADING>
<P>The HR was 0.84 (95% CI 0.71 to 1.00; two studies, 2563 participants; low-quality evidence; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) for disease-free survival after five years of follow-up. For this outcome, the pooled effect did not confirm the statistically significant effect found in diagnostic anticipation in the <LINK REF="STD-Rosselli-Del-Turco-1994" TYPE="STUDY">Rosselli Del Turco 1994</LINK> trial. We did not observe any advantage either in the subgroup analysis for age (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>), or for tumour size (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), or for lymphonodal status (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Occurrence of metastases detected in an asymptomatic status</HEADING>
<P>Data regarding asymptomatic detection of metastases were available only from the GIVIO trial: 31% of cases of metastases in the intensive group and 21% in the clinical group were detected in an asymptomatic phase (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). This information was not available in other studies where only the proportion of distant metastases has been reported. However, it is consistent with results of several prospective non-randomised studies (<LINK REF="REF-Hannisdal-1993" TYPE="REFERENCE">Hannisdal 1993</LINK>; <LINK REF="REF-Hietanen-1986" TYPE="REFERENCE">Hietanen 1986</LINK>; <LINK REF="REF-Logarer-1990" TYPE="REFERENCE">Logarer 1990</LINK>; <LINK REF="REF-Mahoney-1986" TYPE="REFERENCE">Mahoney 1986</LINK>; <LINK REF="REF-Pandya-1983" TYPE="REFERENCE">Pandya 1983</LINK>; <LINK REF="REF-Rutgers-1989" TYPE="REFERENCE">Rutgers 1989</LINK>; <LINK REF="REF-Vestergaard-1989" TYPE="REFERENCE">Vestergaard 1989</LINK>; <LINK REF="REF-Wickerhan-1986" TYPE="REFERENCE">Wickerhan 1986</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Centralised versus decentralised follow-up (i.e. surveillance offered by a specialist at a multidisciplinary breast clinic compared to that delivered by a general practitioner)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Overall survival</HEADING>
<P>Overall survival was available only for <LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK>: HR 1.07 (95% CI 0.64 to 1.78; one study, 968 participants; moderate-quality evidence; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Health-related quality of life (HRQoL)</HEADING>
<P>Quality of life shows an expected small deterioration for both groups during the <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK> trial (British version of the SF-36; European Organisation for Research and Treatment of Cancer core quality of life questionnaire (EORTC QLQ-C30); Hospital anxiety and depression scale. The HRQL scores were assessed at baseline, mid trial and at the end of the trial). The hospital group had a statistically significant increase in symptom scores for fatigue, dyspnoea and appetite loss. There was no difference in overall health, social and emotional functioning and levels of anxiety and depression.</P>
<P>This study also collected data on the patients who were asked about the trial but did not participate (149/445, 33.5%). These women were older than trial participants and had a lower education level, but there were no important differences in clinical characteristics or in baseline quality of life scores.</P>
<P>The <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK> data were used in a new publication that analysed patient satisfaction with care by general practitioners versus hospital specialists over an 18-month period (see <LINK REF="REF-Grunfeld-1999" TYPE="REFERENCE">Grunfeld 1999</LINK>). Questionnaires completed by 93% of patients indicated that they were more satisfied with service delivery, consultation and the continuity of care provided by their general practitioner than by a specialist.</P>
<P>As stated by the authors in <LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK>, no statistically significant differences were detected between groups over time for any of the scores (Medical Outcomes Study Short Form 36-Item General Health Survey (SF-36) 48 and Hospital Anxiety and Depression Scale (HADS) 49). The HRQL scores were assessed at baseline and during the subsequent seven follow-ups at six, 12, 18, 24, 36, 48, and 60 months. Overall, SF-36 PCS declined over time (0.4 units per year; P &lt; 0.001), SF-36 MCS increased slightly (0.2 units per year; P = 0.08), HADS anxiety declined (0.08 per year; P = 0.01), and HADS depression increased slightly (0.04 per year; P = 0.12). The evidence was graded as high quality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Disease-free survival</HEADING>
<P>The two Grunfeld trials (<LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK>; <LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK>), comparing follow-up offered by a hospital-based specialist with follow-up offered by a general practitioner, showed no differences in time to recurrence between groups. The HR was 1.06 (95% CI 0.76 to 1.47; two studies, 1264 participants; moderate-quality evidence; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Occurrence of metastases detected in an asymptomatic status</HEADING>
<P>No information about occurrence of metastases was available in <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK> and <LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Regular follow-up versus surveillance on demand</HEADING>
<P>The <LINK REF="STD-Gulliford-1997" TYPE="STUDY">Gulliford 1997</LINK> trial comparing conventionally scheduled follow-up and less frequent follow-up (restricted to the time of mammography) showed that 7% of eligible patients refused to enter the study. The characteristics of these patients may suggest that younger women with more aggressive primary disease are not willing to reduce the frequency of follow-up visits. Unfortunately, no assessments were available for these patients in relation to their quality of life.<BR/>
<BR/>No significant differences were found between the groups with regards to the use of telephone and visits to general practitioners during the trial. Approximately one-third of the patients in both groups expressed a preference for a less frequent schedule of follow-up visits, but only 56 women answered this question on the questionnaire.</P>
<SUBSECTION>
<HEADING LEVEL="4">Overall survival</HEADING>
<P>No information reported on this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Health-related quality of life (HRQoL)</HEADING>
<P>No information presented on this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Disease-free survival</HEADING>
<P>No information presented on this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Occurrence of metastases detected in an asymptomatic status</HEADING>
<P>No information presented on this outcome.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-05-02 00:24:56 +1000" MODIFIED_BY="Heather Maxwell">
<SUMMARY_OF_RESULTS MODIFIED="2016-05-02 00:23:24 +1000" MODIFIED_BY="Heather Maxwell">
<P>It is important to remember that in the context of this review the terms "routine testing", "follow-up" as well as "surveillance" refer to the regular use of laboratory or instrumental tests in otherwise asymptomatic patients. These are done with the aim of earlier detection of distant metastases. For this reason, this review does not explore other, important, aspects of a follow-up program such as the provision of social and psychological support. Similarly, the review focuses on comprehensive follow-up packages and does not consider individual components of follow-up programs such as tumour markers or other diagnostic procedures. We chose to look only at this comparison (i.e. only clinical versus a package of tests) for pragmatic reasons as it would have been impossible to look at all possible contrasts among various types of intensive versus clinical follow-up.</P>
<P>Concerning the first intervention assessed (follow-up based on routine testing added to a regular visit and yearly mammogram compared to follow-up based on visits and mammography alone), the results of this systematic review confirm that doing more tests in asymptomatic patients does not add a survival advantage nor anticipate diagnosis of recurrences. These data have been endorsed by major international practice guidelines (<LINK REF="REF-ASCO-2013" TYPE="REFERENCE">ASCO 2013</LINK>; <LINK REF="REF-ESMO-2013" TYPE="REFERENCE">ESMO 2013</LINK>; <LINK REF="REF-NCCN-2014" TYPE="REFERENCE">NCCN 2014</LINK>): though with some variation in terms of frequency of visits and mammography, all endorse a less intensive clinical follow-up (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Also, these last documents are similar to the previous in terms of frequency of visits and mammography and all three suggest a less intensive follow-up regimen for women treated for early breast cancer.</P>
<P>This review also allowed us to explore an organisational question, as well as the one about the intensity of follow-up. Despite some limitations in the evidence from <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK>, the results suggest that decentralised follow-up (i.e. surveillance offered by a general practitioner) has the same effect on detection of recurrence as centralised follow-up. This is the result of special training given to general practitioners and this should be taken into consideration when planning to either transfer this experience or further investigate this topic.</P>
<P>In this updated review we added a new trial (<LINK REF="STD-Grunfeld-2006" TYPE="STUDY">Grunfeld 2006</LINK>), conducted in Canada including 968 women. This trial was similar to <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK> in that no difference was found between surveillance offered by a general practitioner versus surveillance done by specialist clinic about primary (rate of recurrence-related serious clinical events) and secondary outcomes (HRQoL). Moreover, this trial was pragmatic because family physicians were provided with only one page of instruction based on published clinical guidelines without any specific training and using the usual procedures when referring patients with recurrence back to the cancer centre (no special procedures were put in place). In this trial, the 45% of approached patients chose not to participate. The authors gave no reason for this finding, but obviously this proportion could be change among different national/regional health systems.</P>
<P>Only one study compared the conventionally scheduled follow-up with a surveillance on demand to evaluate the feasibility of women&#8217;s acceptance of symptom-driven follow-up. A reduced frequency of routine follow-up showed to be popular among women at standard risk, but younger patients with aggressive primary disease seemed to refuse a less intensive approach. However, further data and a multicentre experience are needed to draw more solid conclusions about the effectiveness of a more personalised follow-up with respect to disease outcomes.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-05-02 00:23:42 +1000" MODIFIED_BY="Heather Maxwell">
<P>However, despite the evidence and consensus that intensive follow-up schemes provided no benefit on survival, surveys throughout the late 1990s found this message had not been completely transferred into clinical practice (<LINK REF="REF-Tomiak-1998" TYPE="REFERENCE">Tomiak 1998</LINK>; <LINK REF="REF-Harries-1996" TYPE="REFERENCE">Harries 1996</LINK>, <LINK REF="REF-Stark-1996" TYPE="REFERENCE">Stark 1996</LINK>) and that women still seemed to prefer a frequent schedule of tests in order to be reassured about their health status. In this update, we searched for new information on current clinician behaviour but did not find any new studies on the topic. It would be worthwhile to evaluate whether a good strategy of sharing information between the doctor and the patient would help women to be equally reassured when a less intensive follow-up is offered.</P>
<P>Compared to other areas in medicine, it is worth noting that three of the five RCTs in this review did include quality of life as an outcome. However, different quality of life indicators (stress, anxiety and depression) were mostly used to rule out differences and thus it may well be that small differences may have gone undetected. Besides, authors of these trials noted that choosing the best time and frame for the measurement of quality of life is problematic and far from being totally agreed upon.</P>
<P>Results coming from these different studies have been produced in a very specific socio-cultural and geographical setting. Thus generalisability and direct application of the strategies here recommended should be carefully evaluated.</P>
<P>Finally, we did not find any eligible study that had evaluated the diagnostic value of using mammography as part of a follow-up strategy to monitor ipsilateral recurrences and new cancers in the contralateral breast. We have only found two prospective studies (<LINK REF="REF-Carlotti-1993" TYPE="REFERENCE">Carlotti 1993</LINK>; <LINK REF="REF-Holli-1998" TYPE="REFERENCE">Holli 1998</LINK>) investigating the difficulties in the interpretation of mammograms on an irradiated breast after surgery.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-05-02 00:23:53 +1000" MODIFIED_BY="Heather Maxwell">
<P>Overall, we are confident that all the included studies in the quantitative analyses have a low risk of selection bias (even though some information on the random sequence generation was missing - see <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK> and <LINK REF="STD-Rosselli-Del-Turco-1994" TYPE="STUDY">Rosselli Del Turco 1994</LINK>). Intention-to-treat analysis was performed in all trials and losses to follow-up were absent or in a low percentage in all trials. It resulted at low risk for two trials out of five (<LINK REF="STD-GIVIO" TYPE="STUDY">GIVIO</LINK> and <LINK REF="STD-Rosselli-Del-Turco-1994" TYPE="STUDY">Rosselli Del Turco 1994</LINK>). <LINK REF="STD-Grunfeld-1996" TYPE="STUDY">Grunfeld 1996</LINK> was judged at low risk of selective reporting even if it did not take into account overall survival.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-05-02 00:24:22 +1000" MODIFIED_BY="Heather Maxwell">
<P>This review is based on RCTs that were initiated in the late 1980s. One must consider that now, more than two decades later, knowledge, technology and treatment for breast cancer have improved, which may justify new RCTs.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-05-02 00:24:56 +1000" MODIFIED_BY="Heather Maxwell">
<P>Since the first Cochrane review was published we have not found RCTs or reviews showing new evidence in disagreement with the direction of the results discussed in this update. Again, we highlight that the translation of the results in to practice &#8220;toute coure&#8221; should be done with caution particularly for the risk of indirectness due to old trials on which this review is based.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-05-02 00:34:31 +1000" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2016-05-02 00:32:46 +1000" MODIFIED_BY="Heather Maxwell">
<P>In light of the evidence presented here, less intensive follow-up strategies based on periodical clinical exam and annual mammography seem as effective as more intense surveillance schemes. Further laboratory and radiological examinations may add useful information where women are symptomatic or the clinical visit suggests the need for further investigations.</P>
<P>A general practitioner's participation in the delivery of follow-up care appears feasible and appropriate but, to guarantee the directness of these results, the care should be organised in such a way that access to hospital care is easy when required.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-05-02 00:34:31 +1000" MODIFIED_BY="Heather Maxwell">
<P>The evidence from randomised controlled trials (RCTs) summarised here must, however, be interpreted with caution bearing in mind that the studies were conducted almost two decades ago when a more limited understanding of breast cancer biology and less advanced imaging technologies were available. For this reason, the applicability of the results of these "old" trials to the current clinical practice is controversial. Moreover, among clinicians a substantial variation in adherence to guidelines is observed (<LINK REF="REF-Chopra-2014" TYPE="REFERENCE">Chopra 2014</LINK>; <LINK REF="REF-Grandjean-2012" TYPE="REFERENCE">Grandjean 2012</LINK>). Many physicians perform a more intensive surveillance approach, under the assumption that early detection and treatment of recurrences results in better outcome (<LINK REF="REF-Margenthaler-2012" TYPE="REFERENCE">Margenthaler 2012;</LINK> <LINK REF="REF-Puglisi-2014" TYPE="REFERENCE">Puglisi 2014</LINK>). For these reasons, additional trials, targeted at high-risk patients and incorporating new biological knowledge and diagnostic modalities, are needed. These studies would provide new evidence of the impact of intensive follow-up on diagnostic anticipation of distant metastases and survival in women with early-stage breast cancer. A better understanding of this issue would lead to more personalised and cost-effective follow-up approaches in the case of positive results, and to the reduction of the actual non evidence-based prescriptions of diagnostic examinations in the case of negative results.</P>
<P>Further investigation may be warranted on the effects of less frequent schedules of follow-up and to identify the adequate frequency of mammography.</P>
<P>Further research should also focus on evaluating effects on long-term outcomes such as overall survival and morbidity of follow-up by a specialist compared to follow-up in primary care.</P>
<P>In addition, it would be interesting to evaluate current physician behaviour compared to guideline recommendations to determine to what extent the evidence has been transferred into practice.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-05-13 22:47:55 +1000" MODIFIED_BY="[Empty name]">
<P>We wish to thank the Mario Negri Institute of Milan for the facilities and for paying Michela Cinquini's salary.</P>
<P>We wish to thank the Pontificia Universidad Catolica de Chile for supporting Dr. Rojas with a fellowship at the Italian Cochrane Centre.</P>
<P>The authors thank Laura Coe, Maria Paulina Rojas, Marco Del Turco Rosselli and Elena Telaro who contributed to the prior versions of the Cochrane meta-analysis on &#8220;Follow-up strategies for women treated for early breast cancer&#8221;. Laura Coe, Maria Rojas, Marco Del Turco Rosselli and Elena Telaro received no compensation for their support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-04-29 21:05:04 +1000" MODIFIED_BY="[Empty name]">
<P>Roldano Fossati (RF) and Alessandro Liberati (AL) were members of the Steering Group of the GIVIO study included in this review and wrote several review articles of the effect of follow-up care. The GIVIO trial (of which RF and AL were authors) was originally partially supported by a educational grant from Astra Zeneca Italia. No specific funding was available for the original conduct and update of this review. Ivan Moschetti, Michela Cinquini, Alessia Levaggi and Laura Coe do not have any conflict of interests. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-05-23 11:23:46 +1000" MODIFIED_BY="Melina L Willson">
<P>For the 2014 review update:<BR/>Ivan Moschetti and Michela Cinquini identified, selected and critically appraised the studies and completed the 'Risk of bias' table of all included studies. Both authors wrote the previous and current version of this review including updated analyses and text according to the new findings.<BR/>Alessia Levaggi and Matteo Lambertini reviewed the manuscript from a clinical point of view updating the introduction and the discussion, writing the implications for research section and updating the guidelines table.</P>
<P>For the previous versions of the review:<BR/>Paulina Rojas and Elena Telaro identified, selected and critically appraised the studies to be included in the review, and wrote the first draft.<BR/>Roldano Fossati designed the review, supervised the analysis of the data and reviewed the earlier drafts of the manuscript.<BR/>Antonio Russo analysed the data and reviewed the earlier drafts of the manuscript.<BR/>Domenico Palli and Marco Rosselli del Turco contributed to the development of the protocol and reviewed the manuscript of the final review.<BR/>Alessandro Liberati designed the review, supervised the assessment of the studies and reviewed the manuscript.<BR/>Ivan Moschetti and Laura Coe analysed the search results for inclusion of new studies, updated analyses and text according to new findings for the first update of this review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-05-23 11:24:13 +1000" MODIFIED_BY="Melina L Willson">
<P>In the 2014 review update:</P>
<UL>
<LI>outcomes have now been differentiated into primary and secondary, and</LI>
<LI>additional text has been added to the background section of the review for completeness.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-05-29 02:26:48 +0100" MODIFIED_BY="Melina Willson">
<STUDIES MODIFIED="2016-05-23 11:14:08 +1000" MODIFIED_BY="Melina L Willson">
<INCLUDED_STUDIES MODIFIED="2016-05-23 11:14:08 +1000" MODIFIED_BY="Melina L Willson">
<STUDY DATA_SOURCE="MIX" ID="STD-GIVIO" MODIFIED="2016-04-21 16:16:31 +1000" MODIFIED_BY="Melina L Willson" NAME="GIVIO" YEAR="">
<REFERENCE MODIFIED="2016-04-21 16:16:31 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The GIVIO Investigators</AU>
<TI>Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>271</VL>
<NO>20</NO>
<PG>1587-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3441707"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3441706"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grunfeld-1996" MODIFIED="2016-04-29 00:31:00 +1000" MODIFIED_BY="Heather Maxwell" NAME="Grunfeld 1996" YEAR="">
<REFERENCE MODIFIED="2016-03-16 16:00:22 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grunfeld E, Fitzpatrick R, Mant D, Yudkin P, Adewuyi-Dalton R, Stewart J, et al</AU>
<TI>Comparison of breast cancer patient satisfaction with follow-up in primary care vs specialist care: results from a randomized controlled trial</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1999</YR>
<VL>49</VL>
<NO>446</NO>
<PG>705-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3441709"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-21 16:16:43 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, et al</AU>
<TI>Routine follow up of breast cancer in primary care: randomised trial</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7058</NO>
<PG>665-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3441710"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3441708"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grunfeld-2006" MODIFIED="2016-03-16 16:02:07 +1100" MODIFIED_BY="Melina L Willson" NAME="Grunfeld 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-03-16 16:02:07 +1100" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, et al</AU>
<TI>Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>6</NO>
<PG>848-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3441712"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-11-13 08:44:50 +1100" MODIFIED_BY="Melina L Willson"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3441711"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gulliford-1997" MODIFIED="2016-04-29 00:31:31 +1000" MODIFIED_BY="Heather Maxwell" NAME="Gulliford 1997" YEAR="">
<REFERENCE MODIFIED="2016-04-21 16:17:00 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford T, Opomo M, Wilson E, Hanham I, Epstein R</AU>
<TI>Popularity of less frequent follow-up for breast cancer in randomised study: initial findings from the hotline study</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<NO>7075</NO>
<PG>171-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3441714"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3441713"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rosselli-Del-Turco-1994" MODIFIED="2016-05-23 11:14:08 +1000" MODIFIED_BY="Melina L Willson" NAME="Rosselli Del Turco 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-05-23 11:14:08 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Palli D, Russo A, Saieva C, Ciatto S, Rosselli Del Turco M, Distante V, et al: for the National Research Council Project on Breast Cancer Follow-up</AU>
<TI>Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>281</VL>
<NO>17</NO>
<PG>1586</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3441716"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-05-23 11:13:59 +1000" MODIFIED_BY="Melina L Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V</AU>
<TI>Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>271</VL>
<NO>20</NO>
<PG>1593-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3441717"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3441715"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-05-23 11:32:55 +1000" MODIFIED_BY="Melina L Willson">
<ADDITIONAL_REFERENCES MODIFIED="2016-05-23 11:32:55 +1000" MODIFIED_BY="Melina L Willson">
<REFERENCE ID="REF-ASCO-2013" MODIFIED="2016-03-16 16:13:35 +1100" MODIFIED_BY="Melina L Willson" NAME="ASCO 2013" TYPE="JOURNAL_ARTICLE">
<AU>Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, et al</AU>
<TI>Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2013</YR>
<VL>31</VL>
<NO>7</NO>
<PG>961&#8211;5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burstein-2000" MODIFIED="2016-05-02 00:42:55 +1000" MODIFIED_BY="Heather Maxwell" NAME="Burstein 2000" TYPE="JOURNAL_ARTICLE">
<AU>Burstein HJ, Winer EP</AU>
<TI>Primary care for survivors of breast cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>15</NO>
<PG>1086-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlotti-1993" NAME="Carlotti 1993" TYPE="JOURNAL_ARTICLE">
<AU>Carlotti A, Siragusa A, Grillo Ruggeri F, Vitali ML, Grimaldi A, Barone D</AU>
<TI>The mammographic images of the irradiated breast after conservative therapy for carcinoma</TI>
<TO>Quadri mammografici della mammela irradiata dopo terapia conservativa per carcinoma</TO>
<SO>La Radiologia Medica</SO>
<YR>1993</YR>
<VL>86</VL>
<PG>101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chopra-2014" MODIFIED="2016-03-16 16:15:50 +1100" MODIFIED_BY="Melina L Willson" NAME="Chopra 2014" TYPE="JOURNAL_ARTICLE">
<AU>Chopra I, Chopra A</AU>
<TI>Follow-up care for breast cancer survivors: improving patient outcomes</TI>
<SO>Patient Related Outcome Measures</SO>
<YR>2014</YR>
<VL>30</VL>
<NO>5</NO>
<PG>71-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clinical-trial-2014" MODIFIED="2016-04-29 00:39:23 +1000" MODIFIED_BY="Heather Maxwell" NAME="Clinical trial 2014" TYPE="OTHER">
<TI>Home - ClinicalTrials.gov [Internet]. [cited 2014 Mar 29]</TI>
<SO>Available from: http://www.clinicaltrials.gov/</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Constantinidou-2011" MODIFIED="2016-03-16 16:16:24 +1100" MODIFIED_BY="Melina L Willson" NAME="Constantinidou 2011" TYPE="JOURNAL_ARTICLE">
<AU>Constantinidou A, Martin A, Sharma B, Johnston SRD</AU>
<TI>Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital</TI>
<SO>Annals of Oncology</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>2</NO>
<PG>307&#8211;14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Lena-1995" NAME="De Lena 1995" TYPE="JOURNAL_ARTICLE">
<AU>De Lena M, Ferguson J, Liberati A</AU>
<TI>Consensus Conference on Follow-up in Breast Cancer. Selected Papers</TI>
<SO>Annals of Oncology</SO>
<YR>1995</YR>
<VL>6 Suppl 2</VL>
<PG>1-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duffy-2008" MODIFIED="2016-03-16 16:16:50 +1100" MODIFIED_BY="Melina L Willson" NAME="Duffy 2008" TYPE="JOURNAL_ARTICLE">
<AU>Duffy SW, Nagtegaal ID, Wallims M, Cafferty FH, Houssami N, Warwich J, et al</AU>
<TI>Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2008</YR>
<VL>168</VL>
<NO>1</NO>
<PG>98-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESMO-2013" MODIFIED="2016-03-16 16:17:14 +1100" MODIFIED_BY="Melina L Willson" NAME="ESMO 2013" TYPE="JOURNAL_ARTICLE">
<AU>Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, et al</AU>
<TI>Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</TI>
<SO>Annals of Oncology</SO>
<YR>2013</YR>
<VL>Suppl 6</VL>
<PG>vi7&#8211;23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferlay-2013" MODIFIED="2016-03-16 16:18:32 +1100" MODIFIED_BY="Melina L Willson" NAME="Ferlay 2013" TYPE="JOURNAL_ARTICLE">
<AU>Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al</AU>
<TI>Cancer incidence and mortality patterns in Europe: estimate for 40 countries in 2012</TI>
<SO>European Journal of Cancer</SO>
<YR>2013</YR>
<VL>49</VL>
<NO>6</NO>
<PG>1374-403</PG>
<IDENTIFIERS MODIFIED="2015-03-02 20:51:04 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-03-02 20:51:04 +1100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Globocan-2012" MODIFIED="2016-05-23 10:57:05 +1000" MODIFIED_BY="Melina L Willson" NAME="Globocan 2012" TYPE="OTHER">
<AU>International Agency for Research on Cancer, World Health Organization</AU>
<TI>GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.</TI>
<SO>Available from: http://globocan.iarc.fr/Default.aspx (accessed 15 May 2015)</SO>
<YR>2012</YR>
<IDENTIFIERS MODIFIED="2015-03-02 20:40:02 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Goldhirsch-2013" MODIFIED="2016-03-16 16:19:11 +1100" MODIFIED_BY="Melina L Willson" NAME="Goldhirsch 2013" TYPE="JOURNAL_ARTICLE">
<AU>Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al</AU>
<TI>Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013</TI>
<SO>Annals of Oncology</SO>
<YR>2013</YR>
<VL>24</VL>
<NO>9</NO>
<PG>2206&#8211;23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADE-2004" MODIFIED="2015-03-10 01:10:33 +1100" MODIFIED_BY="[Empty name]" NAME="GRADE 2004" TYPE="JOURNAL_ARTICLE">
<AU>The GRADE working group</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<PG>1490-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grandjean-2012" MODIFIED="2016-03-16 16:20:03 +1100" MODIFIED_BY="Melina L Willson" NAME="Grandjean 2012" TYPE="JOURNAL_ARTICLE">
<AU>Grandjean I, Kwast AB, de Vries H, Klaase J, Schoevers WJ, Siesling S</AU>
<TI>Evaluation of the adherence to follow-up care guidelines for women with breast cancer</TI>
<SO>European Journal of Oncology Nursing</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>3</NO>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greco-1998" MODIFIED="2015-11-13 08:44:18 +1100" MODIFIED_BY="Melina L Willson" NAME="Greco 1998" TYPE="JOURNAL_ARTICLE">
<AU>Greco M, Agresti R, Giovanazzi R</AU>
<TI>Impact of the diagnostic methods on the therapeutics strategies</TI>
<SO>The Quarterly Journal of Nuclear Medicine and Molecular Imaging</SO>
<YR>1998</YR>
<VL>42</VL>
<PG>66-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grunfeld-1999" MODIFIED="2016-03-16 16:20:33 +1100" MODIFIED_BY="Melina L Willson" NAME="Grunfeld 1999" TYPE="JOURNAL_ARTICLE">
<AU>Grunfeld E, Fitzpatrick R, Mant D, Yudkin P, Adewuyi-Dalton R, Stewart J, et al</AU>
<TI>Comparison of breast cancer patient satisfaction with follow-up in primary care vs specialist care: results from a randomized controlled trial</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1999</YR>
<VL>49</VL>
<NO>446</NO>
<PG>705-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grunfeld-2010" MODIFIED="2016-03-16 16:21:13 +1100" MODIFIED_BY="Melina L Willson" NAME="Grunfeld 2010" TYPE="JOURNAL_ARTICLE">
<AU>Grunfeld E, Hodgson DC, Del Giudice ME, Moineddin R</AU>
<TI>Population-based longitudinal study of follow-up care for breast cancer survivors</TI>
<SO>Journal of Oncology Practice</SO>
<YR>2010</YR>
<VL>6</VL>
<NO>4</NO>
<PG>174&#8211;81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hannisdal-1993" MODIFIED="2016-03-16 16:21:56 +1100" MODIFIED_BY="Melina L Willson" NAME="Hannisdal 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hannisdal E, Gundersen S, Kvaloy S, Lindegaard, Aas M, Finnanger AM, et al</AU>
<TI>Follow-up of breast cancer patients stage I-II: A baseline strategy</TI>
<SO>European Journal of Cancer</SO>
<YR>1993</YR>
<VL>29A</VL>
<NO>7</NO>
<PG>992-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harries-1996" MODIFIED="2015-11-13 08:44:22 +1100" MODIFIED_BY="Melina L Willson" NAME="Harries 1996" TYPE="JOURNAL_ARTICLE">
<AU>Harries SA, Lawrence RN, Scrivener R, Friedman NR, Kissin MW</AU>
<TI>A survey of the management of breast cancer in England and Wales</TI>
<SO>Annals of the Royal College of Surgeons of England</SO>
<YR>1996</YR>
<VL>78</VL>
<NO>3</NO>
<PG>197-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hietanen-1986" NAME="Hietanen 1986" TYPE="JOURNAL_ARTICLE">
<AU>Hietanen P</AU>
<TI>Chest radiography in the follow-up of breast cancer</TI>
<SO>Acta Radiologica Oncology</SO>
<YR>1986</YR>
<VL>25</VL>
<PG>15-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-11-13 08:42:03 +1100" MODIFIED_BY="Melina L Willson" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holli-1998" NAME="Holli 1998" TYPE="JOURNAL_ARTICLE">
<AU>Holli K, Saaristo R, Isola J, Hyoti M, Hakama M</AU>
<TI>Effect of radiotherapy on the interpretation of routine follow-up mammography after conservative breast surgery: a randomised study</TI>
<SO>British Journal of Cancer</SO>
<YR>1998</YR>
<VL>78</VL>
<NO>4</NO>
<PG>542-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hortobagyi-2002" MODIFIED="2016-03-16 16:22:24 +1100" MODIFIED_BY="Melina L Willson" NAME="Hortobagyi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hortobagyi GN</AU>
<TI>Can we cure limited metastatic breast cancer?</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>3</NO>
<PG>620-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jatoi-2011" MODIFIED="2016-03-16 16:22:36 +1100" MODIFIED_BY="Melina L Willson" NAME="Jatoi 2011" TYPE="JOURNAL_ARTICLE">
<AU>Jatoi I, Anderson WF, Jeong J-H, Redmond CK</AU>
<TI>Breast cancer adjuvant therapy: time to consider its time-dependent effects</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>17</NO>
<PG>2301-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennecke-2010" MODIFIED="2016-03-16 16:22:46 +1100" MODIFIED_BY="Melina L Willson" NAME="Kennecke 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al</AU>
<TI>Metastatic behavior of breast cancer subtypes</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>20</NO>
<PG>3271-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kobayashi-2012" MODIFIED="2016-03-16 16:23:20 +1100" MODIFIED_BY="Melina L Willson" NAME="Kobayashi 2012" TYPE="JOURNAL_ARTICLE">
<AU>Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, et al</AU>
<TI>Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review</TI>
<SO>Breast Cancer</SO>
<YR>2012</YR>
<VL>19</VL>
<NO>3</NO>
<PG>218&#8211;37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Logarer-1990" NAME="Logarer 1990" TYPE="JOURNAL_ARTICLE">
<AU>Logarer VB, Vestergaard A, Herrstedt J, Thomsen HS, Zedeler K, Dombernowsky</AU>
<TI>The limited value of routine chest X-ray in the follow-up of stage II breast cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>1990</YR>
<VL>26</VL>
<NO>5</NO>
<PG>553-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loprinzi-1994" MODIFIED="2016-05-23 10:57:29 +1000" MODIFIED_BY="Melina L Willson" NAME="Loprinzi 1994" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL</AU>
<TI>It is now the age to define the appropriate follow-up of primary breast cancer patients [editorial]</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>5</NO>
<PG>881-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lucci-2012" MODIFIED="2016-03-16 16:23:37 +1100" MODIFIED_BY="Melina L Willson" NAME="Lucci 2012" TYPE="JOURNAL_ARTICLE">
<AU>Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al</AU>
<TI>Circulating tumour cells in non-metastatic breast cancer: a prospective study</TI>
<SO>Lancet Oncology</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>7</NO>
<PG>688&#8211;95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahoney-1986" NAME="Mahoney 1986" TYPE="JOURNAL_ARTICLE">
<AU>Mahoney L</AU>
<TI>Methods for detecting locally recurrent and controlateral second primary breast cancer</TI>
<SO>Canadian Journal of Surgery</SO>
<YR>1986</YR>
<VL>29</VL>
<NO>5</NO>
<PG>372-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Margenthaler-2012" MODIFIED="2016-03-16 16:24:06 +1100" MODIFIED_BY="Melina L Willson" NAME="Margenthaler 2012" TYPE="JOURNAL_ARTICLE">
<AU>Margenthaler JA, Allam E, Chen L, Virgo KS, Kulkarni UM, Patel AP, et al</AU>
<TI>Surveillance of patients with breast cancer after curative-intent primary treatment: current practice patterns</TI>
<SO>Journal of Oncology Practice</SO>
<YR>2012</YR>
<VL>8</VL>
<NO>2</NO>
<PG>79-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Metzger_x002d_Filho-2013" MODIFIED="2016-03-16 16:24:19 +1100" MODIFIED_BY="Melina L Willson" NAME="Metzger-Filho 2013" TYPE="JOURNAL_ARTICLE">
<AU>Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, et al</AU>
<TI>Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2013</YR>
<VL>31</VL>
<NO>25</NO>
<PG>3083&#8211;90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCCN-2014" MODIFIED="2015-03-11 21:09:43 +1100" MODIFIED_BY="[Empty name]" NAME="NCCN 2014" TYPE="OTHER">
<TI>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer - breast.pdf [Internet]. [cited 2014 Mar 29]</TI>
<SO>Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pandya-1983" MODIFIED="2016-03-16 16:26:09 +1100" MODIFIED_BY="Melina L Willson" NAME="Pandya 1983" TYPE="JOURNAL_ARTICLE">
<AU>Pandya KJ, McFadden ET, Kalish LA, Carbone PP</AU>
<TI>Frequency and patterns of early disease recurrence and method of detection in operable breast cancer with pathologically positive axillary lymph nodes on Eastern Cooperative Oncology Group Adjuvant studies: A preliminary report</TI>
<SO>Cancer Treatment Symposium</SO>
<YR>1983</YR>
<VL>2</VL>
<PG>117-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puglisi-2014" MODIFIED="2016-03-16 16:26:56 +1100" MODIFIED_BY="Melina L Willson" NAME="Puglisi 2014" TYPE="JOURNAL_ARTICLE">
<AU>Puglisi F, Fontanella C, Numico G, Sini V, Evangelista L, Monetti F, et al</AU>
<TI>Follow-up of patients with early breast cancer: is it time to rewrite the story?</TI>
<SO>Critical Reviews in Oncology/Hematology</SO>
<YR>2014</YR>
<VL>91</VL>
<NO>2</NO>
<PG>130-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan" MODIFIED="2015-11-13 08:42:23 +1100" MODIFIED_BY="Melina L Willson" NAME="RevMan" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rutgers-1989" MODIFIED="2016-03-16 16:27:09 +1100" MODIFIED_BY="Melina L Willson" NAME="Rutgers 1989" TYPE="JOURNAL_ARTICLE">
<AU>Rutgers EJ, van Slooten EA, Kluck HM</AU>
<TI>Follow-up after treatment of primary breast cancer</TI>
<SO>British Journal of Surgery</SO>
<YR>1989</YR>
<VL>76</VL>
<PG>187-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SEER-database-2014" MODIFIED="2016-05-23 10:58:46 +1000" MODIFIED_BY="Melina L Willson" NAME="SEER database 2014" TYPE="OTHER">
<AU>National Cancer Institute</AU>
<TI>Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Female Breast Cancer</TI>
<SO>Available from: http://seer.cancer.gov (accessed 15 May 2015)</SO>
<YR>2014</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stark-1996" MODIFIED="2016-05-23 10:57:36 +1000" MODIFIED_BY="Melina L Willson" NAME="Stark 1996" TYPE="JOURNAL_ARTICLE">
<AU>Stark ME, Crowe JP Jr</AU>
<TI>Breast cancer evaluation and follow-up: a survey of The Ohio Chapter of The American College of Surgeons</TI>
<SO>American Surgeon</SO>
<YR>1996 Jun</YR>
<VL>62</VL>
<NO>6</NO>
<PG>458-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tomiak-1998" MODIFIED="2016-05-23 11:32:55 +1000" MODIFIED_BY="Melina L Willson" NAME="Tomiak 1998" TYPE="JOURNAL_ARTICLE">
<AU>Tomiak EM, Diverty B, Verma S, Evans WK, Le Petit C, Will P, et al</AU>
<TI>Follow-up practices for patients with early stage breast cancer: a survey of Canadian oncologists</TI>
<SO>Cancer Prevention &amp; Control</SO>
<YR>1998</YR>
<VL>2</VL>
<NO>2</NO>
<PG>63-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vestergaard-1989" MODIFIED="2016-03-16 16:28:07 +1100" MODIFIED_BY="Melina L Willson" NAME="Vestergaard 1989" TYPE="JOURNAL_ARTICLE">
<AU>Vestergaard A, Herrstedt J, Thomsen HS, Dombernowsky P, Zedeler K</AU>
<TI>The value of yearly chest x-ray in patients with stage I breast cancer</TI>
<SO>European Journal of Cancer and Clinical Oncology</SO>
<YR>1989</YR>
<VL>25</VL>
<NO>4</NO>
<PG>687-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2014" MODIFIED="2015-03-09 21:26:11 +1100" MODIFIED_BY="[Empty name]" NAME="WHO 2014" TYPE="OTHER">
<TI>WHO | Welcome to the WHO ICTRP [Internet]. [cited 2014 Mar 29]</TI>
<SO>Available from: http://www.who.int/ictrp/en/</SO>
<IDENTIFIERS MODIFIED="2015-03-09 21:26:11 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wickerhan-1986" MODIFIED="2015-03-09 21:26:27 +1100" MODIFIED_BY="[Empty name]" NAME="Wickerhan 1986" TYPE="JOURNAL_ARTICLE">
<AU>Wickerham L, Fisher B, Cronin W and Members of the NSABP Committee for treatment failure Criteria</AU>
<TI>The efficacy of bone scanning in the follow-up of patients with operable breast cancer</TI>
<SO>Breast Cancer Research and Treatment</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>303-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-05-02 00:44:38 +1000" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Rojas-2000" MODIFIED="2016-05-02 00:44:15 +1000" MODIFIED_BY="Heather Maxwell" NAME="Rojas 2000" TYPE="COCHRANE_REVIEW">
<AU>Rojas MP, Telaro E, Russo A, Fossati R, Palli D, Del Rosselli TM, et al</AU>
<TI>Follow-up strategies for women treated for early breast cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-04-29 02:11:08 +1000" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2016-04-29 02:11:08 +1000" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD001768"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rojas-2005" MODIFIED="2016-05-02 00:44:38 +1000" MODIFIED_BY="Heather Maxwell" NAME="Rojas 2005" TYPE="COCHRANE_REVIEW">
<AU>Rojas MPMP, Telaro E, Moschetti I, Coe L, Fossati R, Liberati A, et al</AU>
<TI>Follow-up strategies for women treated for early breast cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-04-29 02:28:02 +1000" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2016-04-29 02:28:02 +1000" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD001768.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-05-02 00:40:34 +1000" MODIFIED_BY="Heather Maxwell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-05-02 00:40:34 +1000" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-05-02 00:35:38 +1000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-GIVIO">
<CHAR_METHODS MODIFIED="2016-05-02 00:35:16 +1000" MODIFIED_BY="Heather Maxwell">
<P>Multicentre randomised controlled trial.<BR/>26 general hospitals, Italy.<BR/>Randomisation by telephone, stratified by institution and pathological axillary nodal status.<BR/>Inclusion within 6 weeks of surgery.<BR/>Calculation of sample size reported.<BR/>Intention-to-treat analysis.</P>
<P>Protocols for adjuvant therapy and treatment of metastatic disease.<BR/>Median follow-up of 71 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-02 00:35:22 +1000" MODIFIED_BY="Heather Maxwell">
<P>1320 women younger than 70.<BR/>Histologically-confirmed, non-inflammatory, unilateral, breast carcinoma.<BR/>Stage T1 to T3 (any size tumour without direct extension to chest wall or skin), N0 to N1 (no regional lymphonodal metastases or metastases to movable ipsilateral axillary lymph nodes), and M0 (no distant metastases).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-02 00:35:29 +1000" MODIFIED_BY="Heather Maxwell">
<P>Intensive group (N = 655):<BR/>-Physical exam every 3 months for 2 years and then every 6 months for 3 years.<BR/>-Blood test every visit (alkaline phosphatase, gamma-glutamyl transpeptidase)<BR/>-Chest roentgenography every 6 months.<BR/>-Annual radionuclide bone scan.<BR/>-Annual liver ecography.<BR/>-Annual contralateral mammography.</P>
<P>Control group (N = 665):<BR/>-Physical exam every 3 months for 2 years and then every 6 months for 3 years.<BR/>-Annual contralateral mammography.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-02 00:35:38 +1000" MODIFIED_BY="Heather Maxwell">
<P>Overall survival.<BR/>Disease-free survival.<BR/>HRQoL (quality of life perception, overall health perception, body image, emotional well-being, social functioning, symptoms and satisfaction with care). Instruments used included the Functional Living Index-Cancer Scale, the Sickness Impact Profile, the Profile of Mood States and the Cancer Inventory of Problem Situation.<BR/>Time to detection of recurrence.<BR/>Symptomatic status at diagnosis of metastases.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ipsilateral breast assessment only by physical examination.</P>
<P>123 patients (9.3%) discontinued or were lost before relapsing, and were included in the analysis (similar distribution between experimental and control group).<BR/>Additional 8% of randomised patients lost to follow-up not included in the analysis.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-02 00:36:33 +1000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Grunfeld-1996">
<CHAR_METHODS MODIFIED="2016-05-02 00:36:06 +1000" MODIFIED_BY="Heather Maxwell">
<P>Randomised controlled trial.<BR/>2 district general hospitals, England.<BR/>Eligible patients were invited by letter to participate.<BR/>296/445 agreed to participate.<BR/>Randomisation by telephone in blocks of eight.<BR/>Calculation of sample size reported, N = 300.<BR/>Follow-up 18 months<BR/>Time to diagnosis assessed blinded by masking allocation information on clinical records.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>296 women:<BR/>-initial stage I, II or III breast cancer (no distant metastases),<BR/>-primary treatment completed at least 3 months previously,<BR/>-attending outpatient clinic for routine follow-up, <BR/>-no evidence of disease at last follow-up visit.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-29 01:04:17 +1000" MODIFIED_BY="Heather Maxwell">
<P>Hospital group (N = 148):<BR/>Routine follow-up with clinical visits and mammography, other exams only if clinically indicated.<BR/>Frequency of visits in one hospital was every 3 months for 1 year and every 6 months from second to fifth years: in the other hospital was every 3, 4 and 6 months for first, second and third years and every year thereafter.</P>
<P>General Practice group (N = 148):<BR/>Follow-up with the same schedule of the reference hospital but made by the GP. GPs were sent a letter providing the patient's breast cancer history, a description of follow-up routine recommended, and assuring that rapid referral to specialist care was possible. An educational handbook on breast cancer follow-up care was provided.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-02 00:36:25 +1000" MODIFIED_BY="Heather Maxwell">
<P>Time to detection of recurrence.<BR/>HRQoL assessed by 3 self-administered instruments:<BR/>- British version of the SF-36<BR/>-European Organisation for Research and Treatment of Cancer core quality of life questionnaire (EORTC QLQ-C30)<BR/>-Hospital anxiety and depression scale.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-02 00:36:33 +1000" MODIFIED_BY="Heather Maxwell">
<P>Characteristics of non participants are included.<BR/>Random allocation not stratified by clinical stage.<BR/>Educative intervention with GPs.<BR/>Overall loss to follow-up 0.7%.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-02 00:39:15 +1000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Grunfeld-2006">
<CHAR_METHODS MODIFIED="2016-05-02 00:38:49 +1000" MODIFIED_BY="Heather Maxwell">
<P>Multicentre, randomised, controlled trial; Six of the nine regional cancer centres in Ontario, Canada. Tertiary-care.</P>
<P>The institutional review board of each participating institution approved the study protocol.</P>
<P>All analyses were performed according to the intention-to-treat principle.</P>
<P>Follow-up (maximum of 5 years 31.9% patients). Median follow-up was 3.5 years from randomisation (4.5 years from diagnosis)</P>
<P>The calculated sample size of 1045 women was based on the assumption that the SCE proportion would be 4 % in both arms, with an upper level of tolerance of 5.5% in the FP arm (i.e. a non-inferiority margin of 1.5%).</P>
<P>968 women were enrolled.<BR/>483 allocated to the family physician (FP) group and 485 to the usual practice (CC) group.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-02 00:38:55 +1000" MODIFIED_BY="Heather Maxwell">
<P>Routine follow-up care after patients completed adjuvant therapy for early-stage breast cancer.<BR/>Patients were enrolled between January 1997 and June 2001, and were observed until June 2003.</P>
<P>Women who had completed adjuvant chemotherapy, radiotherapy, or both at least 3 months previously; who were disease-free; and who were between 9 and 15 months after diagnosis were targeted. Patients may have continued receiving adjuvant hormonal therapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-21 16:22:08 +1000" MODIFIED_BY="Melina L Willson">
<P>Patients were allocated in a 1:1 ratio to receive follow-up either in the cancer centre according to usual practice (CC group) or from their own family physician (FP group).</P>
<P>Family physicians were provided with a one-page guideline on follow-up that recommended the following: physical examination and medical history every 3 to 6 months for 3 years, every 6 months for 2 years, and then yearly indefinitely; mammograms yearly; diagnostic tests to investigate signs or symptoms suggestive of recurrent or new primary cancer, but such tests were not to be performed routinely.</P>
<P>For women taking tamoxifen, the guideline recommended that a history of vaginal bleeding be taken at each visit and a pelvic examination be performed annually. Family physicians were instructed to refer patients back to the cancer centre if a recurrence or new primary breast cancer developed. For patients in the FP group, if a surgeon had been involved in the patient&#8217;s follow-up care, that follow-up was also transferred to the FP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-02 00:39:15 +1000" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary outcome</B>: recurrence-related serious clinical event (SCE) defined as any one of spinal cord compression, pathologic fracture, hypercalcaemia, uncontrolled local recurrence, brachial plexopathy, or poor functional status (Karnofsky performance score [KPS]70)47 at the time of diagnosis of recurrence.</P>
<P>
<B>Secondary outcome:</B>
</P>
<P>HRQoL: assessed using the Medical Outcomes Study Short Form 36-Item General Health Survey (SF-36) 48 and the Hospital Anxiety and Depression Scale (HADS) 49 while patients were recurrence-free. The SF-36 is scored to yield two summary scales: the Physical Component Summary (PCS) scale measuring physical health and the Mental Component Summary (MCS) scale measuring mental health. In all cases, SF-36 scales yield a score from 0 to 100, with a higher score indicating better quality of life. The HADS contains two subscales measuring anxiety and depression, with scores ranging from 0 to 21.49 Higher scores indicate greater levels of anxiety or depression. The HRQoL standardised scores assessed at baseline and during the subsequent seven follow-ups at 6, 12, 18, 24, 36, 48, and 60 months were summarised as means and change scores from baseline within each group.</P>
<P>Recurrence, death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-29 01:10:55 +1000" MODIFIED_BY="Heather Maxwell">
<P>Patients were excluded if they had persistent complications of primary treatment; were unable to comply with the study protocol including completing specialist follow-up; or were actively observed at a cancer centre for another primary cancer. KPS&lt;/=70 is one of the SCEs because patients usually have high functional status when recurrence is first diagnosed. Low functional status could suggest<BR/>the potential for poor management of recurrence-related symptoms.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-29 01:12:25 +1000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Gulliford-1997">
<CHAR_METHODS MODIFIED="2015-08-02 01:17:45 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.<BR/>1 Breast clinic, England<BR/>211 eligible patients, 196 accepted randomisation.<BR/>No information about randomisation method.<BR/>Median follow-up: 16 months<BR/>13 excluded after randomisation<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>196 women with:<BR/>-history of breast cancer proved by biopsy.<BR/>-no recurrence of the disease.<BR/>-no symptoms suggesting recurrence.<BR/>-only tamoxifen like adjuvant treatment.<BR/>-home telephone.<BR/>-English speaker.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-29 01:12:25 +1000" MODIFIED_BY="Heather Maxwell">
<P>Conventional group (N = 96):<BR/>1. Breast self examination monthly.<BR/>2. Immediate telephone access if symptoms or doubts were developed.<BR/>3. Mammography scheduled depending on primary surgery (every year for 5 years and every 2 years thereafter if lumpectomy, every 2 years since second year if mastectomy).<BR/>4. Clinical visits scheduled depending on time from diagnosis (every 3 months the first year, every 4 months the second year, every 6 months from years 3 to 5 and annually thereafter)</P>
<P>Mammography only group (N = 97):<BR/>1, 2 and 3 are the same.<BR/>4. Clinical visits scheduled only with mammography.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-02 01:17:54 +1000" MODIFIED_BY="[Empty name]">
<P>Acceptability of randomised allocation.<BR/>Use of telephone and GP.<BR/>Satisfaction with allocation to follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-28 21:59:02 +1100" MODIFIED_BY="[Empty name]">
<P>Calculation of sample size not reported.<BR/>Small sample size and short duration of follow-up -16 months-.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-01 20:12:41 +1000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Rosselli-Del-Turco-1994">
<CHAR_METHODS MODIFIED="2016-05-01 20:12:41 +1000" MODIFIED_BY="Heather Maxwell">
<P>Multicentre randomised controlled trial.<BR/>12 breast clinics in Italy (oncologic centres).<BR/>Randomisation by telephone, stratified by institution.<BR/>Inclusion within 6 months of surgery.<BR/>Follow-up at 5 and10 years.<BR/>Adjuvant therapy and treatment of recurrence according to national guidelines.<BR/>Intention-to-treat analysis.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-29 01:14:20 +1000" MODIFIED_BY="Heather Maxwell">
<P>1243 women younger than 70.<BR/>Histologically-confirmed, unilateral invasive carcinoma of the breast with no evidence of metastases.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-29 01:14:38 +1000" MODIFIED_BY="Heather Maxwell">
<P>Intensive group (N = 622):<BR/>-Physical exam every 3 months for 2 years and then every 6 months for 3 years.<BR/>-Two-view chest roentgenography every 6 months.<BR/>-Radionuclide bone scan every 6 months.<BR/>-Annual mammography.<BR/>Control group (N = 621):<BR/>-Physical exam every 3 months for 2 years and then every 6 months for 3 years.<BR/>-Annual mammography.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 01:14:47 +1000" MODIFIED_BY="Heather Maxwell">
<P>Overall survival.<BR/>Disease-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Calculation of sample size not reported.<BR/>161 patients (12.9%) were lost to follow-up at some point during the study and were included in the analysis (similar distribution between experimental and control group).<BR/>Vital status information available for all except 10 patients (.8%).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CC: usual practice<BR/>FP: family physician<BR/>HRQoL: health-related quality of life<BR/>SCE: serious clinical event<BR/>M: distant metastases<BR/>N: regional lymph nodes<BR/>T: primary tumour<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-02-25 20:59:53 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<FOOTNOTES>
<P>None</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-02-25 20:59:59 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P>None</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-03-29 14:59:38 +1100" MODIFIED_BY="Melina L Willson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P>No ongoing studies were found from the WHO ICTRP and ClinicalTrials.gov searches.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-05-02 00:35:59 +1000" MODIFIED_BY="Heather Maxwell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-05-01 20:07:18 +1000" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-01 20:07:18 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-GIVIO">
<DESCRIPTION>
<P>Computer-generated list, stratified by institution and pathologic axillary nodal status</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-25 21:12:16 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grunfeld-1996">
<DESCRIPTION>
<P>Not described - Authors reported :"random allocation was in blocks of eight"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:11:01 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Grunfeld-2006">
<DESCRIPTION>
<P>Randomisation was conducted using a computer-generated centre-specific schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:12:46 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Gulliford-1997">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:15:03 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Rosselli-Del-Turco-1994">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-04-29 01:15:10 +1000" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:01:48 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-GIVIO">
<DESCRIPTION>
<P>Randomisation was performed centrally via telephone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:04:48 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Grunfeld-1996">
<DESCRIPTION>
<P>Follow-up groups were assigned by a telephone call to the trial co-ordination centre in Oxford</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:11:13 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Grunfeld-2006">
<DESCRIPTION>
<P>By a telephone call to the trial co-ordinating centre of the Ontario Clinical Oncology Group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:13:43 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Gulliford-1997">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:15:10 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Rosselli-Del-Turco-1994">
<DESCRIPTION>
<P>Randomisation was centrally performed, individual case of allocation was communicated by telephone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-11-24 21:15:48 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-11-24 21:15:48 +1100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-04-29 01:15:17 +1000" MODIFIED_BY="Heather Maxwell" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-29 01:01:52 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-GIVIO">
<DESCRIPTION>
<P>Not declared if assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-25 21:15:03 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grunfeld-1996">
<DESCRIPTION>
<P>All clinical information on patients with suspected recurrence (record of visit forms, hospital notes, test results, doctors' correspondence) was assessed independently by three of the authors and any discrepancies or difficulties discussed. The information was masked as far as possible with respect to allocation group so that &#8220;time to diagnosis&#8221; was assessed in a blinded fashion. In some cases, however, the allocation group could have been deduced from the course of clinical events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-29 01:11:17 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Grunfeld-2006">
<DESCRIPTION>
<P>A committee that was blinded to treatment allocation adjudicated all events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-29 01:13:40 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Gulliford-1997">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-04-29 01:15:17 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Rosselli-Del-Turco-1994">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-05-02 00:35:55 +1000" MODIFIED_BY="Heather Maxwell" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-02 00:35:55 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-GIVIO">
<DESCRIPTION>
<P>Overall compliance was greater than 80% in both groups for every procedure. 91% of patients adhered to protocol recommendations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-29 01:05:07 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Grunfeld-1996">
<DESCRIPTION>
<P>One (0.7%) participant in each group moved out of the district and was lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-29 01:11:21 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Grunfeld-2006">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-29 01:13:17 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Gulliford-1997">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-29 01:15:23 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Rosselli-Del-Turco-1994">
<DESCRIPTION>
<P>A total of 161 (12.9%) patients were lost to clinical follow-up at some point. 86 patients intensive vs 75 patients non intensive follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-04-29 01:15:31 +1000" MODIFIED_BY="Heather Maxwell" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:01:59 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-GIVIO">
<DESCRIPTION>
<P>Study conducted before the registration of the protocol was mandatory</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:05:17 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Grunfeld-1996">
<DESCRIPTION>
<P>Study conducted before the registration of the protocol was mandatory.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:11:31 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Grunfeld-2006">
<DESCRIPTION>
<P>Study conducted before the registration of the protocol was mandatory.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:13:10 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Gulliford-1997">
<DESCRIPTION>
<P>Study conducted before the registration of the protocol was mandatory.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:15:31 +1000" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Rosselli-Del-Turco-1994">
<DESCRIPTION>
<P>Study conducted before the registration of the protocol was mandatory</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-05-02 00:35:59 +1000" MODIFIED_BY="Heather Maxwell" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-02 00:35:59 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-GIVIO">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:05:23 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Grunfeld-1996">
<DESCRIPTION>
<P>No other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-11 17:43:16 +1100" MODIFIED_BY="Melina L Willson" RESULT="YES" STUDY_ID="STD-Grunfeld-2006">
<DESCRIPTION>
<P>The sponsors of the research had no role in any aspect of the development, conduct, analysis, or reporting of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:12:55 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Gulliford-1997">
<DESCRIPTION>
<P>No other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-29 01:15:35 +1000" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Rosselli-Del-Turco-1994">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-05-23 11:27:21 +1000" MODIFIED_BY="Melina L Willson">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-05-23 11:26:04 +1000" MODIFIED_BY="Melina L Willson" NO="1">
<TITLE MODIFIED="2016-05-02 00:40:56 +1000" MODIFIED_BY="Heather Maxwell">Summary of findings: Non-intensive versus intensive follow-up for women treated for early breast cancer</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Non-intensive versus intensive follow-up for women treated for early breast cancer</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>women treated for early breast cancer<BR/>
<B>Settings: </B>outpatients<BR/>
<B>Intervention: </B>non-intensive follow-up<BR/>
<B>Comparison: </B>intensive follow-up</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Intensive</P>
</TH>
<TH VALIGN="TOP">
<P>Non-intensive</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Overall survival</B>
</P>
<P>Follow-up: median 71 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>HR 0.98</B>
</P>
<P>(0.84 to 1.15)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>2563<BR/>(2 studies)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>HIGH</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>26 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>26 per 100</B>
<BR/>(23 to 30)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Disease-free survival</B>
</P>
<P>Follow-up: median 71 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>HR 0.84</B>
</P>
<P>(0.71 to 1.00)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>2563<BR/>(2 studies)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>LOW</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>23 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>19 per 100</B>
<BR/>(17 to 23)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
<SUP>4</SUP>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable<SUP>4</SUP>
</P>
</TD>
<TD>
<P>639<BR/>1 study</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>HIGH</B>
<SUP>5</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>HR:</B> Hazard Ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Heterogeneity was considered low (I<SUP>2</SUP> = 28%) and we did not downgrade.<BR/>
<SUP>2</SUP>Heterogeneity was considerable (I<SUP>2</SUP> = 52%) and we decided to downgrade once for inconsistency of results.<BR/>
<SUP>3</SUP>We downgraded once due to possible detection bias in both trials - it was not described whether the outcome assessor was blinded. In <LINK REF="STD-Rosselli-Del-Turco-1994" TYPE="STUDY">Rosselli Del Turco 1994</LINK>, the random sequence generation was not described but we did not downgrade for this because taking into account the period in which RCT was done, it was possible that the authors simply did not report the details of how the random sequence was generated.<BR/>
<SUP>4</SUP>The study provided nominal information on quality of life and it was not possible to extract useful data. The trial authors concluded that there were no difference in quality of life between the two types of follow-up.<BR/>
<SUP>5</SUP>We did not downgrade the quality of evidence for this outcome (as suggested by the GRADE approach).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-05-23 11:27:21 +1000" MODIFIED_BY="Melina L Willson" NO="2">
<TITLE MODIFIED="2016-05-02 00:41:48 +1000" MODIFIED_BY="Heather Maxwell">Summary of findings: Decentralised versus centralised follow-up for women treated for early breast cancer</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Decentralised versus centralised follow-up for women treated for early breast cancer</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>women treated for early breast cancer<BR/>
<B>Settings: </B>outpatients<BR/>
<B>Intervention: </B>decentralised follow-up<BR/>
<B>Comparison:</B> centralised follow-up</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Centralised follow-up</P>
</TH>
<TH VALIGN="TOP">
<P>Decentralised follow-up</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Overall survival</B>
</P>
<P>Follow-up: median 42 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>HR 1.07</B>
</P>
<P>(0.64 to 1.78)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>968<BR/>(1 study)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>MODERATE</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>6 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>7 per 100</B>
<BR/>(4 to 11)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Disease-free survival</B>
<BR/>Follow-up: median 42 months</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>HR 1.06</B>
</P>
<P>(0.76 to 1.47)</P>
</TD>
<TD ROWSPAN="2">
<P>1264<BR/>(2 studies)</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>MODERATE</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>13 per 100</B>
</P>
</TD>
<TD>
<P>
<B>13 per 100</B>
<BR/>(10 to 18)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
<SUP>5</SUP>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>356<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>HIGH</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>HR:</B> Hazard Ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>The publication did not describe how many women were lost to follow-up and how the random sequence was generated. We downgraded once for the first reason.<BR/>
<SUP>2</SUP>There was a low event rate so we decided not to downgrade for imprecision.<BR/>
<SUP>3</SUP>We downgraded once for this outcome because follow-up schedules varied even within a study.<BR/>
<SUP>4</SUP>General practitioners were assured that a "rapid re-referral" would have been possible if any problem developed. This would only be feasible in a clinical trial setting or well organised health systems.<BR/>
<SUP>5</SUP>Trial authors concluded that there were no difference in quality of life between the two types of follow-up. As we were unable to judge the GRADE domains for this outcome due to a lack of information, we did not downgrade the quality of evidence for this outcome (as suggested by the GRADE approach).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-05-02 00:42:18 +1000" MODIFIED_BY="Heather Maxwell">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-05-02 00:42:18 +1000" MODIFIED_BY="Heather Maxwell" NO="1">
<TITLE MODIFIED="2015-02-27 21:07:26 +1100" MODIFIED_BY="[Empty name]">Comparison Guidelines on Selected Breast Cancer Follow-up Components</TITLE>
<TABLE COLS="6" ROWS="4">
<TR>
<TD VALIGN="TOP">
<P>
<B>Guidelines</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Mammography</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Clinical visit (history and physical exam)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Self-breast examination</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intensive follow-up</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Others </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(<LINK REF="REF-ASCO-2013" TYPE="REFERENCE">ASCO 2013</LINK>)</P>
</TD>
<TD VALIGN="TOP">
<P>Yearly.</P>
<P>For women who have undergone breast-conserving surgery, a post-treatment mammogram should be obtained 1 year after the initial mammogram and at least 6 months after completion of radiation therapy.</P>
</TD>
<TD VALIGN="TOP">
<P>Every 3 to 6 months for the first 3 years, every 6 to 12 months for years 4 and 5, and annually thereafter.</P>
</TD>
<TD VALIGN="TOP">
<P>Monthly</P>
</TD>
<TD VALIGN="TOP">
<P>Not recommended</P>
</TD>
<TD VALIGN="TOP">
<P>Gynecologic follow-up for all women.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
<P>(<LINK REF="REF-ESMO-2013" TYPE="REFERENCE">ESMO 2013</LINK>)</P>
</TD>
<TD VALIGN="TOP">
<P>Every 1 to 2 years.</P>
</TD>
<TD VALIGN="TOP">
<P>Every 3 to 4 months in the first 2 years, every 6 months from years 3 to 5, and annually thereafter.</P>
</TD>
<TD VALIGN="TOP">
<P>Not specified</P>
</TD>
<TD VALIGN="TOP">
<P>Not recommended</P>
</TD>
<TD VALIGN="TOP">
<P>Annual gynaecological examination for women on tamoxifen; regular bone mineral density evaluation and lipid profile for women on aromatase inhibitors.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
<P>(<LINK REF="REF-NCCN-2014" TYPE="REFERENCE">NCCN 2014</LINK>)</P>
<P>version 2.2014</P>
</TD>
<TD VALIGN="TOP">
<P>Yearly.</P>
</TD>
<TD VALIGN="TOP">
<P>Every 4 to 6 months for 5 years, and annually thereafter.</P>
</TD>
<TD VALIGN="TOP">
<P>Not specified</P>
</TD>
<TD VALIGN="TOP">
<P>Not recommended</P>
</TD>
<TD VALIGN="TOP">
<P>Annual gynaecological examination for women on tamoxifen; regular bone mineral density evaluation for women on aromatase inhibitors or who experienced premature ovarian failure.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-04-29 00:25:53 +1000" MODIFIED_BY="Heather Maxwell">
<COMPARISON ID="CMP-001" MODIFIED="2016-04-29 00:25:53 +1000" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>Non-intensive follow-up vs intensive follow-up</NAME>
<IPD_OUTCOME CHI2="1.3975049900107914" CI_END="1.1465200799104636" CI_START="0.8371010647916548" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.9796699340584369" ESTIMABLE="YES" EVENTS_1="314" EVENTS_2="338" I2="28.443904877056784" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.059381665274370804" LOG_CI_START="-0.07722210564873654" LOG_EFFECT_SIZE="-0.008920220187182871" MODIFIED="2016-04-21 15:50:29 +1000" MODIFIED_BY="Melina L Willson" NO="1" P_CHI2="0.23714197725991382" P_Q="1.0" P_Z="0.797973135673917" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1286" TOTAL_2="1277" WEIGHT="100.0" Z="0.2559711226549777">
<NAME>Overall survival</NAME>
<GROUP_LABEL_1>Non-intensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Intensive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-intensive fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intensive fup</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.123072766686305" CI_START="0.6597201604711073" EFFECT_SIZE="0.8607634668473212" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="116" LOG_CI_END="0.05040789619602126" LOG_CI_START="-0.1806402440572285" LOG_EFFECT_SIZE="-0.06511617393060365" ORDER="33800" O_E="-8.14" SE="0.1357188212914986" STUDY_ID="STD-GIVIO" TOTAL_1="665" TOTAL_2="655" VAR="54.29" WEIGHT="34.95589466228833"/>
<IPD_DATA CI_END="1.2763501980863041" CI_START="0.8641540726775345" EFFECT_SIZE="1.0502205586633018" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="222" LOG_CI_END="0.10596985011386865" LOG_CI_START="-0.06340881892358755" LOG_EFFECT_SIZE="0.02128051559514056" MODIFIED="2015-02-25 21:18:15 +1100" MODIFIED_BY="[Empty name]" ORDER="33801" O_E="4.95" SE="0.09949386863053564" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="621" TOTAL_2="622" VAR="101.02" WEIGHT="65.04410533771167"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="1.860198317840257" CI_END="1.1613852544648675" CI_START="0.8043029121659822" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.9664913565638977" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="233" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.06497630770970923" LOG_CI_START="-0.09458035883031042" LOG_EFFECT_SIZE="-0.014802025560300561" MODIFIED="2016-04-29 00:25:17 +1000" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.6019237184363759" P_Q="0.6385956575730631" P_Z="0.7161189538745758" Q="0.22058355188371156" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1286" TOTAL_2="1277" WEIGHT="200.0" Z="0.36365057788611865">
<NAME>Overall survival by age</NAME>
<GROUP_LABEL_1>Non-intensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Intensive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-intensive fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intensive fup</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.019594598467521512" CI_END="1.8049962408044193" CI_START="0.6502164568708726" DF="1" EFFECT_SIZE="1.0833458636839361" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.2564763017543653" LOG_CI_START="-0.1869420427793534" LOG_EFFECT_SIZE="0.034767129487505884" MODIFIED="2016-04-29 00:25:06 +1000" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.8886752414352039" P_Z="0.7585769561884401" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="148" WEIGHT="100.0" Z="0.3073500340316677">
<NAME>&lt;= 40</NAME>
<IPD_DATA CI_END="2.529133220529107" CI_START="0.5070543166695903" EFFECT_SIZE="1.1324345088797614" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.40297170614031275" LOG_CI_START="-0.2949455156837056" LOG_EFFECT_SIZE="0.054013095228303554" ORDER="33804" O_E="0.74" SE="0.40996003084539384" STUDY_ID="STD-GIVIO" TOTAL_1="63" TOTAL_2="68" VAR="5.95" WEIGHT="40.36635006784261"/>
<IPD_DATA CI_END="2.0363038521572676" CI_START="0.5427955432764812" EFFECT_SIZE="1.0513308973428372" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.30884258283429755" LOG_CI_START="-0.2653637268530846" LOG_EFFECT_SIZE="0.021739427990606467" ORDER="33805" O_E="0.44" SE="0.3372916286774424" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="61" TOTAL_2="80" VAR="8.79" WEIGHT="59.6336499321574"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.620020167489024" CI_END="1.156993516894353" CI_START="0.7804037098495245" DF="1" EFFECT_SIZE="0.9502220965943707" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="201" I2="38.272373389649466" ID="CMP-001.02.02" LOG_CI_END="0.06333092542979928" LOG_CI_START="-0.10768067474222019" LOG_EFFECT_SIZE="-0.02217487465621044" MODIFIED="2016-04-29 00:25:17 +1000" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.20308903296315417" P_Z="0.6112482408068131" STUDIES="2" TAU2="0.0" TOTAL_1="1162" TOTAL_2="1129" WEIGHT="100.0" Z="0.5082924859383151">
<NAME>&gt; 40</NAME>
<IPD_DATA CI_END="1.104983509836868" CI_START="0.6286728817952256" EFFECT_SIZE="0.8334705558478637" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="104" LOG_CI_END="0.043355796898693864" LOG_CI_START="-0.201575272814596" LOG_EFFECT_SIZE="-0.07910973795795109" ORDER="33806" O_E="-8.8" SE="0.14387372277793536" STUDY_ID="STD-GIVIO" TOTAL_1="602" TOTAL_2="587" VAR="48.31" WEIGHT="48.74873864783047"/>
<IPD_DATA CI_END="1.417157621714999" CI_START="0.817601597632525" EFFECT_SIZE="1.0764155032380818" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="97" LOG_CI_END="0.15141815683464405" LOG_CI_START="-0.08745826857639792" LOG_EFFECT_SIZE="0.03197994412912308" ORDER="33807" O_E="3.74" SE="0.14031719474382226" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="560" TOTAL_2="542" VAR="50.79" WEIGHT="51.25126135216952"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="5.559986992850671" CI_END="1.1513324812951307" CI_START="0.7960078266305468" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.9573242220715465" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="232" I2="10.071732066473043" I2_Q="49.23771690805874" ID="CMP-001.03" LOG_CI_END="0.061200757114302104" LOG_CI_START="-0.09908266210435618" LOG_EFFECT_SIZE="-0.018940952495027006" MODIFIED="2016-04-21 16:22:50 +1000" MODIFIED_BY="Melina L Willson" NO="3" P_CHI2="0.35141302706335387" P_Q="0.13946169536891673" P_Z="0.6432036248632854" Q="3.939933112105253" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1256" TOTAL_2="1253" WEIGHT="300.0" Z="0.46322426741462436">
<NAME>Overall survival by tumour size</NAME>
<GROUP_LABEL_1>Non-intensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Intensive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-intensive fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intensive fup</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.5461229400756178" CI_END="1.1694365920642418" CI_START="0.5457079011549372" DF="1" EFFECT_SIZE="0.7988559245503283" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="59" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.06797667893426511" LOG_CI_START="-0.2630397581407162" LOG_EFFECT_SIZE="-0.09753153960322555" NO="1" P_CHI2="0.45990629170459674" P_Z="0.24809956988648085" STUDIES="2" TAU2="0.0" TOTAL_1="580" TOTAL_2="576" WEIGHT="100.0" Z="1.1549777205520653">
<NAME>T1</NAME>
<IPD_DATA CI_END="1.5459257447389887" CI_START="0.5416440743875136" EFFECT_SIZE="0.9150636694137612" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.1891886296698903" LOG_CI_START="-0.2662860036942328" LOG_EFFECT_SIZE="-0.03854868701217124" ORDER="33808" O_E="-1.24" SE="0.2675480542738834" STUDY_ID="STD-GIVIO" TOTAL_1="335" TOTAL_2="322" VAR="13.97" WEIGHT="52.816635160680526"/>
<IPD_DATA CI_END="1.1950678807663253" CI_START="0.39399852396857477" EFFECT_SIZE="0.6861887357456291" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="30" LOG_CI_END="0.0773925742422958" LOG_CI_START="-0.4045054051630143" LOG_EFFECT_SIZE="-0.1635564154603593" ORDER="33809" O_E="-4.7" SE="0.28306925853614895" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="245" TOTAL_2="254" VAR="12.48" WEIGHT="47.18336483931947"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.6825108777779649" CI_END="1.1696898801288238" CI_START="0.7287419559696238" DF="1" EFFECT_SIZE="0.9232562434789996" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="143" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.06807073251411" LOG_CI_START="-0.13742622605424754" LOG_EFFECT_SIZE="-0.034677746770068775" NO="2" P_CHI2="0.4087238181312267" P_Z="0.5082978603759021" STUDIES="2" TAU2="0.0" TOTAL_1="590" TOTAL_2="596" WEIGHT="100.00000000000001" Z="0.6614904201779324">
<NAME>T2</NAME>
<IPD_DATA CI_END="1.1624503510188045" CI_START="0.6090673017448616" EFFECT_SIZE="0.8414335973250595" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="81" LOG_CI_END="0.06537441296927929" LOG_CI_START="-0.21533471531216394" LOG_EFFECT_SIZE="-0.07498015117144234" ORDER="33810" O_E="-6.35" SE="0.1648899314851148" STUDY_ID="STD-GIVIO" TOTAL_1="296" TOTAL_2="311" VAR="36.78" WEIGHT="53.59172373597553"/>
<IPD_DATA CI_END="1.4544188670956615" CI_START="0.7261669487917778" EFFECT_SIZE="1.0276920311961413" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="62" LOG_CI_END="0.162689499694166" LOG_CI_START="-0.13896352171891774" LOG_EFFECT_SIZE="0.01186298898762412" ORDER="33811" O_E="0.87" SE="0.1771924779845835" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="294" TOTAL_2="285" VAR="31.85" WEIGHT="46.40827626402449"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.39142006289183684" CI_END="2.298099411173521" CI_START="0.9058677923164925" DF="1" EFFECT_SIZE="1.4428354861603552" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="30" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.36136881146727157" LOG_CI_START="-0.04293518119415964" LOG_EFFECT_SIZE="0.15921681513655592" NO="3" P_CHI2="0.5315542734395404" P_Z="0.12266439937655571" STUDIES="2" TAU2="0.0" TOTAL_1="86" TOTAL_2="81" WEIGHT="99.99999999999999" Z="1.5436860830713754">
<NAME>T3</NAME>
<IPD_DATA CI_END="3.1444945937265056" CI_START="0.3514621778267782" EFFECT_SIZE="1.0512710963760241" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.49755085239044833" LOG_CI_START="-0.4541214042001231" LOG_EFFECT_SIZE="0.021714724095162622" ORDER="33812" O_E="0.16" SE="0.5590169943749475" STUDY_ID="STD-GIVIO" TOTAL_1="20" TOTAL_2="17" VAR="3.2" WEIGHT="18.048505358150027"/>
<IPD_DATA CI_END="2.587051299750287" CI_START="0.9251110327353501" EFFECT_SIZE="1.5470325464098411" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.412805040613559" LOG_CI_START="-0.033806139682159564" LOG_EFFECT_SIZE="0.18949945046569966" ORDER="33813" O_E="6.34" SE="0.26234161806670225" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="66" TOTAL_2="64" VAR="14.53" WEIGHT="81.95149464184996"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="8.302947854516495" CI_END="1.1416690982831599" CI_START="0.7906232140935359" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.9500684669621978" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="233" I2="63.868254352963184" I2_Q="79.3625504993343" ID="CMP-001.04" LOG_CI_END="0.05754024610425682" LOG_CI_START="-0.10203043815303486" LOG_EFFECT_SIZE="-0.02224509602438901" MODIFIED="2016-04-04 22:34:29 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.04014857063549604" P_Q="0.027717508167574567" P_Z="0.5847490122156629" Q="4.845560009572615" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1286" TOTAL_2="1277" WEIGHT="200.0" Z="0.546461115252695">
<NAME>Overall survival by lymphonodal status</NAME>
<GROUP_LABEL_1>Non-intensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Intensive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-intensive fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intensive fup</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.20926932210050042" CI_END="1.9403580276516224" CI_START="0.9392562347528852" DF="1" EFFECT_SIZE="1.3499975463402138" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="50" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.2878818717278651" LOG_CI_START="-0.027215913422110702" LOG_EFFECT_SIZE="0.13033297915287725" NO="1" P_CHI2="0.6473407184266871" P_Z="0.10493436930264503" STUDIES="2" TAU2="0.0" TOTAL_1="692" TOTAL_2="687" WEIGHT="100.0" Z="1.6213883891050809">
<NAME>N-</NAME>
<IPD_DATA CI_END="2.3816597489753066" CI_START="0.8927830674201143" EFFECT_SIZE="1.458185686475215" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.37687971697154704" LOG_CI_START="-0.049254055184883495" LOG_EFFECT_SIZE="0.16381283089333182" ORDER="33814" O_E="6.02" SE="0.2503130871608794" STUDY_ID="STD-GIVIO" TOTAL_1="374" TOTAL_2="365" VAR="15.96" WEIGHT="54.67625899280576"/>
<IPD_DATA CI_END="2.108454919915951" CI_START="0.7176701006910245" EFFECT_SIZE="1.2301118057634302" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.32396431996267266" LOG_CI_START="-0.1440751468084912" LOG_EFFECT_SIZE="0.08994458657709076" ORDER="33815" O_E="2.74" SE="0.27492869961410754" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="318" TOTAL_2="322" VAR="13.23" WEIGHT="45.32374100719424"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.248118522843381" CI_END="1.0414923689528628" CI_START="0.6801447439788618" DF="1" EFFECT_SIZE="0.8416445571839595" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="183" I2="69.2129461111965" ID="CMP-001.04.02" LOG_CI_END="0.017656092206180283" LOG_CI_START="-0.1673986537320799" LOG_EFFECT_SIZE="-0.0748712807629498" NO="2" P_CHI2="0.07150555014306259" P_Z="0.11274764481331923" STUDIES="2" TAU2="0.0" TOTAL_1="594" TOTAL_2="590" WEIGHT="100.0" Z="1.5859632567405415">
<NAME>N+</NAME>
<IPD_DATA CI_END="0.931232180637228" CI_START="0.4939553590371099" EFFECT_SIZE="0.6782235075058758" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="90" LOG_CI_END="-0.030942024498646574" LOG_CI_START="-0.306312298444538" LOG_EFFECT_SIZE="-0.1686271614715923" ORDER="33816" O_E="-14.84" SE="0.16175386202065653" STUDY_ID="STD-GIVIO" TOTAL_1="291" TOTAL_2="290" VAR="38.22" WEIGHT="45.16129032258064"/>
<IPD_DATA CI_END="1.3405612770629087" CI_START="0.7540362391782856" EFFECT_SIZE="1.0054013048253694" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="93" LOG_CI_END="0.12728667037563487" LOG_CI_START="-0.12260778132259405" LOG_EFFECT_SIZE="0.0023394445265203997" ORDER="33817" O_E="0.25" SE="0.14678923792502563" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="303" TOTAL_2="300" VAR="46.41" WEIGHT="54.83870967741935"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="1.2189031058964397" CI_END="1.1526441623682997" CI_START="0.7985066969722091" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.9593717125687049" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="233" I2="17.95902437507105" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.06169525510776555" LOG_CI_START="-0.0977214371386737" LOG_EFFECT_SIZE="-0.018013091015454064" MODIFIED="2016-04-04 22:35:04 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.26957609769933566" P_Q="1.0" P_Z="0.6578182571059847" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1286" TOTAL_2="1277" WEIGHT="100.0" Z="0.44292738913381346">
<NAME>Overall survival 5 years</NAME>
<GROUP_LABEL_1>Non-Intensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Intensive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-intensive fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intensive fup</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.123072766686305" CI_START="0.6597201604711073" EFFECT_SIZE="0.8607634668473212" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="116" LOG_CI_END="0.05040789619602126" LOG_CI_START="-0.1806402440572285" LOG_EFFECT_SIZE="-0.06511617393060365" ORDER="33802" O_E="-8.14" SE="0.1357188212914986" STUDY_ID="STD-GIVIO" TOTAL_1="665" TOTAL_2="655" VAR="54.29" WEIGHT="47.60610312171168"/>
<IPD_DATA CI_END="1.3642846038931284" CI_START="0.8216112463393466" EFFECT_SIZE="1.0587311149513907" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="117" LOG_CI_END="0.13490497809692584" LOG_CI_START="-0.08533362468135797" LOG_EFFECT_SIZE="0.02478567670778391" ORDER="33803" O_E="3.41" SE="0.12936924547063017" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="621" TOTAL_2="622" VAR="59.75" WEIGHT="52.393896878288324"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="2.0934703679873823" CI_END="0.9997755550244597" CI_START="0.7126040072611786" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.8440640182309627" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="288" I2="52.23242634375672" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-9.748615491618198E-5" LOG_CI_START="-0.14715173976422846" LOG_EFFECT_SIZE="-0.07362461295957233" MODIFIED="2016-04-21 16:23:39 +1000" MODIFIED_BY="Melina L Willson" NO="6" P_CHI2="0.1479297521948001" P_Q="1.0" P_Z="0.049697019054778975" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1286" TOTAL_2="1277" WEIGHT="100.0" Z="1.962562608489208">
<NAME>Disease-free survival</NAME>
<GROUP_LABEL_1>Non-intensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Intensive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-intensive fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intensive fup</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.2353225532728809" CI_START="0.7529533868186361" EFFECT_SIZE="0.9644378156730794" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="126" LOG_CI_END="0.0917803704025607" LOG_CI_START="-0.12323190889100803" LOG_EFFECT_SIZE="-0.01572576924422367" ORDER="33818" O_E="-2.27" SE="0.12629927718499007" STUDY_ID="STD-GIVIO" TOTAL_1="665" TOTAL_2="655" VAR="62.69" WEIGHT="46.77660050738696"/>
<IPD_DATA CI_END="0.9468359870767452" CI_START="0.5952570874155834" EFFECT_SIZE="0.7507401893648442" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="162" LOG_CI_END="-0.02372524388634798" LOG_CI_START="-0.2252954249744819" LOG_EFFECT_SIZE="-0.124510334430415" MODIFIED="2015-02-25 21:19:48 +1100" MODIFIED_BY="[Empty name]" ORDER="33819" O_E="-20.45" SE="0.1184033221596584" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="621" TOTAL_2="622" VAR="71.33" WEIGHT="53.22339949261305"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="2.527717585773542" CI_END="1.0098089134446084" CI_START="0.7194913638799878" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.8523783152992748" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="288" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.00423919983413918" LOG_CI_START="-0.14297441457209564" LOG_EFFECT_SIZE="-0.06936760736897822" MODIFIED="2016-04-29 00:25:53 +1000" MODIFIED_BY="Heather Maxwell" NO="7" P_CHI2="0.47030302593135354" P_Q="0.6626572513176012" P_Z="0.06473485625076704" Q="0.19031179052246408" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1286" TOTAL_2="1276" WEIGHT="200.0" Z="1.8470847643443837">
<NAME>Disease-free survival by age</NAME>
<GROUP_LABEL_1>Non-intensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Intensive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-intensive fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intensive fup</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.2051215205822472" CI_END="1.47400143474712" CI_START="0.5945472924462838" DF="1" EFFECT_SIZE="0.9361429175563086" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="43" I2="17.02081633088288" ID="CMP-001.07.01" LOG_CI_END="0.16849790625197017" LOG_CI_START="-0.22581359431430917" LOG_EFFECT_SIZE="-0.02865784403116954" MODIFIED="2016-04-29 00:25:37 +1000" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.27230051501546293" P_Z="0.7757259289453582" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="148" WEIGHT="100.0" Z="0.28489324858642895">
<NAME>&lt;= 40</NAME>
<IPD_DATA CI_END="2.523159320726564" CI_START="0.6271964804069593" EFFECT_SIZE="1.2579811785021726" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.401944674190917" LOG_CI_START="-0.20259638741565386" LOG_EFFECT_SIZE="0.09967414338763154" ORDER="33820" O_E="1.82" SE="0.3551104121142175" STUDY_ID="STD-GIVIO" TOTAL_1="63" TOTAL_2="68" VAR="7.93" WEIGHT="42.54291845493562"/>
<IPD_DATA CI_END="1.3690514129589177" CI_START="0.41325962212736006" EFFECT_SIZE="0.7521792802200356" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="28" LOG_CI_END="0.1364197578090043" LOG_CI_START="-0.3837770257464307" LOG_EFFECT_SIZE="-0.12367863396871316" ORDER="33821" O_E="-3.05" SE="0.3055661656760704" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="61" TOTAL_2="80" VAR="10.71" WEIGHT="57.457081545064376"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.1322842746688295" CI_END="1.0078199305034574" CI_START="0.6993508698252506" DF="1" EFFECT_SIZE="0.83953543404958" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="245" I2="11.682956094000335" ID="CMP-001.07.02" LOG_CI_END="0.0033829426505154574" LOG_CI_START="-0.15530488062449171" LOG_EFFECT_SIZE="-0.07596096898698812" MODIFIED="2016-04-29 00:25:53 +1000" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.2872886631654309" P_Z="0.06060063805760324" STUDIES="2" TAU2="0.0" TOTAL_1="1162" TOTAL_2="1128" WEIGHT="100.0" Z="1.8763980798608497">
<NAME>&gt; 40</NAME>
<IPD_DATA CI_END="1.2143793236938345" CI_START="0.714851485828305" EFFECT_SIZE="0.9317193053177066" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="111" LOG_CI_END="0.08435436421501036" LOG_CI_START="-0.1457841758000098" LOG_EFFECT_SIZE="-0.03071490579249971" ORDER="33822" O_E="-3.87" SE="0.13518451760896877" STUDY_ID="STD-GIVIO" TOTAL_1="602" TOTAL_2="587" VAR="54.72" WEIGHT="47.545399252758706"/>
<IPD_DATA CI_END="0.9830597276586985" CI_START="0.5935743782965439" EFFECT_SIZE="0.7638841971617045" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="134" LOG_CI_END="-0.007420094981114314" LOG_CI_START="-0.22652485369362071" LOG_EFFECT_SIZE="-0.11697247433736747" ORDER="33823" O_E="-16.26" SE="0.12870321985377384" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="560" TOTAL_2="541" VAR="60.37" WEIGHT="52.45460074724129"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="8.31047542770086" CI_END="1.007399768496533" CI_START="0.715769944801576" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.849156332302765" ESTIMABLE="YES" EVENTS_1="247" EVENTS_2="283" I2="39.834970411755634" I2_Q="53.91671210702613" ID="CMP-001.08" LOG_CI_END="0.0032018467195385437" LOG_CI_START="-0.1452265415996441" LOG_EFFECT_SIZE="-0.07101234744005278" MODIFIED="2016-04-21 16:26:15 +1000" MODIFIED_BY="Melina L Willson" NO="8" P_CHI2="0.13993466764334905" P_Q="0.11417951578099261" P_Z="0.06073707847535271" Q="4.339968113049789" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1256" TOTAL_2="1252" WEIGHT="300.0" Z="1.8754046313680943">
<NAME>Disease-free survival by tumour size</NAME>
<GROUP_LABEL_1>Non-intensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Intensive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-intensive fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intensive fup</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.074887716787396" CI_END="1.0011464830507886" CI_START="0.5191996363508639" DF="1" EFFECT_SIZE="0.720968022823423" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="82" I2="6.967026938517728" ID="CMP-001.08.01" LOG_CI_END="4.976260571094161E-4" LOG_CI_START="-0.28466562038886684" LOG_EFFECT_SIZE="-0.1420839971658787" NO="1" P_CHI2="0.2998444520597745" P_Z="0.05080496445415508" STUDIES="2" TAU2="0.0" TOTAL_1="580" TOTAL_2="576" WEIGHT="100.0" Z="1.9531234876537356">
<NAME>T1</NAME>
<IPD_DATA CI_END="1.3457979499324457" CI_START="0.5401766162241906" EFFECT_SIZE="0.8526245262223935" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.1289798624019625" LOG_CI_START="-0.26746421997197983" LOG_EFFECT_SIZE="-0.06924217878500873" ORDER="33824" O_E="-2.94" SE="0.23287321641631115" STUDY_ID="STD-GIVIO" TOTAL_1="335" TOTAL_2="322" VAR="18.44" WEIGHT="51.739618406285075"/>
<IPD_DATA CI_END="0.9661970669152329" CI_START="0.37547400952677945" EFFECT_SIZE="0.602313777617345" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="43" LOG_CI_END="-0.014934285235405464" LOG_CI_START="-0.42542011967114757" LOG_EFFECT_SIZE="-0.22017720245327654" ORDER="33825" O_E="-8.72" SE="0.24112141108520604" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="245" TOTAL_2="254" VAR="17.2" WEIGHT="48.260381593714925"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="2.6106088366688454" CI_END="1.0380893627928458" CI_START="0.6699873670668787" DF="1" EFFECT_SIZE="0.8339704784689399" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="174" I2="61.694759247195115" ID="CMP-001.08.02" LOG_CI_END="0.016234740889437268" LOG_CI_START="-0.1739333860527094" LOG_EFFECT_SIZE="-0.07884932258163606" NO="2" P_CHI2="0.10615104870794312" P_Z="0.10409483458418092" STUDIES="2" TAU2="0.0" TOTAL_1="590" TOTAL_2="596" WEIGHT="100.0" Z="1.6253179220974552">
<NAME>T2</NAME>
<IPD_DATA CI_END="1.3542570725561482" CI_START="0.7326307215397794" EFFECT_SIZE="0.9960774750074214" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="83" LOG_CI_END="0.13170111235160697" LOG_CI_START="-0.1351148739386627" LOG_EFFECT_SIZE="-0.0017068807935278869" ORDER="33826" O_E="-0.16" SE="0.15672903110733746" STUDY_ID="STD-GIVIO" TOTAL_1="296" TOTAL_2="311" VAR="40.71" WEIGHT="50.79860244571999"/>
<IPD_DATA CI_END="0.9485496669150759" CI_START="0.5080984945921561" EFFECT_SIZE="0.694230983034783" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="91" LOG_CI_END="-0.02293992412963946" LOG_CI_START="-0.2940520918271343" LOG_EFFECT_SIZE="-0.15849600797838684" ORDER="33827" O_E="-14.39" SE="0.15925262933238246" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="294" TOTAL_2="285" VAR="39.43" WEIGHT="49.201397554280014"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.2850107611948288" CI_END="2.2068926354462506" CI_START="0.8224093671377014" DF="1" EFFECT_SIZE="1.3472079184959553" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="27" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.34378120540114715" LOG_CI_START="-0.08491195176192289" LOG_EFFECT_SIZE="0.1294346268196121" NO="3" P_CHI2="0.5934357050116233" P_Z="0.23659622734624286" STUDIES="2" TAU2="0.0" TOTAL_1="86" TOTAL_2="80" WEIGHT="100.00000000000001" Z="1.1835374681398156">
<NAME>T3</NAME>
<IPD_DATA CI_END="5.567291270999049" CI_START="0.5703510540547645" EFFECT_SIZE="1.78194007885905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7456439434334888" LOG_CI_START="-0.2438577515047316" LOG_EFFECT_SIZE="0.25089309596437864" ORDER="33828" O_E="1.71" SE="0.5812381937190964" STUDY_ID="STD-GIVIO" TOTAL_1="20" TOTAL_2="17" VAR="2.96" WEIGHT="18.76981610653139"/>
<IPD_DATA CI_END="2.18370748997522" CI_START="0.7303719740976284" EFFECT_SIZE="1.2629009265595534" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" LOG_CI_END="0.33919446370414863" LOG_CI_START="-0.13645589994291166" LOG_EFFECT_SIZE="0.10136928188061849" ORDER="33829" O_E="2.99" SE="0.2793993781135563" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="66" TOTAL_2="63" VAR="12.81" WEIGHT="81.23018389346862"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="2.240803932622537" CI_END="0.9890264544882069" CI_START="0.7046748787291641" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.8348305797444248" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="288" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.004792091734879217" LOG_CI_START="-0.152011210585559" LOG_EFFECT_SIZE="-0.0784016511602191" MODIFIED="2016-04-21 16:26:32 +1000" MODIFIED_BY="Melina L Willson" NO="9" P_CHI2="0.5239561497636214" P_Q="0.9797802191228575" P_Z="0.036837493444735844" Q="6.423411944539001E-4" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1286" TOTAL_2="1276" WEIGHT="200.0" Z="2.0875605533050354">
<NAME>Disease-free survival by lymphonodal status</NAME>
<GROUP_LABEL_1>Non-intensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Intensive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-intensive fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intensive fup</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.9844785561031204" CI_END="1.1391433913110722" CI_START="0.6158853292331674" DF="1" EFFECT_SIZE="0.8376047412720433" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="88" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.05657839496195286" LOG_CI_START="-0.21050014094784572" LOG_EFFECT_SIZE="-0.0769608729929464" NO="1" P_CHI2="0.3210958454102404" P_Z="0.25866193310696683" STUDIES="2" TAU2="0.0" TOTAL_1="692" TOTAL_2="687" WEIGHT="100.0" Z="1.1295594291851307">
<NAME>N-</NAME>
<IPD_DATA CI_END="1.4948800901728596" CI_START="0.6347163724349798" EFFECT_SIZE="0.9740764179774567" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.17460635770071067" LOG_CI_START="-0.19742029896592453" LOG_EFFECT_SIZE="-0.01140697063260692" ORDER="33830" O_E="-0.55" SE="0.2185302996876323" STUDY_ID="STD-GIVIO" TOTAL_1="374" TOTAL_2="365" VAR="20.94" WEIGHT="51.53827221265075"/>
<IPD_DATA CI_END="1.1095592961054803" CI_START="0.4586661445165999" EFFECT_SIZE="0.7133843875900658" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="46" LOG_CI_END="0.045150516377210494" LOG_CI_START="-0.3385033152250139" LOG_EFFECT_SIZE="-0.14667639942390165" ORDER="33831" O_E="-6.65" SE="0.22536015980024166" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="318" TOTAL_2="322" VAR="19.69" WEIGHT="48.46172778734925"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.2556830353249624" CI_END="1.0213916847429956" CI_START="0.6803724155189136" DF="1" EFFECT_SIZE="0.8336226530868296" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="200" I2="20.362068143955877" ID="CMP-001.09.02" LOG_CI_END="0.009192317896912631" LOG_CI_START="-0.1672533023945189" LOG_EFFECT_SIZE="-0.07903049224880312" NO="2" P_CHI2="0.2624699092879993" P_Z="0.07913164822123285" STUDIES="2" TAU2="0.0" TOTAL_1="594" TOTAL_2="589" WEIGHT="100.0" Z="1.7557468213978462">
<NAME>N+</NAME>
<IPD_DATA CI_END="1.2852117594884833" CI_START="0.7000409063556865" EFFECT_SIZE="0.948525595316913" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="84" LOG_CI_END="0.10897469062488487" LOG_CI_START="-0.1548765815779069" LOG_EFFECT_SIZE="-0.02295094547651105" ORDER="33832" O_E="-2.2" SE="0.15498754337678153" STUDY_ID="STD-GIVIO" TOTAL_1="291" TOTAL_2="290" VAR="41.63" WEIGHT="44.72016328284456"/>
<IPD_DATA CI_END="0.986871324621858" CI_START="0.5714052990325199" EFFECT_SIZE="0.7509350866434275" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="116" LOG_CI_END="-0.005739470075793495" LOG_CI_START="-0.24305573642455366" LOG_EFFECT_SIZE="-0.12439760325017354" ORDER="33833" O_E="-14.74" SE="0.13940074958772602" STUDY_ID="STD-Rosselli-Del-Turco-1994" TOTAL_1="303" TOTAL_2="299" VAR="51.46" WEIGHT="55.27983671715544"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.049380429500936" CI_START="0.44444230235573295" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6829268292682927" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.020932960530315334" LOG_CI_START="-0.3521846112853478" LOG_EFFECT_SIZE="-0.16562582537751624" METHOD="MH" MODIFIED="2016-04-04 22:38:17 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.08185114483154013" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="126" WEIGHT="100.0" Z="1.740044839324958">
<NAME>number of metastasis detected in an asymptomatic way</NAME>
<GROUP_LABEL_1>Non-intensive</GROUP_LABEL_1>
<GROUP_LABEL_2>Intensive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-intensive fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours intensive fup</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.049380429500936" CI_START="0.444442302355733" EFFECT_SIZE="0.6829268292682927" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" LOG_CI_END="0.020932960530315334" LOG_CI_START="-0.3521846112853477" LOG_EFFECT_SIZE="-0.16562582537751624" MODIFIED="2015-02-25 21:37:03 +1100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.2191711086462884" STUDY_ID="STD-GIVIO" TOTAL_1="123" TOTAL_2="126" VAR="0.04803597486524315" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-04-04 22:39:23 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Centralised vs decentralised follow-up</NAME>
<IPD_OUTCOME CHI2="0.0" CI_END="1.7826976728856623" CI_START="0.6424061497896887" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.0701476291977272" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.25107769756103365" LOG_CI_START="-0.1921903101843215" LOG_EFFECT_SIZE="0.029443693688356077" MODIFIED="2016-04-04 22:38:50 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7945723488904918" Q="0.0" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="483" TOTAL_2="485" WEIGHT="100.0" Z="0.2603778219616477">
<NAME>Overall survival</NAME>
<GROUP_LABEL_1>Decentralised</GROUP_LABEL_1>
<GROUP_LABEL_2>Centralised</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours decentralized fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours centralised fup</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.782697672885662" CI_START="0.6424061497896887" EFFECT_SIZE="1.0701476291977272" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.2510776975610336" LOG_CI_START="-0.1921903101843215" LOG_EFFECT_SIZE="0.029443693688356077" MODIFIED="2014-11-25 00:55:33 +1100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="1.0" SE="0.2603778219616477" STUDY_ID="STD-Grunfeld-2006" TOTAL_1="483" TOTAL_2="485" VAR="14.75" WEIGHT="100.0"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="0.08106026727509781" CI_END="1.4659360749374915" CI_START="0.7627481881876793" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.0574214321440292" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.1661150324420742" LOG_CI_START="-0.11761881529621108" LOG_EFFECT_SIZE="0.024248108572931554" MODIFIED="2016-04-04 22:39:23 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7758656886022892" P_Q="1.0" P_Z="0.737625086791416" Q="0.0" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="631" TOTAL_2="633" WEIGHT="100.0" Z="0.33499999999999996">
<NAME>Disease-free survival</NAME>
<GROUP_LABEL_1>Decentralised</GROUP_LABEL_1>
<GROUP_LABEL_2>Centralised</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours decentralised fup</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours centralised fup</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.523594313640661" CI_START="0.54235308223963" EFFECT_SIZE="1.1699056176997424" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.4020195401488828" LOG_CI_START="-0.2657178873669392" LOG_EFFECT_SIZE="0.0681508263909718" MODIFIED="2015-02-25 22:23:47 +1100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="1.02" SE="0.3922322702763681" STUDY_ID="STD-Grunfeld-1996" TOTAL_1="148" TOTAL_2="148" VAR="6.5" WEIGHT="18.055555555555554"/>
<IPD_DATA CI_END="1.4835204435387888" CI_START="0.7208679569760622" EFFECT_SIZE="1.0341287885297596" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="64" LOG_CI_END="0.17129353545563206" LOG_CI_START="-0.1421442787041596" LOG_EFFECT_SIZE="0.014574628375736245" MODIFIED="2014-11-25 00:56:08 +1100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.99" SE="0.18411492357966466" STUDY_ID="STD-Grunfeld-2006" TOTAL_1="483" TOTAL_2="485" VAR="29.5" WEIGHT="81.94444444444444"/>
</IPD_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-05-02 00:44:48 +1000" MODIFIED_BY="Heather Maxwell">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-11-13 08:43:22 +1100" MODIFIED_BY="Melina L Willson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmMAAAQVCAYAAAD+Y82bAACAAElEQVR42uy9D2Qd2f///2Gttapq
iVhVVSWiIiJCRFVVlYha661Kxapaa6mKiqplRVRUlIqoiCoRsSJWqapYK0JFVFSFFRFRFSKqomqJ
WFVR5/d7Hs79njuZmTNzc9Pc5D4eXMm9M3PmnDmv12uec/7M+T/j8X//9398+OzZp9KgTvhgn3z4
VJ7tH0T+z3dsgL2+uZAXwD6xT8D2q1KMcaEBpyfwAPYJgN3t2fXlAgNOT8AB7BMA+0OMAXCzA+wT
+wRsHzEGwM0OAPsEwP4QY4DDE2wA+8Q+AdtHjAFwswPAPgGwP8QY4PAEG8A+sU9AjCHGALjZwc5Y
XFzEPrFP7BPbhzxizH/77ldffWW+/fZbc/nyZfP+/Xsq+gCW8a+//jJff/21aW5u5mYX8Ad9dK0O
Hz5srl+/bjY3N6vW/vPk+ZtvvsGHsU/sE9uHvGLM5/Pnz+bJkyfmypUrXLUDiIL333//zc0uoz8I
3eRu375tbty4QXCuokCOfWKfXE/YMzEW9/SgfV6+fGlqa2tNS0tL4fe+vj5z5MgRc+jQIdPd3V0I
DMeOHTMfP34sSu/Tp0+msbEx9py//fabTUOtcufOnTNv375NzZ//m2vpUaue0p+ZmYkNVqE8JZUn
7RqknTtvGUdHR83x48dtWlHBlKWMWc5VaeuQ7ZebnXtI0TX1KZf9J9ndiRMnzIcPH+z/q6ur9rhX
r17Z7+vr63Z71jL4v+n/sbExU1NTY8/Z1dVVlF+VVTd2tbgcPXrUTExMFB2/srJifvjhB2tfssv6
+nrz9OnTVBsL+RY3JOwT+8T2EWMBx9Y+cgj9/u7dO/vbw4cPrYDQb1tbW9Yh7t27Z7epyXxgYKAo
zcHBQWvw0XNqv6GhIZuOPkr36tWrmR3XFy5TU1Pm5MmTseUM5SmtPEnXIO3cecuo4OFEk9JU2nnL
WOr15GaXLU++T5TL/tPS+emnn2wrtfjzzz/tA5L2d9/9es17s1M3texN51W+bt68WZTX/v5+u03D
Fc6cOVN0fFNTkxkfHy/YmOxNDylJ5w/5Fjck7BP7xPYRYzHdlDJev8lb+/gtOULOon19nEhYXl62
T19uu/7qKclvoXE0NDTYpzL/CU1PRFkdV072+PHj4AUI5SmtPEnXIO3cecsYTbuUMpZ6PbnZpf++
trZmbwAS4+W2/7R01DqgG6f45ZdfTGdnp/2Ia9eu2ZtGqTe7ubm5wvf//vvP5tehll/fhubn54N1
pVbbpPOHfIsbEvaJfWL7iLFIs+133323bTBo3LFqrYke6xv82bNn7dOG0FOKWn7i0vOP8dPO6rhq
KXJPUnfu3Em9CGl5CpUnLh9p596rMpZyLm52yf6gj7pC1PWrp+Zy239aOrpp6ilfqAtpYWGhcFNS
14u6hkq92UVvPtGW2OgDWjRNddn39vbam68eAKLp54kV3JCwT+wT20eMZbjocfuEjHVyctI6pHPU
6enpRGcPOWYoP3I8na+9vd0OZC0lT6HyJF2npHPvVRlLORc3u/jfNe6lo6PD3mR2y/5D6ejhSF0x
7iancYVLS0tFLQWl3OzS7CZkQ2oROXXqlBkZGbHlUrd9Wvr79caGfWKfiDGoeDEmB97Y2Eg9To6p
5vPoQE4/PaUT7VaLTh7wcQNF41BQCpUnKU+h8oTSjZ57J2VMO1+ojKWci5td8u9qbVCrwbNnz3bN
/tPSuXTpkvn5558L3T+uK8h9z1KGqM/of/8G/u+//9rB0I62trYiG9LN1T9e+/p5jks/77XihoR9
Yp/YPmKshIrRAFA3iFIffdfMPR8NglQTenQwZHRw+4MHDwrpDA8Pm7q6uqKnIDd4XWMjFHj84/UE
pNmGIjrwPY6kPIXKE3cN0s6dp4whMZanjKWci5td+u9qgdAYEr/bpZz2n5aO6lJj/lSP4tGjR3aW
mOtiiiPkM/pf51CLhs75+++/25uqQ91Wd+/eLQyQPn/+fNHxuom72Wm6Eba2thZtV/40/sjdMLNc
K25I2Cf2ie0jxkqsmJ6eHvsUopYXOZSbZejQtGdti75ANum1D/poBs6bN28K25z4UFOyRIVEiX+8
uu80JsC9EsKJliSS8hQqT9w1SDt3njKGxFjeMuY9Fze78O/Pnz+342x2w/7T0nnx4kXRKwPcYOXX
r18nli3kM/pfN6vvv//eTg65deuWbX3wuX//vr3Jarq/Zpv5x8/Oztqbv86hBwVNLvG36+ausvgt
snl9C/vEPrFPxFhViTEAbnZcd8A+ue5AHSDGAIcn2FB2rhN1hH1SB4gxAG52Bx/W5sM+sU/A/hBj
ANzsAPvEPgHbR4wBcLMDwD4BsD/EGODwBBvAPrFPwPYRYwDc7ACwTwDsDzEGODzBBrBP7BMQY9Un
xhYXF7k6wM0OdsxBiyXVbp/cG4jN8AXFWHQacagSdlJJeuNzd3e3fauy3o6st8pPTExUlQEpj/5H
10Fvfr5+/brZ3NysKkdCjO1+fnfTn/PEEr1lXbbe3NxclvN+ifo7KPaZxwb8//PeG6pdDBwkAYMY
2wMxFv19typBQqOlpcWuWebWBNMSGlqkdmxsrKrEWNy1uX37trlx4wZPXwSbL5rfL3XT99cj3C/1
V41iDP9EwCDG9kCMRVtp3G9a/FWLrbq1EP0gGve0q/208v3MzExiBnp7e+0CrFEkyCTSfNzailrQ
VQu2alFXh4Sc1lvUtvr6ejM3N1eUt1Detc6jWubcOVdWVuxaZEpP+ytNt8isO0YCMilN0dfXZ9dI
U57V8leKkWuBWh0fSlfC7dixY+bjx49F++q6qA7izpGUPwlhtVYKLTLsrzGnxYe1fb8IgXKdO85G
QnWcZpMhe447n2xBwlwtplrIWa3Hpfqdf1wo3VA503whKZaEtmU5b5Z8V4t9huJV6FqFtueps5Bd
p8XNLHE37docJB9FjCHGElvGLl68WDBGt6hr3P6+g01NTdnFWZPQgq1ra2vBjEqwDQ0NWWPXR4vA
yol8UaeFX8Xk5KRNN0/eu7q6bLpuIdimpiYzPj5eOJ/OLafzj1HQSEpT+VPQ0bFbW1vWKbUQbSlG
7ouxtHTVpRkVtoODgzYYRc+Rls5PP/1knjx5Yv//888/bbeE9nff/eteTWIsaiOhOk6zyZA9x51P
ddnf329/0yLOZ86cKdnv/ONC6YbKGfKFtFb2tG2h84byXU32GYpXoWsV2p61zrLYdZqtZIm7adfm
IPkoYgwxluhw/lNBmoPKeZyBh/AdMQ2NI3PdmO6JpqampkjUyQGSyhLKe3R7HHqayZqmxsBE85P1
5uiQSJVzy+GzpLu8vGxbx9x2/VUrlstn1vype1jCTvzyyy+ms7PTfsS1a9fKOp5vP4mxaH2H6jjN
JkP2HHc+PX37x8zPz5fsd/5xoXRD5cwTG/JsC503lO9qss9QvApdq9D2rHVWil2HyhSNu2nX5iD5
KGIMMRZ0uJCDSvHruxzhzp07qRlQ82/ewBIn5NJEXZ68+6gJWk9OEiJyzNAx0SegaJN+XBn8Y6Mf
NXOrmVxPdFnTPXv2rH0SFHrC1FNo3vxJ1OkJVagpfWFhwYo8oaZ8dV1WoxiLs7+0ukizyZA9J53P
RzeRUv0uagtp6YbKmde/sm7Le32j+a42MZYWr7LUcdr2rHVWil1Hf8sbdw+qjyLGEGM7FmPOodTs
297ebgehJ6Gbvppzo0iA+GMF4pwmLZjsVIypdUhPTSMjI2Z6eto2Q+cRY2nCK5RHjcvq6OiwIihL
gPDRNZdgckJKeS8lf999952tFyfCNMZjaWmp8B0xFr6GaTYZsucsgX4nfhfynTy2sltirJTrW61i
LBSvSomfpYixUuza/62UuHtQfRQxhhgrixhzSFCkVaCeDlxLjs8ff/xhTp8+XfguYRFtMvanWNfV
1aV2U+bNuwZgbmxsFL67gexZ01R+/ePzGrnEqFq1nj17VvR7lnQlnNS96Qbal5K/S5cumZ9//rnQ
Pem6Kt13xFj4GqbZZMie487X1tZWdIzEcal+528LpRsq526JsdB581yPg26foXgVulah7XnqLK9d
+7+VEncPqo8ixhBjFnUfqj/cGVaegKsnG80aEdEBmlH+/fdf2xQ9PDxs/vvvP+sYGjyulpnZ2dnC
fhpMqRmRbjCl9pcjOdSsrSZg8fz5820D+POKMQka1zInh2ptbc0lxpRfN5BTH33XbJw8Rq4WMo1v
8LsFs6SrAarq4oxOGMiTP11rjY/QdRaPHj2yNhEnnKtVjIWuYZpNhuw57nzqdr57925hcPD58+dL
9jv/uFC6oXKGfCEtloQGg6edN5TvarLPULwKXavQ9qz1WYpd+7+VEncPqo8ixhBjhRu6ngLck0Ae
QaNmWAksN3XZGV8SGqiuGXyaNahjNAhSjhHFTTPWR7Na3rx5U9imVzpcvny58NJYDZzciRiTEJQQ
UnpyIA26zCPGRE9Pj33S0zVUK5ebcZPHyHUdNA4sT7p6LYW2Rbt/8+TvxYsXRa+0cANRX79+veuO
uV/EWOgaptlkyJ6Tznf//n0rkjVVX7O7SvW7aPpp6YbKGfKFtFgSaoEP2Xoo39Vin6F4leVapW3P
Wp+l2LX/Wylx96D6KGIMMQZQtQ6PPwD2CYD9IcYAo+RmB9gn9gnYPmIMgJsdAPYJgP0hxgCHJ9gA
9ol9AmIMMQbAzQ4A+wRsH/tDjAEOT7AB7JMKAOwPMQbAzQ6wT+wTsH1AjAEOT7AB7BMA+0OMQYjF
xUUuwgG52VGXgBirLF+oRp/c6zKjFypQjMW94Xm3Km6n6ezV8f46ZuU4d7U4QiXe7KJ1WYl1kTdP
WmrGLT0TRUuSabufdtInbR+9ZVzLvuTJZzTNiYmJ4D6hvB10+/xSsTjkC3qjvOq8ubl512PvQfTJ
nVx7xFgVijEtX6T1vb5UxexXMVaO61ONxr8fbnYHIfBrfwkuLQnjozUHm5qacj8IxO0jIaa1DH1B
lleMaXm0aB738iFlP7aMlTPPaWnFie/dOtdB9Mm86SHGqlyMtbe32zUK8wZVLTKthWDduly+0+oG
oLW/FLjr6+vN3Nxc5sDr/6YFWm/cuGHXItNi2Xqqjh7T19dn1w3TemPd3d1F27Ic7+OeBFWmxsZG
MzMzE/u0Xo685ylHUr4QY/nPnVSXWkQ4yZ61XevQ1dbWWjHhcGvdyc71QKMFl7Patqtz2cd3331n
hoaGttlHWp7i0tY6eloE3uePP/4wd+7cKYsYc4LMXxA5b9xQ/pQfxFi2h4WdxsC0WJ0W17LEvHLF
3oPqk2n5KaXMWeo67pogxvaBGNOK9DK4UoKqFml1hhUN0L29vbbrU0xOTtpFYksRY4ODg6a/v986
thbKPnPmTNF2LdyqQKPtW1tb1uG18G3W49OeBKempuwit3meYvLkPU850vKFGCtPy9jFixcT7Vnb
u7q6bP24hYkHBgas7+g3fVSHegDJah+q79u3bxfs4/Tp09vsIy1PcWmvrq7adEIPWzsRY3nFU9y+
asFLukkixsobA0OxOi2upW0rd+w9iD6ZNz+h9LPUdfSaIMb2gRh79eqVuXDhQslB1Q+m0e0SXzKI
UgK5/5vUvVrZHPPz80XbNZYheh5fqISOj6InCiciS2lSzpP3POVIyxdirDxiLM2e47Y3NDQU1a/+
r6mpyWwfbW1tZn19PdU+0vKUlLZuIBJfQumrizKuPFnGjO2WGJudnTVXrlxJ3IcxY+WLgVlsu5Rt
5Y69B9En8+YnlH4pdY0Yq3Axtrm5aZ3FN7xSgmrS9tATfKnpyBCj26MBW827WY+PolYnbZfRp3Wl
lCPvecqRli/EWHnEWF479esnrs5DaUYH76bZRx6BpG6O33//vdA64Z6cK6llTEiMSZTRMmZ2NQbm
te2s28odew+iT+bNT5Z7St66RoxVkBiLe7q8du2anWGVp2IqQYxFt8cZe5LhZy2n+tzVtaruHTVZ
l0uMpZU9VI60fCHG9kaM5anfnYr1PAJJ3RMao6P0JN7VdVmJYkwTh9wMT8TY7sXA3RJj5Y69B9En
8+YnlH4pdY0Yq/CWsVK6AvIYZV1dXUndlLpxRJuN/WbepaWlou0azL6xsZGY59DxaSwsLORynLx5
z1OOtHwhxvZGjKnOol0Q/pN1yD4kRDQuxfHPP/+URYwJDRRW65hssBQBlbbPTgfw+6iVVwP6EWPJ
v+80Bu6WGCt37D2IPpk3P6H0S6lrxFiFi7FSKiaPUWoAv7rWxPPnzxMH8PsD0/WkrIGm/vbx8XE7
ycANqDx//nzRdg2QdINE9dF33YiyHh9F+dTMxbibjmbDqD/eOddO856nHGn5QozlP3e0LksJ/Koj
dQm6OhseHrYPIVltOzpYOPp6mZ2IMQ301VO0uinLKcZkg7p2zhZ3Gjf0igu13iHGkn/faQwM2VGa
L6SJhXLH3oPok6H85C1zKXWNGKtyMaYge/nyZWv8GsSogZBx+zlhoRuHjFRBPpq2putr0KOm8+om
E93e09NjpyLriUPOFZ1FEjreR12Byq+bVuzfdDT2RudwTzY7zXuecqTlCzGW/9zRuiwl8As3bV0f
zZJ68+ZNLtvWzUq2oW5F2UfaU3MeMfbvv//a8/o2VMoA/qwvfU1LK3Qd4175kqXVvlJeQv0lWm53
EgNDdpTmC6FrXs7YexB9MpSfvGUupa4RY/tQjAFUixirRPQAc+zYMQwmI7/88gv2Cfgk9ocYA+Bm
VzpqMdCEDPfOID1B76eJGXuNhkJgn4BPYn+IMQBudiUzPT1tXy+j7ga97fvWrVv2BgDYJ+CT2B9i
DICbHWCf2Cdg+4AYAxyeYAPYJwD2hxgD4GYH2Cf2Cdg+IMYAhyfYAPYJgP0hxgC42QH2iX0Ctg+I
McDhCTaAfQJgf4gxgH19s8vylnetU/f06dPY4588eVJY5DouPS1zogXd/bdtO7Q8mPbRNPoom5ub
5ubNm/Z9R3pT+MmTJ01fX1/uvANiDAD7Q4wBVLwYy3KsBJfewu2jdeSamppSl2bRPlpWRUtYRfnf
//5nXyT5448/btvW2dlp/vjjD/vSSZeOXjypDwEUMQaA/SHGAKpOjGltvUePHhX9LrF0586dTOvk
qYXMR+vIueVVTpw4YdbX14u2xy0Ar9YyvYCSAFo99qk1E90aio2NjWZmZqZou1vvUPalhaK12HRa
mlFb1Vq3tbW19gWnTvRr3USlV19fb+bm5oqOV+us1mvUObu7u3PlFbB9xBgAN7sdibHV1VVz+vTp
ot/V/fj69etUMaaWrf7+fjMwMFD0u1rLfv/9d/u/FvyNdkGeOnXKLh6smyMBtHrt01+QfWpqynZX
O2RTQ0ND1sb00WLWElJ5xFhXV5c91i0yraWlHj9+bP/XckCyQ4fSHx0dLSwRpIXdZaNZ8grYPmIM
AIff0Zgx97/EmMSXUEuWuijjbnBxH7Wi+Rw/ftysrKzY/yX01DrmMz8/b29musFdvHjRtsrNzs7m
zjvsb/tUq5UTR1HU9e2Ldf2vMYZ5xJjfkuYeAlzXeJTm5uZt23zBlZZXwPYRYwA4/I5bxsSDBw8K
rVmDg4OFVoFQy9j4+Ljt8nGo1UBdSj7nz5+PHcivbiSd64cffrDCTN2lBNDqsU/ZirZJCKlL3Efd
gVH87u0sYizt+LhtUdHv5yEtr4DtI8YAcPiyiDF15Rw9etQKLN1w1KKV5QYntOCwQ8IqrjVLv6ex
uLhY1BKBjx98+3SCXF2G6hbXhI804RSyxZ2IsTjxlzWvgO1X7bXlAgPOXl4xJtSipdaxtra2zDc4
ja9x3UfqFlIXZbS7R9/1uxvIr4H6cd1FGjhNAK0uMeZYWFgo2k+D5KPdlL7oj6aph4eQrdbV1SV2
U+p8GxsbmcoTzStg+1UtxrjIgKOXV4xpELNaCNR1mEWM6XUYEm+ulUDdN9HB/A51QbqB/Jolp/3W
1tYK6aibVAOu8e3qEWMaw6VZikKD4/2WK9mHbMIN4B8eHrZiyuEPqJcduRbZtHNqAL+6G4Xeg+cP
4Nf5NBnFnU/f/e72tLwCtl/1YsxdaD589upTycEmzwB+8e+//1ox5mafxYkx/6MWLgko944yDfqP
vq/M8d9//9nWB4eEmW6uOp9a1iTQ/JaQrNecQLt/xZi6/TRQXzYgcePEjsO92kIfzaT0Xy7sBJGO
lR3p2JAYk21evnzZHqfzaiKJj2b+Hj582LbASdz5fhDKK2D7VS/GAEOlDqu3Dn/55RcMYJ+KMQDs
DzEGGCp1eABQ1xMgxgCwP8QYhgrUIWAj2Cdg+4gxwFCpQwDEGAD2hxjDUIE6BGwE+wRsHzEGGCp1
CIAYA8D+EGMYKlCHgBjDPoH4iBgDDJU6BGwEMQbYPiDGMFSgDgExBoD9IcYAQ622Ovzw4YPp7u42
tbW1hTePT0xMbDs+y5v6o8dFz501Hf+jPOmt59evXzebm5vb0teyNdpvenoa2z2AYkzLE128eLEk
my2lbOW6Dnntfqd5wda5xyHGMFTYp3UocdPS0mJGR0cLSw29evXKnDhxwoyNjeWyAe2jtKLLHeVd
FzPud+VT61veuHFj27b//e9/dtuPP/6I7R5AMdbc3GyWl5d3xWb3oky7lS9snWuHGMNQYZ/Wod5O
H7dwt25uuuHlFWOPHj2yi4GXW4wJLc6sNQh9tDbgsWPH7P+6Ga+vr2O7B0iMvXjxwly4cGHHNhv9
X0Lu+PHjhXUk3YLi0X0l9rTm5bfffmvq6+vN3NxcYdvKyopdn1LblIa2P336dEd2r/Ut1drnyuHv
m+d8WhfTrcup9V5nZmZSr7/WgVXrs9aSHRoa2pZHtwaozq3F0d++fWtFsXwv+vCla+bWmN0v/kec
QIxhqLCndXjq1CmztrZWFhtw+7S2ttpgXW4xJqJi7O7du+b333+3/2sRZ91UsN2DI8Zu3rxZ1NpV
qs1G/5eocTbqFhSP21fC7/Hjx/b/yclJe26HFr0fHx+3Dwn6SMRISO3E7ru6umxabgFyf9885/MF
prp5T548mXidJEzVsqw0379/b06fPl2UloSvzuXO+/DhQytQhYYORIXx4ODgNj/E9hFjgKFCSh36
N6HQ8VnGeonZ2Vlz5cqVsoox3XwV5HWz8lHrhloMxOrqqm0dw3YPjhiTsF9aWirZZpP+9x8W0vaV
+JIAyYpaonZi92n5ynM+iTQnIkO0tbUVtSjPz88XpaXxeK47WOj/mpoa+7+6j9U65q6R/soHo+XA
9hFjgKFCSh2q26FcNuDvIzEmUVbqTSn6OXr0qO0q2draKuynJ351mficP3++aCA/tru/xZjsMyqG
SrHZ0GD+pO0h4aduRbWedXZ2WtGSZdJAnt+jv2U9n3xD3zXeLjpsIMo333xT9F3X20/LF3xx1+Xs
2bO2dU2o5U6tjtg+IMYwVMhRh+r6UNdEFImeLONfks6hliy1auz0pqQn9o6ODrOwsLBtPwX9OOHm
3wyw3f0txuKEQCk2uxtiTN2najkbGRmxDwDqWtxNMZb3fBJu6lptb2+33ZBJRMsYFWNx18DfrnNo
/JrQWLG4Wc3YPmIMMFRIqUM9NbunWp8//vjDjh0pVYy5tDWgf6c3Jd1kJbCePXtW+E3dIOqijLaa
6Lt+d90u2O7+FmNxLWOl2GypYqyuri6xm1ID3jc2Ngrf1U2+m2Ks1PPpQSatbvXQ5Ivbf/75p2h/
CaxoN2W0NU0+p2EE0WEC2D5wZTFUyFCH//77r+3uGB4eNv/995+98Tx58sTOqnLdjKWKMc2yUjdJ
OW5KElcahKwbkLshx82oE/fv3y8MIMZ297cYk1DQGKad2mypYkxdguryE3qfnT+AXwLEtcRpXJvy
uptiLM/5lE/NqBTRCQpRogP41fUfHcD/4MGDwgB+XXeJVJ979+7ZoQT6i+0DYgxDhRLqUF2KP/30
k52pqG4hTavXjSd6fNYB/D56EWe5ZlMqTxqfItRVFZ1S79AN2p9aX0q+sZHKOLdmU2r2Xqk2u1Mx
Jhu7fPly4cWyvjCU8NMDgrZJ/GjA/G6KsTznUxel8ute3eGEWdK5NCv5yJEjVlDpekdbvtyrLfTR
TMo3b94UbddLeHVMtPuYV1sAVxZDBeowE7/88gsXoULFmN7rFZ2kAbuLBKh7d1+1+BbxETGGoQJ1
uMeoKwoq+w38i4uLVNAuoddUaBC+uiA1PlOtYGkD/g+ibxEfEWMYKlCHgBhLObfGPMUtdQXlQbMf
1c2rbkaNu7t161bRK2SwfUCMYahAHUKVizEA7A8xBhgqdQjYCPYJ2D4gxjBUoA4BMQaA/SHGMFSg
DgEbwT4B2wfEGIYK1CEgxgCwP8QYhgrUIWAj2Cdg+4AYw1BhZ3W4ublp33Kudw3pTd16w7dbSqjS
bOtLvTW/Wu290sSY3iCvNUh9tByQ9tV7sXy0n/ZPK0f0d9m+3qn1/fffW9vXi0713V//MUs6evt8
d3e3qa2tLbypXytPRI/JshKE/1FaWo/y+vXrNq9x++kN+1q/U6sE+G+/11qu0RUJ4tBSTxcvXvyi
da1rozUs9SoNLemktTOzbtd10AoA2qaYpeuu5bHylhufR4wRpKGi6rCzs9MusOwWQ9YiwLoh6VOt
dogYq4xz9/T02IXmfbq6usyZM2fsA4SP9vv9998zizHZudLp7++3YkrIB7SM0IULF1IFmZ+OxIHe
0aX1Hd1i2q9evbJiYmxsLNd1jvtd6esFrDdu3Ejcz63NeeXKlcJvy8vLNl8h9EJd7ful0LVpa2uz
a8wq3+Pj40XrfYa2//rrr3b9S7dOptbMvHTpUu5y4/OIMYI0VFQdxi0grBuAXv7oH6sbi55EtTad
bojRdSHVmqa17bRdT6s+uknpaVZP8PX19XaJm7h8rays2Cdb7ad8aV+3MHJ0X/9/rbun/dVKoDUp
Z2ZmMudNAV03OrVAaF2+tLU08fMve27ZSfRlr2p1evHiRaEVzKH9nF1lETsSYUkLzcvW094cH11I
PC4diYokUZB3zUrZqGw3tF90PUmJSl2rJLRN+0TzIGGpRcndupZ66W650MPf/fv3S96uMroHR3dt
5Lt5ys09DjFGkIaKq0M9depJ0z3VJx2rJ2h1BSn4Sdz4LRNaWFgB3C2nIkGjNP0blhY1Fupe8p90
/Xxp8W89Cbun3qGhIdv1ExJj/g1D3S7qas2at8HBQXtj1nZ186i1BDFWOeeWQHY33/X19YLtSKi/
e/fO/q96VVdjHrEjW0tq/ZIdRMVeUjrKjxYtL0dZ065/SIxFBZsYGRnZ1oLoo23R1julrQci1z0s
v4p7YPP3T+t6jSKRl7a0VWh7VIwpbkVFaKjc3OMQYwRpqLg6nJ+ft+JFAVdjR9TdMzs7u+1YvzXr
v//+K1pIWELND5DCF0S6YUW3Z7UtPZ2HxJgEmxN7UUJ5U+uFL0R1PRBjlXPun3/+2bZ8Cglpd5PV
Xwl3J/CvXbsWFAj+OaI38FArU1Je04RKOcSYhJ4eGNQanbSfe3DxuzLF0tKSHXOVhLZpn2geouP0
ymkXul56YJKYdmPd/DFfoe1qYVfXpMqs1nnZgR8jspSbexxijCANFVuHGiujoK+nYgVEv6tAx0YF
jX8T0v/Rm54fIENP1tF8qCVN3RVqnUgSYP7/Ct6u9e7OnTvb8pknbyonYqxyzq1uaidENCZKde3q
3I2RkghJ6s5OOke5xJgEQznFWPSjlkGN3/TXiozuoyEF0UH+Sa1lPsp71K/j8lZOu1BayqtaJXVu
tVzL17NulzBTvctv6+rqrB1E6ypUbu5xiDGCNOyLOlQ3gd96FHesL2KiT6Zp+6blS10makVTN4MW
L1Y3VBYx5kScWkja29vtgOed5A0xVjnnlgjRTVf4XZb6q3GAbrvfuplFjEm4R8WLQy2/GnuYJa/q
7vRnMfr59gVi3pYxdcl2dHRsm2mYt57SfC/ON/KKsbzdlBrf5deV6tEXU6HtUdQKJrvIU27ucYgx
gjRUXB3qqTquCzE6RsW/Kejp1B80qxtX2uwz3SyzdFMqTT8dzajKKsYcyqe/LZQ3zdzyg7+CO2Ks
ss6t1tqffvrJ/O9//yv6XYP29Vv01QxZxI4G3au7Kw6JKM3kzJJXtcRqTGIUzVA+ffp0yWLMCTqV
/dmzZyXVk46vtJYxCUwfnd9vXQxtj6JZpH7LWZZyc49DjBGkoeLqUF0gujG5Qcgah6GbVHSMyrlz
52wLgIKjXiHgTyfX8W4QvD76rv0d6nZ03Ut6B1DSAH4N3nWtCW7cRxYxpvTcuKLogONQ3jTu6O7d
u4UB/OfPn0eMVdi5NY5R29VlleX3LGJHN2zVtWzdiXXZgOxTgsAfp5SWjvZTd/rw8LBtUXOvmdBD
TnTsZV4xJtRCplZqPZjkrad//vknOGZMYyS/pBjT2E59/FdT+HkMbZev6/oKzb5WS3i0DKFyc49D
jBGkoSLrULMj1Xqlbgu9vkICLdrtI5GkGWsaLH/r1q1tNyu1JKhlS10Kepp3M92cwNNAXPdCTD94
+vnSzctNJlDQVVDOIsbURal03VR8J8yy5E1ofJzKrW4v3dgRY5V1btddHZ21qO95BpxHf5ddyjb0
EOBe+qou7jQhFpeO8qGWO7XGyAY1KSTtxaN5Z1MqrbNnz+auJ4nV0GzKLEK23HYhgaU44vzx9evX
mbcrduj6ujFjcRN3QuXmHocYI0jDvqxD6h8bIcbsP/SaFj2oJKEZ0n4rcbWUG/tDjBGkATEG+Dk2
tuuom1+TFEJon7T3eh3UcmN/iDGCNOy7Ogy9BgCwEWJMZaHJDVnWaNQYy+gqB9VQbuwPMUaQBuoQ
sBHsE7B9xBhgqNQhAGIMAPtDjGGoQB0CNoJ9AvERMQYYKnUIgBgDbB8QYxgqUIeAGAPA/hBjgKFS
h3vLQZpmj40QYwDbR4wBhgrBOowu8Ks3W+tt9devX09cSHk3bWi3XqOh5Ziiaxh+CfSWd7fQdRLR
lQaErv3Vq1ft9dDqAN3d3dveDK+VElRXWrtPKxxo6RyH3lyed4o/YgyIj4AYw1Bhj8RYFAkBLQtz
48aNA2NrehHk8vLyFy2L1j/UGp5pZdJSOnoLenSfX3/91dy7d69ojT5/PVAt4TQ0NFTYrvU1/bep
q6xaNgYxBoD9IcYwVNiHYkzoBq+19ny0hqXWb9TvaqmJou1qqdEiyRIKSWtJau1ItcBpHb/GxkYz
MzNT2Mf/ZDmv9tPSJ1rLLkl8vHjxwly4cGHbcaOjo3ZdQrempV6AWU4kjtz6iUlooWOtvRfdRy1i
qgO/PnRtHVrDUwtT+/gLpAuVWWVHjAFgf4gxDBX2oRgTvhjTgsISLxIFavGZmJiwLTcObVNrmra/
f//enD59OlGM+cJH3YcSFkn5CZ1X+3d1ddnt0QXAHVo0eGxsbFu51ZXnFplWfqJiJrp/3CeN6enp
1Gus1iyJ1rh9omJMC7cndeFubGxYwdrZ2Vn0+8jISK4FkxFjQHwExBiGChUixtSaMzg4aEWOQ918
vjgQvohqa2srGrM0Pz+fKMbUiqVxUlnyEzqv9neCKonW1la7Zl30PNHjdsvO49J99epVUWtddB+N
F1PXpMqucWcSVWrBi3LlyhUrmvX5559/irapzCo7YgwA+0OMYahQ4WIs+jl69KgdHK6WKIdajaL7
+eIg2mojEZEkxtQapu8SWnfu3EnNZ+i8WWxTA9yjgi7uuC8lxjQmT12qvniN7qPB+hJaKr8mAOia
pU1uUH2pyzdaB9GuZsQYAPaHGMNQoQLFmEPioKOjwywsLGzbL65VJiqasooxoXFek5OTdsyUujeT
9gudN4ttxqWRV4yV0k2ZlO61a9fMkydPcpVDrVwSyUlIOMd1s6Z1vSLGALA/xBiGChUmxtxNXWOp
nj17VvS7Wl00NikJdYdprJhDXWZpYswh4Ze2X+i8+7FlLEnYpZ1f4s0fE6auXv96a0yZXoERrcv9
0jJGnAHsDjEGGCtizEMtZBqXtbq6WvhtYGDA9Pf3F16loO/+qxSiA/ijr2vw/z916pSdUSmiA+cl
nDSWS+Iiy3mz2KaEosawVYoYy7KPrpFrPVtZWbEtiH4Z1C2pLl53XX7//Xf78ZEg3i9jxog1gL0h
xgCDRYxF0AtDz549W/RbT0+Pfb2Cxi6p9Sw6e1GzA/UKCnWnaRakP8bJP4+6KBsaGgqvlHDCTGim
pI7zj007bxbb1OB35Wc/iTEJL40rc2PGohMe1OqlCRa6Jmr9kjiL8ujRo30zmzKaDz58vsQHEGOI
MTjQdagZgMeOHauIss/NzRW1plULZ86cscIXP8e/ARBjODpUQR1qvJIG5Lv3gamlxh+Yv9do5mY1
rXupAf8qM36OfwMgxnB0qJI61AtO1a2mbjO9gf/WrVtFr8bYazQ27ccff6ya+lZZ99PalECMBsQY
4OjUIWAj2Ah1B4AYw9GBOgRsBKg7QIwBjk4dAjYC1B0AYgxHB+oQsBGg7gAxBjg6dQjYCFB3AIgx
HB2oQ8BGgLoDxBiODtQhYCNA3QEgxnB0oA4BGwHqDhBjODpQh4CNAHUHgBjD0YE6BGwEqDtAjOHo
QB0CNgLUHQBiDEcH6hCwEeoOADGGowN1CNgIUHcAiDEcHahHwDaoPwDEGI4O1CVgE0AdAmIMcHSI
r08+fNwHiNEAiDEcHQC7BsCWATEGODpg1wDYMgBiDEcHwK4BsGVAjAGODtg1ALYMgBjD0QGwawBs
GRBjgKMDdg2ALQMgxnB0AOwaAFsGxBiODoBdA2DLAIgxHB0AuwbAlgExhqMDYNcA2DIAYgxHB8Cu
AVvGlgExhqMDYNcA2DIAYgxHB8CuAVsGQIzh6ADYNQC2DIAYw9EBsGvAlgEQYzg6AHYNgC0DYgxw
dADsGrBlAMQYjg6AXQNgy4AYAxwdALsGbBkAMYajA2DXANgyIMYARwfsmg+fA/MBQIwhxgAAiB0A
gBgjoAIAsQMAEGMEVAAAYgcAIMYIqABA7AAAxBgBFQCIHQCAGAMCKgAQOwAAMUZABQBiBwAgxoCA
CgDEDgBAjBFQAYDYAQCIMSCgAgCxAwAQYwRUACB2AABiDAioAFDOmMHaiQCA5yPGAAAxBgCIMcQY
ACDIAAAxBogxAECMAQBiDDEGAIgxAECMAWIMABBjAIAYQ4wBALEDABBjQEAFAGIHACDGCKgA5bBR
Pnz4ZPsAIMYQYwDYJwA+A4gxwHEB2wTAdwAQYzgtAHYJgA8BYgxwWMAuAfAhAMQYDguAXQLgQ4AY
AxwWsEsAfAgAMYbDAmCXAPgQIMYAhwXsEgAfAkCM4bAA2OUOWVxc5CJwHfAhQIzhsABfxi6jbxv/
+uuvzeHDh83169fN5uZmVfjWX3/9Zcvd3Nxsv3/zzTf7rjx+WuVK90tdB2I7AGIMh4WqF2NRJMJu
375tbty4URW+JSH2999/f3Ef3i0xRiwjtgNijIuJw8I+F2Pi8+fP5tChQ0W/9fX1mSNHjtjfu7u7
i7Z9+vTJXL161Xz77bemvr7ezM3NFW3/7bff7HHafu7cOfP27duiPLx8+dLU1taalpaWwvklBtVK
d/ToUTMxMVGUV9ea9dVXX5nGxkYzMzOTWPaVlRXzww8/2HPrGOXv6dOnhXNnWZcwrexx+Y+7nmnl
iauH6PaxsTFTU1Nj89DV1WU+fvyYuG+WeslzXbJchzx1QmwHQIzhsIBdZrBXX4w9fPjQjI6OWlGx
tbVlxcS9e/cK23t7e83jx4/t/5OTk+bUqVOFbQMDA2ZoaMgeq4/SkkDw8yBxoW3v3r2zvw0ODpr+
/n772/v3782ZM2eK8uq3Zk1NTZmTJ08mlqOpqcmMj48Xzq+8SDglXYPo91DZ4/IfJVSeLGJM3agS
sUpDoujmzZtBMZZWL3mvS+g65KkTYjsAYgyHBewy5fe1tTUrHiQwHBICugn7+Ddb3eSj2x0NDQ22
hcZvrVELj58Hv6VMqIXJP2Z+fr4orxINTmSUglpvsoqxUNnj8h8lVJ4sYsxv1frvv//MsWPHgmIs
rV7yXpfQddhpnRDbATEGOCxUrRiLftSNpm5FtX74rR7R/fwbt7ZnucHH7R+Xt2h6EgH+fmp5ca1F
d+7cCZZf3YhqJers7LTiME0IRb+Hyp7F50PlySLGokIo6RpGWxDLdV1C1yFvnRDbARBjOCxgl5Hf
19fXTUdHh1lYWMgkqNLERmhbSIiEjnFCQl1v7e3tdsJBEhprpRaikZERMz09bbsS84ixUNlLEWNZ
rkGea1SKGMt7XULXIU+dENsBEGM4LGCXCb+rNUyDup89e1b0uwZkb2xsJKZfV1eX2B2mY6PdlP5r
E+Ly1tbWVnTM0tJSYhkkHtP8ToPm/byvrq7mEmOhsmfx+VB5omnE5dEXyf/++68tV0iMpdVL3usS
ug556oTYDoAYw2EBu0z5XS1kGgukm7NDg/DdAHR99F2zIh3q6lI3lXj+/Pm2AfwPHjwoHDs8PGxF
QloeNLD87t27hQHv58+f3zYWSrP3hAaNp7UAHT9+vDBLUCKotbU1VXRodqHGgDnxFCp7Fp8Plccf
/K4xexLE0TzqnDpWafz+++/m0qVLQTGWVi+h65L3OuSpE2I7AGIMhwXsMvC7btxnz54t+q2np8e2
pqhVS2LBnzmo1yxcvnzZ3oA19kgD1H3cqy300UzKN2/eBPNw//59O9Bfr1LQTD5/P3WH6TzqOtM5
nQiIY3Z21opL7SfBoEHmaWJMMwRVRr/1Lq3sWX0+rTxOvKg8EqoqTzSPEk7ff/+9HSh/69Yt2zoW
EmNp9RK6LnmvQ546IbYDIMZwWMAugfoD6gAQYzgsAHYJ1B91AIAYw2EBu4SKh3Ui8SFAjAEOC9gl
AD4EgBjDYQGwSwB8CBBjgMMCdgmADwEgxnBYAOwSAB8CxBjgsIBdAuBDAIgxHBYAuwTAhwAxBjgs
YJcVX04tDXTx4sU9yVv0DfdCaz3qt+jHobfcazUEwIcAMQY4LGCXB6Kczc3NZnl5+YvnS+tNah3H
aP4mJyftckVJKK8tLS0YMD4EiDHAYeGg2qV+15qCWu/Qv+n39fXZNRS1lmR3d/e2Y0ZGRuw6i999
9535888/7aLRWrPQX/Da4dal1MLTEiRafHpzc9McO3bMrp3oo0WpGxsbM+VDi1XfuHHDnvfo0aNm
YmIi1f9evHhhLly4sK0so6OjdtFst6ZiNP/loL293bx+/Xpb/rR4uBZRT0N5Vt6B2A6IMcBh4YCK
sa6uLits3KLPWsRaAkW/bW1tWZGjRaP9Y65du2a3PXv2zIqhX3/91X53C147JNKGhoZsWvoobS0U
Lq5fv263+wwODloBliUf2re/v99uf//+vTlz5kyq/928edOMjY1tK7+6AiUQRTT/cdcrrVsxDgku
XYO4erh06ZIVWxKcuo4SrlEkfJV3ILYDYgxwWDigYswJEYe68iRwfE6ePJl4jL5r7FPcuRoaGmxr
l0P/q0VNqAtOrWPuXPp74sSJQtqhfKglz097fn4+1f9aW1vN0tJSsPzl9OFXr14VtcZF0/7+++/N
H3/8USj/o0ePTG9vb9E+yrPyDsR2QIwBDgsHVIxFUctQtOVHXXhJx6R994/z03ecPXvWtn6J8fFx
20qVNR/RFiyJmTT/UzdpVNzF7V8uH1ZXrATj+vp65rSVPwm06G/qpgViOyDGAIeFKhFjcQIqq/iK
fo/r8vO3awB7fX29/V9jxaanpzPnI5R2lnLlFWN5uinVlfvkyZPc8SEkYIHYDogxwGHhgIsxiSK/
23EnYkxpRbspv/nmm6L9NXhe47/URZknH21tbUVpqzuvklrGkoSbn766bNWC5l8fJ04dGi9Hyxix
HRBjgMNCFYkxDap3A+P10XfNgixFjOlYzRZ0aQ0PD5u6urqi/TUoX7Mh/cH5WfKhbk0NjncD+M+f
Px8cM6ZxZV9KjGW53rdu3bITFlwZdQ10jXz++ecfxowR2wExBjgsVJMYEz09PXZ2n1qxNI7LzbTM
K8aEe7WFPppJ+ebNm6LtHz58sOeRoMqTD3H//n3buqTZiJp9GZpNqX0qSYzp1R6aiary6TUhEp9R
NKif2ZTEdkCMAQ4L2OW+Z25urqhlbb+gV3boXXCADwFiDHBYwC73PXpdxuLi4r7Jr8bBKc+ADwFi
DHBYwC4PBHqp648//rhv8qu8sjYlPgSIMcBhAbsEwIfwIUCM4bAA2CUAPgSIMcBhAbsEwIcAEGM4
LAB2CYAPAWIMcFjALgHwIQDEGA4LgF0C4EOAGAMcFrBLAHwIADGGwwJglwD4ECDGuJg4LGCXAPgQ
AGIMhwXALgHwIUCM4bAA2CUAPgSAGMNhAbBLAHwIEGM4LAB2CYAPASDGcFjANgEA3wHEGE4LgH0C
4DMAiDEcF6rXRvnw4ZPtA4AYQ4wBALEDABBjQEAFAGIHACDGCKgAQOwAAMQYEFABgNgBAIgxAioA
EDsAADEGBFQAIHYAAGKMgAoAxA4AQIwBARUAiB0AgBgjoAIAsQMAEGMEVAAAYgcAIMYIqABA7AAA
xBgBFQCA2AEAiDECKgAQOwAAMUZABQAgdgAAYoyACgDEDgBAjBFQAQCIHQCAGCOgAgCxAwAQYwRU
AABiBwBiDAioAEDsAADEGAEVAIgdAIAYAwIqABA7AAAxRkAFAGIHACDGgIAKAMQOAECMEVABgNgB
AIgxIKACALEDABBjBFQAIHYAAGIMCKgAQOwAAMQYARUAiB0AgBgDAioAEDsAADFGQAUAYgcAIMa4
mARUACB2AABijIAKAMQOAECMEVABAIgdAIAYI6ACALEDABBjBFQAAGIHACDGCKgAQOwAAMQYARUA
gNgBAIgxAioAEDsAADFGQAUAIHYAEAO4BARUACB2AABijIAKAMQOqNr651M9H8QYARUAiB1A3UOF
1TlWgFMBALEDqHfYw7rHEnAsACB2AHUOe2gDWAPOBQDEDqDOATGGcwEAsQOoc0CMAc4FAMQOoM4B
MYZzAQCxA6hzQIwBzgUAxA6gzgExhnMBALEDqHNAjAHOBQDEDvgCdR59W/vXX39tDh8+bK5fv242
Nzex213Ky14cjxgjoAIAsQMqVIxFkQi7ffu2uXHjBnaLGAMCKgAQO+BLizHx+fNnc+jQoaLf+vr6
zJEjR+zv3d3dRds+ffpkrl69ar799ltTX19v5ubmirb/9ttv9jhtP3funHn79m1RHl6+fGlqa2tN
S0tL4fwSg2qlO3r0qJmYmCjK619//WVb8b766ivT2NhoZmZmUsuflPcrV66Y58+fF6Xb0dERLFOR
sIlbbsj7LVSW0LXNcjxijIAKAMQOOGBiTPhi7OHDh2Z0dNQKg62tLSsI7t27V9je29trHj9+bP+f
nJw0p06dKmwbGBgwQ0ND9lh9lJZEjp+Hrq4uu+3du3f2t8HBQdPf329/e//+vTlz5kxRXiXE/v77
b/v/1NSUOXnyZGI50vKu87W2ttptHz9+tOksLy8Hy5RHjIXKErq2oeMRYwRUACB2wAETY2tra1YA
SCA5mpubrRjw8QWQhEp0u6OhocG2Mjn0f01NTVEe/JYyoRYy/5j5+fmivKoVzQmlEKG8SwypvBJA
N2/ezFSmPGIsVJZQ/kLHI8YIqABA7IB9LsaiH3WFqVtRrTQOtURF91MXob89CX+/uP3j8hZNT2LF
30+tYfouIXPnzp3Usofy7gSRBOKHDx8ylSmPGAuVJe+1jR6PGCOgAgCxA/a5GHOsr6/b8VILCwuZ
BFWaeAptC4mZ0DFC48zUfdje3m4nHOQRg1EuXrxoW8K+hBiLbi/l2iLGCKgAQOyAAyjGhFrDfvjh
B/Ps2bOi3zVIfmNjIzH9urq6xC49HRvtpvzmm29S89bW1lZ0zNLSUmIZJB7TbDqU9+HhYTtma2Rk
pKibMq1MaWJsdXW16LdQWUL5y3MtEGMEVAAgdsA+F2NCLWQasyRR4dAgfDeIXB9916xIhwa7q+tQ
aHZidAD/gwcPCsdK/EjopOVhfHzc3L17tzBo/fz580X7KX3NfBQayJ/WipWWdw3gP336dJEwev36
dbBMSZMJNN5OYtbfHipL6NqGjkeMEVABgNgBB0yMOfFx9uzZot96enrs6xXUqiXB4WY+Cs1EvHz5
shUmGrCvQeY+7tUW+mgm5Zs3b4J5uH//vh3HpVc+aJC9v5+6KHUedfHpnE6YJZGUd+XZf7WF/tf2
UJn8vDgxqLxIZCov0TKllSV0bbMcjxgjoAIAsQOoc9hHNoA14FwAQOwA6hwQYzgXABA7gDoHxBjg
XABA7ADqHBBjOBcAEDuAOgfEGOBcAEDsAOocEGM4FwAQO4A6B8QY4FwAQOwA6hwQYzgXABA7gDqv
dhYXF0vahhjDuQAAiB3wxet8N8+zW2nrjfl6g35zc3Psdn8dzWg+0rYhxnAuAIDYmBH9APeLar8v
+WtL5i1TdBtiDOcCAECMQe77hVs38ttvv7ULVL99+7bouNHRUXP8+PHCOpAh4aLjtf6k0uvo6Cha
03FlZcWuvahtSqu+vt48ffq0sN21UulcWrR7ZmYmtgxp++UpY8gf4rb7f5O2Ofr6+ux6kjp3d3c3
YgwxBgBgEGLcL4oYGBgwQ0ND5vPnz/ajRaglpPzjJJ6ceHGLYqedp62tzayvr9v0njx5Yq5du1bY
3tTUZMbHxwvn07lra2sL232xNzU1ZU6ePBlbhrT9SiljnmtXJGpStuk8ErI659bWlpmYmDD37t1D
jCHGAIC4gRjjfvH/aGhoMJ8+fSp81/81NTVFx/ktZaF7j7b5LWESIkljsRxq3XJImD1+/DhYhrT9
SinjbogxlVvl90kTjYgxxBgAIMagCu8XvhBy+C1fSV13ec4TbUl7+fKl6e3tNZ2dnVYo+ceolUvf
JWTu3LmTmHbafuUoYznEmM4R7cqMywtiDDEGAIgxqOL7RVyXY5rYKEWM+TMOx8bGzKlTp8zIyIiZ
np42796923aMxNrk5KRpb283t2/fTkw7ab9ylLEcYmwvhRdiDDEGAMQO2Cd1rsHv0S48XzyVIsaW
l5eL0jt27Fjh++HDh83Gxkbh++rqamJ6CwsLmURTdL9ylLEcYkzn9cuKGCOgAgAQO6jzbWhw+4MH
DwqD24eHh01dXd2OxNiFCxfMhw8fbHr9/f1FA/g1K9PNnlxaWjKtra1F6anVTDMlRXSyQNb9ylFG
H83A1Lg5J+j8/dO26bwqvzuvvmsmJ2KMgAoAER/iUz0f7hfxuNc+6KNZhm/evNmRGNMsQr3OQa1P
Emb+BIDZ2Vk7iF3iSYJKg/D99NT1qHFk7jUaTnBFz5u2XznK6KMZkCqLa03z90/bJnp6emxroLZr
Vqq6ZRFjiDEAwH+oc8oOVW4DWAPOBYDvAHVPuQExhnMB4DeADVBmQIwBzgWA3wA2QJkBMYZzAeA3
gA1QZkCMAc4FgN8ANkCZATGGcwHgN4ANUGZAjAHOBYDfADZAmQExhnMB4DeADVDm/cLi4uK+Th8x
hnMBVL3fRN/Wrrd6683Z169fN5ubm/j+AYqJiLHKPddOjvXXm9wNsqQ/NTVlLl68iBjDuQCgVDEW
RSLs9u3b5saNG/g+Yoz7RYWLsd0uY5b0m5ubixZKR4zhXACwQzEmtMCv1rPz6evrs2vv6ffu7u6i
bVowWGvfaQHh+vp6Mzc3V7TdrZGn7Vo02F+3T3nQmnu1tbWmpaWlcH6JQbXSHT161ExMTBTlVWvy
qRVPa/Q1NjaamZmZxLKn7ZuW77h8ha5DaLvSHB0dtQtHu/UFteBz1uND14XYma3MKysrds1E1bvq
QHXvFvLOUk956yHL+eQTzhY7OjrM/Px80Ibj1iGNs9vQ+ZP8IMs6py9evLBrcea1c8QYYgwAv8ng
T74Y0yLICq66CW1tbdmbjxYLdvT29trFj8Xk5KRdDNkxMDBghoaG7LH6KC0Ffj8PXV1ddptbUHhw
cND09/fb396/f2/OnDlTlFc/uKuLRIswJ5G2b1q+4/IVug6h7UpTN0UnRpUv5S/r8aHrQuzMVuam
piYzPj5esEnZp8RL1nrKWw9ZztfW1mbW19ft9idPnphr165lsuHoeePsNnT+kB+kcfPmTTM2NrYt
D2nXL66edmuRe8QYYgxgX4qxtbU1e7NRQHeoG0JB3Me/ISh4R7c7Ghoa7JO3/xReU1OzrVXAR0/0
/jFqJfDzqhuJu3mESNs3Ld9x+Qpdh9D2uDT9coWOD10XYmfpZVYLTtZ62kk9JJ3PbwmTDcgWsthw
nBiL5j10/pAfpNHa2mqWlpaCedgr+0OMIcYA9oUYi37U7aJuRbXM+E/m0f38YJ721OvvF7d/XN6i
6elG4e+n1gF91w3rzp07qWVP2zf0tB6Xr9B1SNsel2a0xS/PdY5eF2Jn9jKrK08tQp2dnfaBoeim
naGe8tZD3vP550iz4Tgxlvf8ef3AR12bUSEXun6IMcQYAH6T8Lu6SDRWZWFhIZOgyipq4rbluREl
7aebi7pU2tvb7YSD0I0wbt+8N6HQdQhtD92kSrnOiLH8ZVa3mlqDRkZGzPT0tO3O24kYC13fUs4X
ncWYZMNZxFjo/DsRY3E2m1eM0U2JGANAjHmoNUxjPZ49e1b0uwYNb2xsJKZfV1eX2M2hY6PdlP6N
Ji5vGj/jH6NukKQySDxmjQvRfdPyHZdm6DqEtoduUqHj81wXYmdymTXw3r/Oq6urucRY3nrIcj5/
NqLSPnbsWCYbziLGQufP6wc+tIxxUwGAMosxoRYyjVNSwHZoEL4bsKyPvmtWpEPdH+pKEc+fP982
gP/BgweFY4eHh23wT8uDBhvfvXu3MED6/PnzRfspfc0wE6HBwWn7puU7Ll+h6xDaHrpJhY4PXRdi
Z7Yya5afm00oIaVxT3nEWN56yHI+zUj88OGDTVM24A/gT7NhiSGNz3LiMC4fofOn+UE0/ShKyx/v
hhhDjAFAGcSYC8hnz54t+q2np8c+YatVS61nbqaW+Pjxo7l8+bK9SWg8SjQ4u1db6KOZlG/evAnm
4f79+3agv17zoFmG/n7qstF53LR5d6OKI23ftHwn5SvtOoS2Z7lJhdJPuy7Ezmxlnp2dtQ8cqncJ
Dw2OzyPG8tZDlvMpDaWlepcw8wfAp9mwZtvqGNfaHJeP0PnT/CCafhTNplTeEWM4FwDgN4ANUOY9
QO8k81tvK9kGsAacCwC/AWyAMh9INMuzUtewRIzhXAD4DWADlPnAo3FsP/74I2IM5wIA/AawAcoM
iDGcCwC/AWyAMgNiDOcCAPwGsAHsHhBjOBcAfgPYAGUGxBjOBQD4DRxUGwgtm4PdA2KMgAKA3wA2
8AXEWNKahtg9IMYIKAD7wm+0DMrFixe/WF7+++8/c/36dfs2fr3VW2/+/vfff7ftp7eC+8smZd0e
d3P2FzPWW+21wkC12kCSgDmon92wQe0rO9JSQUrjypUrdlmkrOlXqw0ixhBjAPhNAnpho79I8W6j
5VO0PqVbf1FLJelm5aMFyy9dupSY79B2Hy16riWGHCprS0sLNnBAylRKy9hObbCvr8/cuXOncPwf
f/xRZGOh9KvVBhFjBBQA/CaGFy9e2HXwovuOjo7axYXdWnh6qWO5+O677+wNyr/pRde90/Iqa2tr
ifkObXfoPE1NTWZzc7Pod5VZZccGDoYYy1vmndqg7EcLbvvHd3R05Eq/Gm0QMUZAAcBvEloIxsbG
tu2rbhS3ULGEmARZqa0TIT59+mRqa2uLfpuenk7Nd2i7QwsY+y0WjpGREVt2bIAyl2KDWsjdF1vu
tzzpV6MNIsYIKAD4TQytra1FT/huXyfEvoTfqYunt7e3JH8PbVer2Orq6rbfVWaVHRugzKXYYNzD
SdoDS1z61WiDiDECCgB+E4MGIEef8OP23S2/+/Dhgx38rG6ccosxjctJutmpzBpcjQ1Q5lJs0J8Q
EhJjSelXow0ixggoAPhNDHE3lbxirNRuSt2cfvrpp6JZaOUUYw8ePLADp5NIa8kgdlZHmUu1wbgu
ybjfQulXmw0ixggoAPhNDHvVMqbWAk39j+tCLJcY00y4ycnJxJswLWPVXead2GB7e7t9fYVDr8DQ
gP886VejDSLGCCgA+E0M6sabn5//omJMM8jOnj1r1tfXd+zvadtPnjxp3r17F7vtn3/+YcxYFZd5
pzaoV1v09/cXXl2hwfh61UWe9KvRBhFjBBQA/CYGzebSjMMvKcaOHTuWuVtzJ2JMXUDRVj/Ho0eP
mE1ZxWXeqQ1K5J8/f96+rkIfvTTZf6lrlvSr0QYRYwQUAPwmhrm5uW3dK9XAmTNnzMuXL7EByowN
IsaAgAKw936jN/AvLi5WzbXQKwVUZmyAMmODiDEgoABUhN/opa4//vhj1VwLlbWa16akzNggYgwI
KAD4DWADlBkQYzgXAH4D2ABlBsQY4FwA+A1gA5QZEGM4FwB+A9gAZQbEGOBcAPgNYAOUGRBjOBcA
fgPYAGUGxBjgXAD4DWADlBkQYzgXAH4D2ABlBsQY4FwA+A1gA5QZEGM4FwB+A9gAZQbEGOBcAPgN
YAOUGRBjOBcAfgPYAGUGxBgXFgDwG8AGKDMgxnAuAHwHqHvKDvuh7rEEHAsA/wHqnGsAe1jnWAFO
BVBRPsSnej6A3WP3iDHEGAAQOwBg72MAl4CACgDEDgBAjBFQAYDYAQCIMSCgAgCxAwAQYwRUACB2
AABiDAioAEDsAADEGAEVAIgdAIAYAwIqABA7AAAxRkAFAGIHACDGgIAKAMQOAECMEVABgNgBAIgx
IKACALEDABBjBFQAIHYAAGIMCKgAQOwAAMQYARUAiB0AgBgjoAIAEDsAADFGQAUAYgcAIMYIqAAA
xA4AQIwRUAGA2AEAiDECKgAAsQMAEGMEVAAgdgAAYoyACgBA7AAAxBgBFQCIHQCAGCOgAgCxAwAQ
Y0BABQBiBwAgxgioAEDsAADEGBBQAYDYAQCIMQIqABA7AAAxBgRUACB2AABijIAKAMQOAECMAQEV
AIgdAIAYI6ACALEDABBjQEAFAGIHACDGCKgAQOwAAMQYEFABgNgBAIgxAioAEDsAADFGQAUAIHYA
AGKMgAoAxA4AQIwRUAEAiB0AgBgjoAIAsQMAEGMEVAAAYgfE1j+f6vkgxgioAEDsAOoeKqzOsQKc
CgCIHUC9wx7WPZaAYwEAsQOoc9hDG8AacC4AIHYAdQ6IMZwLAIgdQJ0DYgxwLgAgdgB1DogxnAsA
iB1AnQNiDHAuACB2AHUOiDGcCwCIHUCd7xaLi4sVlc5up4kYw7kAAIgdkFrned/cHrzJB4775ptv
ylKecqWTlmbWa7Bf/AkxRkAFAGIHVKgYK+tNPpBeuWxvN2y41DQRYzgXFwEAiB2wq2IsdjmdBAGW
ll5Sy1tfX585cuSIOXTokOnu7i78fuXKFfP8+fPC97/++st0dHRkasFbWVkxP/zwg/n222/N119/
berr683Tp0+L8vLy5UtTW1trWlpaYtP00/706ZO5evWqTU9pzc3NJZY5qTyuDMrPV199ZRobG83M
zAxijIAKAMQOQIx9GTEWt/3hw4dmdHTUfP782WxtbZmJiQlz7949u+3du3emtbXVbvv48aM5efKk
WV5eznSepqYmMz4+bo/VZ2hoyAovPx9dXV12m84Tl6b/vbe31zx+/Nj+Pzk5aU6dOhW7X1p5hITY
33//bf+fmpqyZUKMEVABgNgBVS7GQuPFdlOMNTc3W+Hi4wsUiZvBwUEraG7evLkjG1ZrlH/827dv
U/Pmf5f4iuYzbr9QeSQInajbSxsgAhBQAYDYARUkxko5tlxiTC1FUSHoiyYncGpqasyHDx9y5Vvd
kGrR6uzsNA0NDcF8pokx5TNLmULlUWuYflOZ7ty5gxgjoAIAsQMQY7sjxpJa2qJpRYVXHBcvXrQt
U3nE2NjYmD1mZGTETE9P267ILyHGspRHIlFdne3t7eb27duIMQIqABA7ADGW79jV1dWytYxpEPvG
xkbi/sPDw3YMlkRVnm7Kw4cPF6WblucsYqyuri5TN2WoPD4LCwtf1BcRYwRUACB2wD4VY/6g87W1
NTtLsVQxptmIGqul2YliYGDA9Pf3Fwba6/u5c+fsNrVmnT59ukjovH79OjadKMePHy/MnlxaWrIT
AUL5jKYZHcCvLkahGZ5JA/jTyiN0nGZUCl3TtBY3xBgBFQCIHYAYKxIN6oJTC5HERKliTAPx9XJV
/wWrPT09tiVLv0noudmNly9fLnq1hf7X9qR0fGZnZ+3AeeVbAkiD5kP5jKbp76PZnMqP0tP4s/n5
+cS0ksoj1EWp43UtlZYTZogxAioAEDuAOocqsgGsAecCAGIHUOeAGMO5AIDYAdQ5IMYA5wIAYgdQ
54AYw7kAgNgB1DkgxgDnAgBiB1DngBjDuQCA2AHUOSDGAOcCAGIHUOeAGMO5AIDYAdQ5/D8WFxcR
Y4BzAQCxAyq7znd6rr0+Pi296Bv/95MvIcYIqABA7ADE2L4UY2lpI8aAgAoAxA7YcZ339fWZI0eO
mEOHDpnu7u7C71euXClaG1LrKHZ0dNj/tZj21atX7eLa9fX1Zm5uLv6mH3Ne/zctpn3jxg27luPR
o0fNxMTEtmOS8pf1+CROnDhhPnz4YP9fXV21x7169cp+X19ft9v9/Oqv/3G/PXjwwC5M7tabdIuq
I8ZwLgAAYgcE6/zhw4dmdHTUipqtrS0rZrRgttAC162trXabFsrWwtvLy8t2W29vr118W0xOTtrF
uEsRY4ODg6a/v9+e4/379+bMmTNF29Pyl+X4NH766Sfz5MkT+/+ff/5puyB1PvddYjNUHn2/ePGi
efv2rf3uFlVHjOFcAADEDshU583NzVbI+Eh0+WJIgkcC6ObNm4XfJb6ix5UixlpaWmwrm2N+fr5o
eyh/oePTGBsbM9evX7f///LLL6azs9N+xLVr16zwyyLGnBCrdP9CjBFQAYDYARVY52rFiXa/qbst
KthqamoKXXruuEw3/YAYi6Yj4RXdnpa/0PFpqJWvqanJ/t/Y2GgWFhbMsWPH7Hd1varrMosY2y/+
hRgjoAIAsQMqsM6jwisOdcOpJexLiLHo9lD+QseH+O6772z3phNhGvu1tLRU+I4YAwIqABA7YFfr
XC1CGxsbiccNDw/bMVsjIyNF3ZR1dXUldVO6gfKOtra2om5GCSF/eyh/oeNDXLp0yfz888+F7knX
Vem+I8aAgAoAxA7Y1TofGBgoDIDXR9/PnTtnt2kA/+nTp4uE0evXr+3/GsA/NTVl/9eMy6QB/P7s
wrW1NfPDDz8UbR8fHzd3794tDMA/f/580fa0/GU5PoRmQqoLVqJTPHr0yM4QlQCNK4+2aYyYE4CI
MSCgAgCxA3Zc5z09PfbVEJpNKLEkESYuX75c9GoL/a/tQrMrtV1iq6GhwQ6cjzuXm12o7ka1pun1
GNG83L9/3woivb5CEwai25Pyl/X4tLK/ePGi6JUWbgKAE53R4zWRQflwL39FjAEBFQCIHUCdB9BM
SUCM4VwAQOwA6nyPUJcqIMZwLgAgdgB1DogxnAsAgNhBnQM2gBjDuQCA2AHUOSDGcC4AIHYAdQ6I
McC5AIDYAdQ5IMZwLgAgdgB1DogxwLkAgNgB1DkgxnAuACB2AHUOiDHAuQCA2AHUOSDGcC4AIHbA
Qa9z/f7y5UtTW1trWlpaCr/39fXZtR4PHTpkuru7i45ZWVmxa0Rq0WytO1lfX2+ePn1a2K71J916
lFpcfGZmpuj43377zaar47Xotxbe9vOjRbqPHz9uj/cXGg+ljV0jxgioAEDsgH0pxrq6usznz58L
C3BrsW0JIv22tbVlJiYm7ALZjqamJjM+Pm636zM0NGTFnMMXUFNTU+bkyZOFbQMDA3Z/d6zOdfXq
1aL8SOg5geYWGs+SNiDGCKgAQOyAfSnG/JYp0dzcbIWST0j0qKXKIWH2+PHj2P0aGhrMp0+fCt/1
f01NTWp+/LynpQ2IMQIqABA7YF+KsShqfdLv/scXW0Jdm1qAu7Oz0wosPx21WOm7RN2dO3cSRZt/
vrT8ZE0bEGMEVAAgdsCBEGNxgslnbGzMnDp1yoyMjJjp6WnbvRlNR2JtcnLStLe3m9u3b8cKr1iR
EBBjaWkDYoyACgDEDjgQYkwD4zc2NhLTOnz4cNH21dXVxPQXFhaKtintaDflN998k0uMJaUNiDEC
KgAQO+BAiDENsu/v7y8Mstd3zXp0aKajmz25tLRkWltbi9JRq5lmPYroAHyl9eDBg0Law8PDpq6u
LrMYS0sbEGMEVAAgdsCBEGOip6fHtoCp1UqzG91MSzE7O2sH9EsISRxpQL2fjroRNY7MvZrCiSeH
e7WFPppJ+ebNm8xiLC1t7BoxRkAFAGIHUOeAGMO5AACIHUCdA2IM5wIAYgdQ54AYw7kAAIgdQJ0D
YgznAgBiB1DngBjDuQAAiB3UOWADiDGcCwCIHUCdA2IM5wIAYgexgzoHxBjgXABA7ADq/P9ncXHx
QF3rSi0PYoyACgDEDqjgOv/48WPRskRxRN+0Xy78tSnz2Gel2nG0PHnRqgJaXaC5uRkxRkAFAGIH
VEOdb21tmUuXLqXus7a2Zten3A3bKTXNSrXjneZLQkzrbu5mvogABFQAIHZABdW5RJbEVto+7e3t
5vXr10HbWVlZsWtZfvvtt1ZU1NfXFxYVd/nQ+pK1tbWmpaXFfvc/0bx++vTJrl+p9JTW3NxcYpn6
+vrMkSNH7JqX3d3dRdtca5PWtGxsbDQzMzOp5XDrZ+q8uj5v375NvZZ+3qPlyZN+1uMRYwRUACB2
wAGq8+np6dR97t69a4aGhjLZTlNTkxkfHzefP3+2Hx0n4eXno6ury25zi49H0/S/9/b22u5RMTk5
aRcmj9vv4cOHZnR01Karlr6JiQlz7969wna/tWlqasoudJ7EwMCAzbcrg9KWIMwixrJco1LSR4wR
UAGA2AFVUOdx+7x69cpcuHBhR7aj1ij/eL+VKSTGJL4kWEL51fiq6H6+4JIgdKIuRENDg22Rc+j/
mpqasomxUtJHjBFQAYDYAVUoxjY3N21X4vr6eq501A2pFq3Ozk4rPEJCJU2MqUUrS361X7SLzxeB
ag3TbxJtd+7cySwe4/KxUzFWSvqIMQIqABA7oArF2LVr18yTJ09ypTM2NmZbs0ZGRmz3p7oiv4QY
ixM4cSJRXZ0a/3b79u3E/eLOmacMoWtUSvqIMQIqABA7oArFWLSlKcvA8sOHD5uNjY3C99XV1R2J
Mb1uI0s3pQbl++dNY2FhIbUMSivajei/riJ6bJYy7iR9xBgBFQCIHVClYqyUfY4fP16YPbm0tGRa
W1uDQkUzCjWOzAmU6AB+dTGK58+fJw7g16D4/v7+wqB4fdcsRYeO04xKoYH8aS1uOvbBgweFtIaH
h4veweZPBtAsVM0e9fMSLU/e9BFjBFQAIHYAYqzkfWZnZ+3AeQkWCaDoi2LjjtesR7UMudYhfx+9
jPby5cs2PY0/m5+fT0yrp6fHtswpHQkkN1tTqItSx6s7U2k5YZaEe/WEPprp+ObNm8I2J+aUlkSU
0vLzEi1P3vQRYwRUACB2AHUOB9wGsAacCwCIHUCdA2IM5wIAYgdQ54AYA5wLAIgdQJ0DYgznAgBi
B1DngBgDnAsAiB1AnQNiDOcCAGIHUOeAGAOcCwCIHUCdA2IM5wIAYgdQ54AYA5wLAIgdsMt1rjfd
+0vyOLTeY561KfGb/XE8EYCACgDEDqigOt/a2jKXLl2K3WdyctIuRwSIMSCgAgCxA3apzrWgtha8
jtvn7t27dlHrLJw4ccJ8+PDB/r+6umrTe/Xqlf2+vr5utzv6+vrMkSNH7NqM3d3d2/KqtSRra2tN
S0tLpmPiSNr/ypUrdtFxh9aW7OjosP9rcW+tFanFvuvr683c3Fy8mIm5Vv5vWgD8xo0bdq3Mo0eP
momJiW3HpJUny/GIMQIqABA74IDU+fT0dOI+ajG7cOGCFQ0SBlrgOomffvrJPHnyxP7/559/2oWy
Hz58WPgukSP02+joqBUcapWT0NDi2n5eu7q67Ha32HfomChp+yvN1tZWu03ds1rYfHl52W7r7e21
i5sLtQpqsfNSxNjg4KDp7++353j//r05c+ZM0fZQeULHI8YIqABA7IADWOdx+3z//ffmjz/+sP9L
GDx69MgKljjGxsbM9evX7f+//PKL6ezstB9x7do1KzhEc3OzTctHgsjPx9u3b4u2h46JEtpfYkiC
RwLo5s2bhd8lvqLHlSLG1KKnVjbH/Px80fZQ/kLHI8YIqABA7IAqEWNRJCAk0OJQ61JTU5P9v7Gx
0SwsLJhjx47Z7+ryU9el+Prrr7dNCPjqq69S8xE6ppT9JYhqamoKXavuuExiJiDGounoukW3p+Uv
dDxijIAKAMQOqFIxJtJE0HfffWe71ZwIO378uFlaWip8Dx2flI/QMaXsf/HiRdsS9iXEWHR7KH+h
4xFjBFQAIHZAlYgxtRxtbm4WvqvrTK1cSWiM2c8//1zonnRdle67UKuZXpmRJx+hY/LuPzw8bMds
jYyMFHVT6vUepXRTugkLjra2tqJuRglSf3sof6HjEWMEVAAgdkCViLFbt27ZWX8SKPpojJWETBKa
eSkB5/bRGDPNTJTwcQwMDBQGp+uj75rRmZaP0DF59tcA/tOnTxcJo9evX9v/NR5uamrK/q8Zl0kD
+NVy9ffff9v/NRP1hx9+KNo+Pj5uZ6K6Afjnz58v2h4qT+h4xBgBFQCIHVAlYkyzDX/99Vc7M1Jd
kBIQabx48aLolRZu4LkTO46enh47O1PpSsi4WZNpeU07Js/+em+a/2oL/a/trrzaLrHV0NBg8x+X
Lwkx7aPuRrWm6fUY0Xzfv3/fClPNRNWEgej2UHlCxyPGCKgAQOwA6hz2qQ1gDTgXABA7gDoHxBjO
BQDEDqDOATEGOBcAEDuAOgfEGM4FAMQOoM4BMQY4FwAQO4A6B8QYzgUAxA6gzgExBjgXABA7gDoH
xBjOBQDEDqDOfRYXFw/sNSpX2Sr1GiHGCKgAQOyAfVjnerO83jTf3Nxsv+tt8XtNNE+5REjKdShX
2SrhGiHGCKgAQOyAA1Ln/hqMlWI70TyVS4yVq2yV6l+IMQIqABA7oALrfGVlxa6LqMW8JXLq6+vN
06dPC8ekfRxaSFzrJx46dMh0d3dvO+/Lly9NbW2taWlpyZ2HuHJE8xBXtiQBlnQd8pbtypUrRetb
qrWuo6MjMR3EGAEVAIDYQZ3H/t7U1GTGx8fN58+f7WdoaMgKp6Tjot+1gPXo6Kg9dmtry0xMTJh7
9+4V7d/V1WW3Jy3sHcpDqCzlEGN5y6aytLa22m1aXPzkyZNmeXm5ov0LMUZABQBiB+yTOv/qq68y
Cx+N25Ig8ZEw8fd/+/Zt7vz6edgrMRYqm8Ta4OCgFWg3b96seP9CjBFQAYDYARVa5+pG7O3tNZ2d
naahoSFVvES/q1sx2jWXJuZKycNeibFQ2Zxgq6mpMR8+fECM4VwAAMQOyF/nY2Nj5tSpU2ZkZMRM
T0/b7rc8YiytBSurrYXysFdiLFQ2cfHiRZt3xBjOBQBA7ICS6vzw4cNmY2Oj8H11dTWXGGtsbCw6
vhRbC+UhrxhLK0OedENlGx4etmPKJCLppsS5AACIHVBSnR8/frwwc3FpackOSk8TL5rxqDFgnz59
st8HBgZMf39/YfC9vp87dy6XrYXyECqL/6qLtbU1OzOzFDGWp2xqvTt9+nSRcHv9+nVsOogxAioA
ALEDEut8dnbWDkqXoFF32+PHj1PFiwar66Wm/otNe3p6bOuWfpMQ8mdNZrG1UB5CZZEQ07HqVqyr
q7OvmShFjOUp2+XLl4tebaH/tT0pHcQYARUAgNhBnXMRsAHEGM4FAMQOoM4BMYZzAQAQO6hzQIwB
zgUAxA6gzgExhnMBALEDqHNAjAHOBQDEDqDOATGGcwEAsQOoc0CMAc4FAMQOoM4BMYZzAQCxA6jz
imJxcZFKRIzhXABA7ADqfK/OGX2bPTaMGCOgAgCxA6jzL3hObBYxhnMBALEDDmyd9/X1mSNHjphD
hw6Z7u5u+9vm5qY5duyY+fjxY9G+Wvxai2KLlZUVux6jFsbW2pD19fWFBb+33fxjzu//lpaW9vM/
cen99ttvNv86Xot5a6Fu/zyjo6N2QXKtX+kvLI4YAwIqABA7YE/r/OHDh1aofP782WxtbZmJiQm7
0LW4fv26GRgYKNp/cHDQijfR1NRkxsfH7bH6DA0Nmdra2pLEWJ60ot+VR+3vjlWZrl69WrSvhJ4T
aG5hccQYEFABgNgBe17nzc3NVsD4nDx50v5dXl62rWNuu/6eOHGiqNUpilqeShFjedKKfm9oaLAt
dg79X1NTU7RvNM/V6AOIMQIqABA7oALrXC1E0W5AXwSdPXvWtpwJtVyphcnn5cuXpre313R2dlpR
lCTAsoixrGlFv/v59cu1EyGIGAMCKgAQO+CL1HmckPGZnJy047eExopNT08Xto2NjZlTp06ZkZER
+/u7d+9KFmN50op+j+ty3GmrHGIMCKgAQOyAL1LnElgbGxupx2rgu8aKqYvS5/Dhw0XHrq6uZhZj
0X3zpBX9rjJEuyn9V2EgxhBjBFQAIHZAxda5Br/39/cXBr/ru2Yj+mhA/9GjRwsD+32R5mY8Li0t
mdbW1kQB5c9gXFtbs92d/vZQWpolqXFfTnRFB/A/ePCgUIbh4WFTV1eHGEOMEVABgNgB+6POe3p6
bMuUWpMkktRF6PPhwwe77f3790W/z87O2sH+ElrqYnz8+HGiGHMzGNUtKqH0119/FW0PpSUhqDy4
Fq+kV1voo5mUb968QYwhxgioAEDsAOocEGM4FwAAsQOoc0CM4VwAQOwA6hwQYzgXAACxgzoHbAAx
hnMBALEDqHNAjOFcAEDsAOocEGOAcwEAsQOoc0CM4VwAQOwA6hwQY4BzAQCxA6jz3WJxcREbQIzh
XABA7IDKq/NqsQV/rcpylHs/XjfEGAEVACokZkQ/gBirxvKzHBIgxgAAMQYVI8a0ALfWc9Ri3B0d
HWZ+fr5on76+PnPkyBG77mN3d3fRNi3c7Y6tr683c3NzhW0rKyt2rUtt05qT2u4WA0/Kk/+b1q90
61k2NjaamZmZzPlKs3v3mxYX1wLlSt9fyDxL+tE1OF++fGlqa2tNS0sLYgznAgDILsiA+4V+b2tr
M+vr6+bz58/myZMn5tq1a4XtDx8+NKOjo3bb1taWmZiYsIt2O3p7e+2i3mJyctIu8u1oamoy4+Pj
9lh9hoaGrGDJKsZ8gTQ1NWUXEs+ar1D59f3ixYtWiAq3kHnW9KNirKury+4bXWQdMYYYAwBAjEFQ
jPktYRIUzc3Nhe/6X7/5+KJI4iu6PQ21QmUVYxJuTuhFCeUrixhzQixun1D6UTEWTQsxhnMBACDG
ILMYi+K3EOn/aDefL6j8feNQ951azzo7O01DQ8M2EZOWH7WG6buE0Z07d7blMS1fWcRY2j6h9EPl
QIzhXAAAiDEoWYz5Mw/TBE5IjI2NjdmWs5GRETM9PW278PKIMSfm1P3Z3t5ubt++nTlfOxVjofQR
Y4AYAwBiB5RNjC0vLxe+a0D+sWPHCt81cH5jYyMx3bq6usRuysOHDxcdu7q6mipiott9FhYWiraF
8rVTMRZKHzEGBFQAIHZA2cTYhQsXzIcPH6yo6u/vLxrAPzAwYH9zg/D1/dy5c4Xt6oJUd6J4/vx5
0QB+zVR0syeXlpZMa2tr4gD9tbU1O/PS3660NKNSRAfYh/IVRTM6Na5LYjOLGAuljxgDAipAGX2I
T/V8uF/E/66Zg3qFg7onJcyig9F7enpsK5e2SzD5MwY/fvxoLl++bIWSxoT5kwFmZ2ftoHdtk7DS
YHw/H05gqUtQLWwSXv52dVEqTffqCSfMsuQrimZCaj/XBZulizQtfcQYIMYA8B+gzik7IMZwLgB8
B6h7yg2IMS4sFwEAvwFsgDIDYgznAsBvABugzIAYI6AAAH4D2ABlBsQYzgWA3wA2QJkBMYZzAQB+
A9gAdg+IMZwLAL8BbIAyA2IM5wKACvSbxcXFikpnt9PEBijzQafS/QYxhnMBVLzflOPN7Xneyu0v
xrwTypVOWppZr8F+fBM5dv//7FxvuteyQXqj/vv37xOP1dJJ3d3dpra2tvDm/YmJiW1pb25umt9+
+818//33dj+teanvedaULLff7Wbd74YvIsYIKABVd1PajzeF3YgDpaaJGNv/dq91GJ88eWKuXLkS
u48EVktLixkdHS2s8/jq1Stz4sQJMzY2VthP286cOWPXd5R4c2lriSMtuVROQVbqA1O12RVijIAC
cCDEWGg9u6xiLKnlra+vz64ReOjQIdvy4NCNUYswO7RGX0dHR6YWvJWVFbuunlo81DpRX19fWLzZ
5UU3SLVy6CYbl6aftm6yV69etekprbm5ucQyJ5XHlcGtS9jY2GhmZmaInRVk934rj7+PFgbXotlR
JMhkPw6JsLj9hESb0inFFiTobty4YdeMPHr0qG2RS/K70L5x10IiUwucu/Uw3ULmDrXsyZ5l/1o4
3K3juR/WQUWMEVAAEGOBtLRYs24EuoFsbW3ZG4cWNxZaoLi1tdVu08LMWnx5eXk503mamprM+Pi4
PVafoaEhK7z8fHR1ddltbiHkaJrRm7EWfBaTk5N2Aei4/dLKI/wb3dTUlC0TsbMy7F51JsERt4/q
e21tLXg+2V1S65e6QNW1WYotDA4OWqGnPCodtb4l+V1o37hroQcXJ7DcQuYOiUv5j/Ml2bgeTGgZ
46bCRQAo400pNF5sN8VYc3OzDfA+/k1JgV83Fwmamzdv7igO6KnfP97dfJLSjN6Mo/mM2y9UHglC
J+qInZUjxpxgV4tS3D6+OEkjNH7K357HFtT65rpHxfz8fKLfhfaNuxZpviAB6aen/2tqahBj3FS4
nAD/X3v3H6FV/vcP/I+1VpJERpK1IskYYwxJsjKWccvqj7X/5JZ1u8VYWeMj+89IMsaSJFkrMrIy
PiLrY2QlVrLG+IgkY6xEMpJkybglI+f7fb3v75nvuc5c13WuM9PUTPN4cKlrrnOd65xr3j+ec877
nPdqHiHoZJl3FcaikysHwWJoygNONP75GJxOtztOQ8YRrWPHjqUOpWo724Wxdp1xebl2+xNHQOJn
sU9nzpzRdq6RP0K2bduWDQ0NpbFhzd4bp+fedRirUxbK5S/CY6vyXLVs3fpdro/lzxDGdCrAGg1j
rY60ldfVrKEvO3LkSDoyVSeMxficeM+VK1ey27dvp1OR7yOMdbI/ERLjVOfg4GB26tQpbec6KPdx
+rF4pWUuTkUXxyJGsCoGuqL/+Z//SWPDllMWmpW/TsNY1f5W1YU6ny2MqVzAewpjT548eWdHxqJz
aneF2c8//5zGYEWoqnOaMgYvF9fbbps7CWN79uzp6DRl1f4UPXjw4L22Z8LY8st9HLmKclj266+/
ZgcPHlx8HuOrLl682HR9EdpGRkaWVRYOHDjQcKpwZmamZXmuWrZuGIsyXT5N2epCB2FM5QJWqVMq
DjSOQcwx2He5YSxO98T4lLxxj84rH2wcj3geV2uFOJpV7OiiU/jrr7+arqcsrgzLj1hEZxQXAlRt
Z3md5QH8cVopxBWerQbwt9ufEO+Lq+hCeaC0tnPthrG///47neqOPw7iCFd+K4w4vXn37t3F5eJI
2cDAQApkeSiPZaPMxJXAsZ7llIW4GGV0dHRxUH58RqvyXLVs3TCWB8y8TMd3EH+ctKo3wpgwBqxC
p5R3FHEKLhrh6ECWG8ZiIH78VV38yzqOFsSRrPhZBL386sa4CWfx1hbx/3i91XqKooOMgfOx3dHp
xUDpqu0sr7O4TFzNGduT3+wzBkW3Wler/QlxWiren99CIO+MtZ1rO4zlf4j853/+Z7riMn5/MVC+
WD6LZSXKQPxBkN/0NU5BFoPYcsrCuXPn0tjJuG1KXNjSrjy3W7ZuGAv5rS3iEVdSPnr0qG2dFsaE
MUC9QRlQ7hHGVC5Qb1AG7DPCmMoFqDcIYyj3wpjKBeoNyoB9RhhTuUC9QRmwzwhjqFyg3qAM2GeE
MZUL1BuUAfuMMIbKBeoNyoB9RhhTuUC9QRmwz8v28OHDdbluYQwNCqg3a2Lf467ncffzmOBZGbDP
y1HnzvN1t6e87vU0D+RaWZ8wpkEB9WaN73tx3k1lwD6v9mfU3Z52k9f7/QljGhT4SOrN48eP0/yJ
MdlvBJO9e/cuTrAd8iNHMX9eTNR9586djl4LZ8+eTXPjxXx2w8PDDa+t1npjIuPvv/8+zQ25c+fO
bGJiou38hMVHLp+HL76TmOQ7JkEuvifmFOzq6kpzE2o71+c+x8+vXLmS5m+Myb7/+c9/pgmxo9yU
A3q7OtKsDMWE2TF/Yywfy05NTTV8bky6HfNW5nNStvpjoNm6O3l/u/rR7DOaledm65ifn0/zbMbc
m0Wxv1FPm33frbbliy++yF6+fJn+/+TJk/S+f//73+n58+fP0+shtqvTdkEY06DAuq03vb292bVr
11KIicelS5caGsBiY3/r1q00+XYnr8XkxOPj42mdCwsLKRTFhMKrvd4LFy5kY2Nj6fUXL15khw4d
qjVJcnTI8R3k30d8XnSsxeVPnjyZXitOAK7tXH9h7Lvvvktl6F//+lcKYSdOnEjPo+xFGey0jpQ/
4/Tp02li+jA5OZkmqi8ue+TIkcWAX/6sTo6MtXt/Vf1otv5yeW63jqGhoVRHiqLORegqb2+79cSE
6zdu3Ej/jyAcp2Nj+fx5Xuf+67/+q6N2QRjToMBHV2/iL89cdDp5x1LW7rUYgxWNcFGx8Vyt9cZf
9/GXeu7evXu1wlh3d3fD++P/cfSkuHzxSJm2c/2GsfIRz1evXnX8XRXrSHnZCF/lMtqu/NQpn1Xv
r6ofnWxPu3XMzs6mo2P56/FvHMXK19Hptly9ejUFu/Df//3f2bFjx9IjREiO4FanXRDGNCiw7utN
nKaIv+ajMYwwUlw2/gKN59GwnjlzpuF97V6Lv2LLp1mKHdhqrbd8lCE6gzqdXXFdzda5ntsfYax9
yGn3vF0dKS9b50jXcsJYu2Wq6kcnn121ji+//DId8QpxxDBO4dbdlgh1ccQxxCnHBw8epJAX4tRu
nLosa9cuCGMaFFjX9Sb+Qo2/5GP8zO3bt9OpimYdUZxuGRwczE6dOtXRa+06gNVcb7OOsE5nV/V+
YWzjhbGqOrKWwlgn9a5qfVXriHoZgSkPUvGdLGdbYqxeDCXIQ1iMg5uZmVl8XrfNEMY0KLBu602M
lSmenskH0zYTf712+lo00sX1tvMu13vgwIGG04zRuNfp7GL95dOUxdsLCGNrb5/q/H6XE8aq6kj5
vXv27Gl7mnI1w1idetdqfZ2sI4JTjBXLB9ovZ1u++eabNCYsPz2Zn6rMny+3zRDGNCiw7upNNKr5
lWERXPbv39+wbBwRiKuYQnmwcLvXYpBvPpA+HvE8rkxc7fXGaZPR0dHFAfwDAwO1B/DH1Wr5+n/+
+efUuQpjazuMtboy9l2Esao6EldNxpipPMTH6cw4pRb++OOPJQP46/xeyuuuen9V/ejksztZRwzE
j6uVyxcH1NmWqGcxHjPqWLh8+XLa3/wUaFm7dkEY06DAuq43d+/eTYNqo2GLxi4GyBaXjdMCMUYm
v4w+bwyrXgsjIyPpqEIcWYpxJcWrD1drveHcuXOpkY9L6uMKrbpHTvJbW8Qjrup69OjRRxXGWgWY
j/Wx0jBWVUcikERZzI+gxq0fvv3227R8lOO4iGS5Yay87k7eX1U/OvnsqnXEbSnitfiDZ7nb8uef
fzbc0iK/2Oavv/5quk1V7YIwJoyBeoMysI6OjLExy73SoEEB9QZlYJXCmHKPMKZBAfUGZcA+I4yp
XIB6gzKg3COMqVyg3qAM2GeEMZULUG9QBpR7hDGVC9QblAH7jDCmcgHqDcIYyr3SoHKBerMCDx8+
9EvUdir36pswpnLBxqs3y72BZp33tVq2+P/i/JDLEdPTHDly5L1/73E39uJ0SrmYs6/dzUrjbuUx
lY62U7n/EN/Vu/jctVLehDFhDD6qTul9fHan09fU1dfXl83Ozr7X73xhYSFNhtxs2ycnJ9OUOa3E
tvb392s7lXv9rDAmjMFGqDdnz55N8zjGXIzDw8Md/6Uf74t557Zt25ZdunSp7V/6MdlxzPMYEwH/
x3/8R8v5+pr9v3z0qLe3t2nw2bVrVzY/P7/ktZgD76uvvlqyXzEhcUwCnc91F5MPv0sxKfLTp0+b
fvcxmXlMlNxObHNsu7ZTuV9OuY/JxfPP3rt3bzY1NdXwGTHXY1dX12Lob/W5nX5frdYXHj9+nI72
xrZEXYvtySdfF8aEMdjw9SYm0o5Q8vbt29SwT0xMpMmJqzqMeM+pU6fS+2Ky4IMHD7btXA4cOJA9
f/48LX/jxo3su+++67hTKv9/YGAgu3PnTsN+xPacOHGi6T7+8MMP2dWrV5d8H9E5RGcZIohFJ9Hu
++t0Eurc7du3W373ccQswlZ0btGxx+TkZVeuXEnbru1U7pdT7k+fPp0mNQ9xJDYmOS+u9+TJk2m7
8sm72wXQTr6vduuLIHnt2rX0ejwixEZwE8aEMVBvsv89fReNY9Hu3bsrO4a8k8nFX/ztOpTiEYH4
vPjc5XZK0bEMDg42bHP8NX7//v2m+7h///5sZmZmyfeRB7HVbluarXfHjh3Zr7/+uvh9XL58OXWe
RbHNse3aTuV+OeU+wld5Hzst/+XvrZPvq259iiPSwpgwBurN/xVHg8pHe4qNZKcDi6Oh7qRDKX7u
cjulEKcX8zFg0eG1G18Vp0bKHUmzbXqfYawsti8CWvlncUpI26ncL6fcVx3pbRtaSq/X+b5a/SxO
Y8YfHMeOHcu6u7vfW3kUxoQxWPP1puqv01YNdLmhr9spFTu15XRKMeZqaGgo/T/GxcSRpTp/gdcN
Y8s5TVm3zWq2ne06VG2nct+u3L/LMFbn+2r2sxgmEEfq4tR7nL6PU5nCmDAG6s3/09PTk26zULdT
itNnMWYmF6dK2nUoxSsZY2BxDDpeSacUnx1HvOKUUYy7iltItLIWj4xt3769YdB1fCcxqLkoxuY4
MqbcL7fcxy1V2p2mrBPG6nxfzX4W4yKL73/y5IkwJoyBepM7f/58NjY2tjiwNp7HVYBVDXR5IHO8
p12HEoPVX758mZaPz6s7kDk6oBiTEh1aLo4MHD16NA0cbic60OLYnbUQxv7xj3+kq9Py7z0GQ//8
888Ny0RHb8yYcr/cch+nBOP+eiHuWVcewN/uuyp/bp3vq9nP4vRqfvVkPhZSGBPGQL0pGBkZSX+5
ximUuMIwvxqq6q/lOGUSf53v3LkzXW3V7hRMvB7LxjLRQRUH+3bSKUVYifcWPyMu1Y9lqu4WHlck
xuevpTAWRzTiKrjYn7hFQnR0ZXEKytWUyv1yy32UsbiXXZyujDFarW6r0enndvp9NfvZ3bt304D/
2JYIhXGVpzAmjIF6845Fw188BfM+RGcQf3FXic6r+Ff8enHo0KE06Fnbqdwvp9wjjAlj8JHXmxjz
FJfa5/cdivtkxemb9yU+N/5SP3PmTEfLx6X562m+vTiVU7wNgrZTuV9OuUcYE8bgI643cUVUXFaf
n2aLMVDROb0vMaYlTvu0G8BcFDd1jXE260Vsq7kplfuVlnuEMWEM1BuUAfuMMKZyAeoNwhjKvTCm
coF6gzJgnxHGVC5Qb1AG7DPCGCoXqDcoA/YZYUzlAvUGZcA+I4yhcoF6gzJgnxHGVC5Qb1AG7DPC
GCoXqDcoA/YZYUzlAvUGZcA+I4yhcoF6gzJgnxHGVC5Qb1AG7DPCGCoXqDcoA/YZYUzlAnUHv3v7
znr+3SsJKhaoP/id+w74gL9zpUClgjVVhzw2zgPlXrkXxoQxQNsBfPg2wFegQQW0HYAwpkEFtB2A
MIYGFdB2AMKYBhXQdgDCGBpUQNsBCGMaVEDbAQhjaFABbQcgjGlQAW0HIIyhQQW0HYAwpkEFtB2A
MIYGFdB2AMKYBhXQdgDCGBpUQNsBCGMaVEDbAQhjGlQAbQcgjGlQAW0HIIxpUAG0HYAwpkEFtB2A
MKZBBdB2AMKYBhXQdgDCmAYVQNsBCGMaVEDbAQhjGlRA2wEIY2hQAW0HIIxpUAFtByCMoUEFtB2A
MKZBBbQdgDCGBhXQdgDCmAYV0HYAwhgaVEDbAQhjGlRA2wEIY2hQgRW3GeUHIIwhjAHCGCCMCWPA
xgtkgDCGMAYIY4AwJowBwhggjCGMAcIYIIwJY4C2AxDG0KAC2g5AGNOgwkaoQx4b5wEIY8IYqD/4
nYMwpmEB1B2/exDG0KiAeoMyAMKYBgXUG5QBEMbQoIB6gzIAwpgGBdQblAEQxtCggHqDMgDCmAYF
1BuUARDG0KDAOq03Dx8+9EVrO0EY06AAy6k3r1+/zvbs2bOiz/jss88+WP2+efNm9umnn2Z9fX1+
2dpOEMY0KLC+6s3CwkL2zTffrLhuvYu6udx1RBD7/fff/aK1nSCMaVBg/dWbw4cPZ0+fPu2obuVH
oD755JOsp6cnu3PnzuL6y/MhNltf8Wdv377Nvv/++2zLli3Zzp07s4mJifT6o0ePst7e3qahcdeu
Xdn8/PySdTabi/HHH3/MNm/enG3atCnt49zcXMN7pqens66urqy/v1/bCcIYGhT4cPXm9u3bHdet
4hGoW7duZbt37275GVVh7MKFC9nY2FgKZS9evMgOHTq0+PrAwMBi0MuNj49nJ06c6Gj/zp8/n126
dCmtOx6//PJLdvz48YblT548mV579uyZthOEMTQo8OHrTSfLxJGk69evd/T+qjAWR6TevHmz+Pze
vXuLr09OTmaDg4MN743l79+/39Fnd3d3N6w7/r99+/aG5YtHypQBEMbQoMC6CGNxNCyWi4HyZ86c
WVEYi6NsRXGUqvj6559/ns3Ozi4GtXanE8ufFadRy4qftxHbEW0nwhgaFPgIwliIsVb5katTp069
szBWfn10dDQbGhpK/49TjJcvX+5426vWLYyBMIYGBdZtGMs9ePCgbcApP3/y5EnDzw4cONBwKnFm
Zqbh9RhHFoPvnz9/nm3dujXdfqPTbY+LC8qnKYu33hDGQBhDgwLrMozt27cvXVEZYiB/8QhUBKcY
h5WHoOJg/7ha8+uvv274jGvXrqWjX/kA/hi0X96GOCJ29OjRNNi+zrbHAP6LFy8uDuD/+eefG+6j
JoyBMIYGBdZlGItTlDE4PsZkRdjKg1n46aef0tGn/AhUHtZi2QhCsWz5M86dO5cG1seRr7jisfz6
1NRU+lnV3f2bbXt+a4t4RKiLW2YIYyCMoUEB9aaGuO1EDORH2wnCmAYF1Jv3LE4vjoyMLLlqE20n
CGMaFFBv3oMYg/bVV1+1HbiPthOEMQ0KqDcoAyCMaVAA9QZlAIQxDQqoNygDIIxpUAD1BmUAhDEN
Cqg3KAMgjGlQgLVZb6pu4rrS5dF2gjCmQQH1Jms9OXdxnshOlJdfT+3AWtlWbSfCGBoU2OBhbCXb
s57rvTAGwphOBWhbb2IOxy1btmRdXV3Z1atXWx7Navazx48fpwnA4watMQ/l3r17s99++63psvn/
49/io2o9zZaPf+fn57Ndu3YtuSlsTFTe09Oz+Pzs2bNp7suYo3J4eLjt99TJ/oyPj6cpmvL5OfPJ
0EPMGvD999+n73Pnzp3ZxMSEMAbCmDAGtK43Fy5cyEZHR1OIiHkg+/v7a4Wx3t7e7Nq1a+n98bh0
6VIKde3CWLP11llP8fnQ0FB2/vz5JfsUASzE5OMRnmKdCwsLKRzFhOatdLIdEdbm5ubS83wy9OJn
j42Npfe+ePEiO3TokDAGwpgwBrSuN319fQ1HlqampmqFsWbiiFHdMFZnPcXns7Oz6ehYhJ8Q/37x
xReLYSn2L38tt3v37lrfXXk78nU327YIs3FkLnfv3j1hDIQxYQxoXW+KR3XyMFM3jE1PT2enT5/O
jh07lnV3d3cUwJqtt9P1lJ9/+eWX6ehXiKNaceSquH/l05zFcNVMne0o/6zq+9R2gjAmjIF60zaM
dRKaij+LMWb79u3Lrly5kt2+fTud6lxOGKuznvLzycnJNLYrxFixeH+uKniV1d2OqjC2ltosbSfC
GBoUWIP15uDBg9nff/+9+HxmZqZt+Hjy5EnDz2Kg+qtXr1q+3mkYq7OeZs9jQH2M14pTlEURzorr
rVJ3O8o/O3DgQMNpyvL3qe0EYUwYA/WmwY0bN9LVlPmA84GBgSVHevKrBZ8+fZpOARZfjxCUX20Y
wWP//v0dBbC4WjHGXuXBpWo95eXL+xOD8uPqxfLg/Bjcnw+oj0c8P3z4cMvvqc7+NPtZnCbNL4ho
9n1qO0EYE8ZAvVkirjiMKwZ37NiRgkhx2fxqwTjdt2fPnuzmzZsNr9+9ezcNiI9l4vTe9evXOwpj
EZriRq75zVyr1lNevrw/L1++TK9FACobGRlJR7zi9QiTceqxlTr70+pn586dy7Zv355upxHfrTAG
wpgwBtSqN+qYMgDCGBoUEMbQdoIwpkGBjVlv6s4bibYThDENCqDeoAyAMKZBAfUGZQCEMQ0KoN6g
DIAwpkEB9QZlAIQxDQqg3qAMgDCmQQH1ppWHDx8u67V3sbwyAMIYGhTY8PWmfBuN4nbWvcVGu3Xh
+wA1QIMC6k3N7aq7zdoG3w8IYxoUWJf1JiYKj7kbY37Kq1ev1pqL8fHjx2m+x5jIO+Zz3Lt37+JE
2/my4+PjaQLumN+yOPF4vFZ8FNfd7LV2n9VqXfPz89muXbuy169fN+xDTDje09Oz+Pzs2bNpLsnN
mzdnw8PD2k4QxtCgwPupNxcuXMhGR0ezt2/fpgm0+/v7a4Wx3t7e7Nq1a+n98bh06VIKdcVlI0DN
zc2l5/nE463W3+6zO/msZusaGhrKzp8/v2S/I4CFmMw7AmOsc2FhIZuYmEgTk2s7QRhDgwKrXm/6
+voajhpNTU3VCmPNxBGw4rJ5EOskcFV9dtVnNVvX7OxsOjoWYSvEv1988cXidsV3kL+W2717t7YT
hDE0KLD69aZ4lCoPKnXD2PT0dHb69Ons2LFjWXd3d6331w1jdT6r+PzLL79MR79CHF2Lo3XF76B8
mrMY8rSdIIyhQYH3FsY6CUTFn8UYs3379mVXrlzJbt++nU51rlYYq/tZxeeTk5NpjFmIsWLx/tzH
GLy0nSCMaVBgndSbgwcPZn///ffi85mZmbYB58mTJw0/i4H/r169avn6uwxjdT+r/DwuIoixYnGK
sijCWXG92k4QxtCgwHurNzdu3EhXU8bpyRcvXmQDAwMNyxavfnz69Gk6vVd8PQJOfkVjBLn9+/fX
CmNxZWSM3YqrG6teq/qsdusKMSh/586dSwbnx+D+sbGxxQsD4vnhw4e1nSCMoUGB91Nv4mrCuCpx
x44dKewUl82vfoxTeXv27Mlu3rzZ8Prdu3fTYPdYJk4hXr9+vVYYi2AUN2vNb9ja7rWqz2q3rvDy
5cv0WoTOspGRkXTkLV6PwBmnQLWdIIyhQYEPUm/UMWUAhDE0KCCMoe0EYUyDAhuz3tSdExJtJwhj
GhRAvUEZAGFMgwLqDcoACGMaFEC9QRkAYUyDAuoNygAIYxoUQL1BGQBhTIMCG6/ePHz40Jeu7QRh
TIMCfKh6U749xmp+vjbB9wTCmAYF1JuKz1NvtZ0gjGlQQDrociIAAB0YSURBVL1pIuaazOee7Onp
ye7cuZM9evQo6+3tXbLswsJCtmvXrmx+fj6tb3x8PE3eHe8tTigerxUf+c8uXrzYdPnc2bNns61b
t2abN2/OhoeHK7ez2b61W04Z0HYijKFBgTVXb4qh6NatW2ki7jAwMLAkyET4OnHixOL6YkLtubm5
9DyfULzV58XzI0eOtFw+JiuP9b99+zaFvomJiTTxd9V2lj+r3XLKgLYTYQwNCqy5etPV1ZVdv359
yc8nJyezwcHBhp/19/dn9+/fX1xfHqyafUazMNZu+b6+vhTEiopBqtV2ltfTbjllQNuJMIYGBdZc
vYmjR/FahKEzZ840vBanFGdnZ9P/7927l8JYu/VVhbF2y8cRrfLpzTjV2Ml2FtfTbjllQNuJMIYG
BdZkvZmenl48Enbq1KnFn4+OjmZDQ0Pp/8ePH88uX768amGsGLzqbmd53a2WUwa0nQhjaFBgTdeb
Bw8eNCz34sWLbNOmTdnz58/TwPrXr1+vWhiLwfavXr3qaF/K29lq38rLKQO+C4QxNCiw5urNvn37
0hWIoTyoPsQRsaNHj2YnT56sFa4ixMUYsTdv3nS0/Pnz57OxsbE0biwe8fzw4cMdbWdxPVX7owyA
MIYGBdZUvYlTet3d3Yu3m8iDTG5qaiq9t3xH/apwFVdCxo1f85u/Vi0fRkZGsi1btqT3xJWaz549
62g7i+up2h9lAIQxNCiwrupNBKIYyI+2E4QxNCjwnutNnC6Mo1WuStR2gjCGBgU+QL2JcV9fffVV
w8B9tJ0gjKFBAfUGZQCEMQ0KqDcoAyCMaVAA9QZlAIQxDQqoNygDIIxpUAD1BmUAhDENCqg3KAMg
jGlQAPUGZQCEMQ0KqDcoAyCMaVAA9QZlAIQxDQqoNygDIIxpUEC9QRkAYQwNCqg3KAMgjGlQQL1B
GQBhDA0KqDv43YMwplEB9Qe/cxDG0LDA+6tDHhvnAQhjwhig7QCEMQ0qoO3QdoAwhgYV0HYAwpgG
FdB2AMIYGlRA2wEIYxpUQNsBCGNoUAFtByCMaVABbQcgjKFBBbQdgDCmQQW0HYAwhgYV0HYAwpgG
FdB2AMIYGlRA2wEIYxpUQNsBCGMaVF8CoO0AhDENKqDtAIQxDSqAtgMQxjSogLYDEMY0qADaDkAY
06AC2g5AGPvIG1QPDw+P5TwAYQxw5AMAYQyEMQCEMUAYA0AYA2EMAGEMEMYAEMZAGANAGAOEMQCE
MRDGABDGAGEMAGEMhDEAhDFAGANAGIO1GcLMQQiAMAbCGADCGAhkACCMgTAGgDAGwhgACGMgjAEg
jMHGCGQAIIyBMAaAMMZqd/oeHh6dPQCEMRx9AXUGEMbQqYC6AyCMoTMBdQgQxtCRgDoEIIyhIwF1
CBDG0JGAOgQgjKEjAXUIEMbQkYA6BCCM8c47kocPH/oCeW/lZ62WN2EMEMZYlY5kfn4+++GHH7Lt
27dnn376abZ79+7s7NmzDct89tln7/TzV6tTe1frXel6VvP9azkQtPod1y0/5eXXyj4LY4Awxqp0
JMeOHct+/fXX7O3bt+n5mzdvsh9//DE93mUntJ46srUcxtbj91Z3f9bq/gtjgDDGqnQkcTSsLI6W
bdu2bfF95Xn6mq2r+LMIdt9//322ZcuWbOfOndnExETbI2NxJG7r1q3Z5s2bs+Hh4YbXbt68mbbx
k08+yXp6erI7d+50tI/x//Hx8ezzzz9P7411/P7774uvR+g8fvx4tmnTpmzv3r3Z1NRUy/WsZF+r
9q+T9y93H5uJkB2f1dXVlV29erXWvj5+/Dj7+uuv03cWnxXf22+//db2e2tWftqtp1V5izK5a9eu
7PXr1w3bF7/HKBedfNfCGCCMsSbD2L59+7KffvopdWqdvreq075w4UI2NjaWgsaLFy+yQ4cOtez0
f/nllxQoYtmFhYUURmJ7imExDxi3bt1Kp1E7DSrR4c/NzaXnsY5i8Dx9+nR2/fr19P/Jycn0PSwn
jFXta9X+Vb1/JftYFp81OjqaPuvZs2dZf39/rX3t7e3Nrl27lt4fj0uXLqVQV/W9lddbZz3F50ND
Q9n58+eX7FN+Wr3quxbGAGGMNRnG7t27lwJOdOJHjhzJLl++nN29e3dFYSw6+WK4i89o1Tn39fUt
niLNFQNXdNJ5aKqzj/H/PKQ0ez3CV/lzlxPGqva1av+q3r+SfSyLbSkeWYqjgXX2tZk4Ilc3jNVZ
T/H57OxsOjqWf5/x7xdffLH4HVR918IYIIyxJsNYbnp6Oh1liCMtEczOnTu37DBWPjoTHWSrzjmW
LZ+aKnbMcTQsfhYd7ZkzZ2qFsTrb+K7WU97Xqv2rev9Ktq2szu+l1c+inMRRxRhr2N3d3VEAa7be
TtdTfv7ll1+mo18hjq5Fee30uxbGAGGMNR3GiuLWAsUjCisNY+065046y+i441Ti4OBgdurUqTUd
xuruX9X7VzOM1V1fjDGLI4pXrlzJbt++nU51LieM1VlP+XmUgxhjFmKsWLy/TlkSxgBhjDUXxmKg
frPTdTEAutMw9uTJk4afHThwoOHU28zMTMvONjrUV69edbQPDx48eGdBZc+ePcs6TVl3X6v2r+r9
7zKMHTx4MPv77787+r0029cY+F/cl/LrnYaxOutp9jwuWIijuHGKsqhOWRLGAGGMNRPG4uq6GBT9
9OnT9DzGFF28eDE7efLk4jJx1VuMy8lDQ3FQfbwvThUV1x+nj/KB4jEofWBgoGVnG5+dD2CPRzw/
fPjw4utxBCWuqAxVA9TrBJU4RRanQMMff/zRcgD/Sve1av+q3v8uw9iNGzfS77vVZ1Xta4Sg/KrH
CHL79+/vKICVy0/VesrLl/cpBuXHlaflwflV37UwBghjrMkwFuJqtDhSFKd54uav0WEXj9ZEpxc3
4sxvxpmHolg+3hdhqbz+GHMW64rbDMRVbu1CxMjISDpaEuuPABCnrXJxijLGFOW3bsiD2UqDSoTO
b7/9Nq0z1h8D55stt9J9rdq/Tt7/rsJYiPXHRRE7duxIgajOvsaFHfnFHhFe48KKTsJYufxUrae8
fHmfXr58mV6LQFlW9V0LY4AwxpoMYygX+K4AYQwdCcqF7wpAGNORsLG8i3lH1SEAYQwdCahDgDCG
jgTUIQBhDB0JqEOAMIaOBNQhAGEMHQmoQ4AwxsbsSGJ+S1CHAIQxPlBHUr5lwmp+/krWHVMiHTly
ZNW2LeZKjO0rP3Jxl/iYjgl1CEAY05Gs6uet1Y6sr68vm52dXbX1T05OpmmXWonP7u/vV0DVIQBh
bKN2JDH/YD4fYU9PT3bnzp3s0aNHWW9v75JlFxYWsl27dmXz8/NpfePj42nS53zeyHyS6WZHgeLf
mIC82fK5mCMz5mfcvHlzNjw8XLmdzfat3XJlf/75Z/bVV18t+Z5a7ddyxCTgsd/txDbEtiCMAQhj
G7AjKYaNOGUXEziHgYGBJUEmQsqJEycW1xen2Obm5tLzfJLpVp8Xz+N0YKvlYwLrWP/bt29T6JuY
mEgTRldtZ/mz2i1X9sMPP2RXr15dsp1V+9XutGPZN998k8JWhMyYwDomYS+7cuVK2haEMQBhbAN2
JF1dXdn169eX/DxOrw0ODjb8LE6n3b9/f3F9eWBp9hnNwli75eN0YQSxomKQarWd5fW0W65s//79
2czMTK3trGvHjh3Zr7/+mv4f+3f58uXs9OnTDcvENsS2IIwBCGMbsCOJo0fxWoShM2fONLwWp+ry
8VT37t1rGNvUbH1VYazd8nH0qXy0KU4TdrKdxfW0W65s06ZNSwJg1XauVHxeBLTyz+LULMIYgDC2
QTuS6enpxSNhp06dWvx5jHcaGhpK/z9+/Hg6qrNaYawYvOpuZ3ndrZYra/aZnexXndOUnX5u8VQo
whiAMLZBO5IHDx40LPfixYt09Oj58+dpzNPr169XLYzFYPu4DUQnytvZat/Ky5W9jyNj27dvTxc8
5N68eZPt3bu3YZkYI+fImDAGIIxt0I5k37596QrEUB6sHuKI2NGjR7OTJ0/WCi0RdGLsVYSPTpY/
f/58NjY2lsJRPOL54cOHO9rO4nqq9qcoxmnF6dfVDGP/+Mc/0lWi+X7FRQk///xzwzIxDs+YMWEM
QBjboB1JnNLr7u5evI1DHmRyU1NT6b3lO+pXhZYIHXHj1/zmr52EnJGRkXTFYbwnrmh89uxZR9tZ
XE/V/hTFFYxxFedqhrE4mhhXoMY+bdu2LQXOsjj962pKYQxAGNORNBWBKAbyf4wiaBaPvn0ohw4d
SiESYQxAGNORNIjTanG0quqqxPUsrrr8kPNoxm0tYhsQxgCEMR3JEjHuK25YWhy4/7GJcWUxJu5D
ic82N6UwBiCM6UgAdQgQxtCRgDoEIIzpSAB1CBDG0JGAOgQgjOlIAHUIEMbQkYA6BAhj6EhAHQIQ
xtCRgDoECGPoSEAdAhDG0JGAOgQIY+hIQB0CEMbQkYA6BAhj6EhAHQIQxtCZgLoDCGPoVECdARDG
aNW5eHh4dPYAEMbAERgAhDFAGANAGANhDABhDBDGABDGQBgDQBgDhDEAhDEQxgAQxgBhDABhDIQx
AIQxQBgDQBgDYQwAYQwQxgAQxkAYA0AYA4QxAIQxEMYAEMYAYQwAYQyEMQCEMUAYA0AYA2EMAGEM
hDEAEMZAGANAGANhDAD0ECCMASCMgTAGgDAGCGMACGMgjAEgjAHCGADCGAhjAAhjgDAGgDAGwhgA
whggjAEgjIEwBoAwBnQQwsoPABDGQBgDQBiDjRfIAEAYA2EMAGEMhDEAEMZAGANAGIONEcgAQBgD
YQwAYYyNHko8Ns4DAGGMNRbE8DsHQBhDp4zfPYAwhs4YZQAAYQwdMcoAgDCGjhhlAEAYAx0xygCA
MIaOGGUAQBgDHTHKAIAwho744cOHvkBhDEAYg9XoiOfn57Mffvgh2759e/bpp59mu3fvzs6ePduw
zGefffZOP3+1QsG7Wu9K1/Oh3y+MAQhjrKMwduzYsezXX3/N3r59m56/efMm+/HHH9PjXXbi6ykI
CGMAwhi8t444joaVxdGybdu2Lb6vPM9hs3UVfxbB7vvvv8+2bNmS7dy5M5uYmGh7ZCyOxG3dujXb
vHlzNjw83PDazZs30zZ+8sknWU9PT3bnzp2O9jH+Pz4+nn3++efpvbGO33//ffH1CJ3Hjx/PNm3a
lO3duzebmppquZ6V7GvV/nXyfmEMQBjjIw5j+/bty3766acUTjp9b1VAuXDhQjY2NpaCxosXL7JD
hw61DDi//PJLCk2x7MLCQgojsT3FsJiHqFu3bqXTqJ2Gsa+//jqbm5tLz2MdxeB5+vTp7Pr16+n/
k5OT6XtYThir2teq/at6vzAGIIzxkYexe/fupYATQeXIkSPZ5cuXs7t3764ojPX39zeEu/iMVgGn
r69v8RRprhi4urq6FkNTnX2M/+dBrNnrEb7Kn7ucMFa1r1X7V/V+YQxAGOMjD2O56enpdJQmjiZF
MDt37tyyw1j51GeEkVYBJ5YtnwqN04q5OBoWP4tQc+bMmVphrM42vqv1lPe1av+q3i+MAQhjbJAw
VhS3sigevVlpGGsXcIrBpF1QjFOJg4OD2alTp9Z0GKu7f1XvF8YAhDE+8jAWA/Wbna6LweadhrEn
T540/OzAgQMNp95mZmZaBpwYlP/q1auO9uHBgwdtA0WdELVnz55lnaasu69V+1f1fmEMQBjjIw9j
cQuL8+fPZ0+fPk3PX79+nV28eDE7efLk4jJxxWGMv8pDQ3FQfbwvTm0W13/t2rVsdHR0cVD6wMBA
y4ATn50PYI9HPD98+PDi6zG2K66oDOVB+CsJYzGAP06Bhj/++KPlAP6V7mvV/lW9XxgDEMb4yMNY
iFsvxJGiOKUWN3+NgFY8WhNX/8WNX/Obv+ahKJaP90VYKq8/xpzFuuKWDnFFYbugNDIykm7tEOuP
sPPs2bPF1+IUZXd39+LtKfJgttIwFqHz22+/TeuM9cfA+WbLrXRfq/avk/cLYwDCGB95GEMZABDG
QEeMMgAgjKEjRhkAEMZAR4wyACCMoSNGGQAQxkBHjDIAIIyhI0YZABDGQEeMMgAgjKEjXitiDs3l
vPYullcGAIQxeCcd8XruoPMZAZrtS/m1laxLGAMQxkBHXHOf6u7vRggqwhiAMMYa7IjL8zmOj49n
n3/++eJckPkk2a3EPJYx72JXV1d29erVWvNDPn78OM3VGBORx2ft3bs3++233zrannit+Ciuu9lr
7T6r1brm5+ezXbt2pXksi2Lezp6ensXnMbdnzCu5efPmbHh4WBgDEMZg+WEsAsvc3Fx6nk+S3cqF
Cxey0dHR7O3bt2ny6/7+/lphrLe3N7t27Vp6fzwuXbqUQl2n21Nef7vP7uSzmq1raGgoO3/+/JL9
jgAWYmLvCIyxzoWFhWxiYiJNrC6MAQhjsKwwlgefTjrwvr6+hqNGU1NTtcJYM3EErNPtqRPGOvms
ZuuanZ1NR8cibIX494svvljcrvgO8tdyu3fvFsYAhDFYXhir04GXj5pFKKm7vunp6ez06dPZsWPH
su7u7lrvrxvG6nxW8fmXX36Zjn6FOLoWR+uK30H5NGcx5AljAMIYvLcwVnd9McZs37592ZUrV7Lb
t2+nU52rFcbqflbx+eTkZBpjFmKsWLw/t1aDlzAGIIyxAcLYwYMHs7///nvx+czMTNv1PXnypOFn
MfD/1atXLV9/l2Gs7meVn8dFBDFWLE5RFkU4K65XGAMQxuC9hbEbN26kqynj9OSLFy+ygYGBhuWL
Vz8+ffo0nd4rvh4BJ7+iMYLc/v37a21PXBkZY7fi6saq16o+q926QgzK37lz55LB+TG4f2xsbPHC
gHh++PBhYQxAGIPVD2MhriaMqxJ37NiRwk5x+fzqxziVt2fPnuzmzZsNr9+9ezcNdo9l4hTi9evX
a21PBKO4WWt+w9Z2r1V9Vrt1hZcvX6bXInSWjYyMpCNv8XoEzjgFKowBCGPwQTpiHb4yACCMgTCG
3w2AMMbG7IjrzgmJMAYgjKEjRhkAEMZAR4wyACCMoSNGGQAQxkBHjDIAIIyhI0YZABDGYH12xA8f
PvSlC2MAwhh8qI64fIuL1fx8IcP3BCCMoSOu+DxBQBgDEMbQETcR80Xm80f29PRkd+7cyR49epT1
9vYuWXZhYSHbtWtXNj8/n9Y3Pj6eJuCO9xYnBY/Xio/8ZxcvXmy6fO7s2bPZ1q1bs82bN2fDw8OV
29ls39otpwxoagCEMdZcR1wMRbdu3UqTaYeBgYElQSbC14kTJxbXF5Niz83Npef5pOCtPi+eHzly
pOXyMeF4rP/t27cp9E1MTKTJu6u2s/xZ7ZZTBjQ1AMIYa64j7urqyq5fv77k55OTk9ng4GDDz/r7
+7P79+8vri8PVs0+o1kYa7d8X19fCmJFxSDVajvL62m3nDKgqQEQxlhzHXEcPYrXIgydOXOm4bU4
pTg7O5v+f+/evRTG2q2vKoy1Wz6OaJVPb8apxk62s7iedsspA5oaAGGMNdkRT09PLx4JO3Xq1OLP
R0dHs6GhofT/48ePZ5cvX161MFYMXnW3s7zuVsspA5oaAGGMNd0RP3jwoGG5Fy9eZJs2bcqeP3+e
Bta/fv161cJYDLZ/9epVR/tS3s5W+1ZeThnwXQAIY6y5jnjfvn3pCsRQHlQf4ojY0aNHs5MnT9YK
VxHiYozYmzdvOlr+/Pnz2djYWBo3Fo94fvjw4Y62s7ieqv1RBgAQxlhTHXGc0uvu7l683UQeZHJT
U1PpveU76leFq7gSMm78mt/8tWr5MDIykm3ZsiW9J67UfPbsWUfbWVxP1f4oAwAIY6yrjjgCUQzk
RxgDEMbgPXfEcbowjla5KlEYAxDG4AN0xDHu66uvvmoYuI8wBiCMgY4YZQBAGENHjDIAIIyBjhhl
AEAYQ0eMMgAgjIGOGGUAQBhDR1xUvlkswhiAMIaOuOTWrVvZkSNHVuVz8zvwf+whpdN1xMwCf/zx
hzAGIIwhjP1/fX192ezs7IYNAO9zG+N77u/vF8YAhDGEsf/1559/phu7lpe9cuVKtn379mzbtm3Z
P//5zzRxd8wbGfM9xgTcRWfPns22bt2abd68ORseHm5YT/ERHj9+nI4OxQ1lY1179+7Nfvvtt7bb
XvWeWPf4+Hiatimfk7K4jZ28/9GjR1lvb++Sz15YWMh27dqVzc/Pp3ku4/3xGT09PdmdO3eafr/t
lgvxfcf3LowBCGMIY9kPP/yQXb16dcmy3333XQoi//rXv1IIO3HiRHoeISeCRu6XX35JQSimTorX
JyYm0iThrT43As+1a9fS8vG4dOlS1tXV1Xbbq94TnxFha25uLj0vb2Mn7w8DAwNLglPsW+x7KIa8
OLW7e/fupvvZbrkQQTe+d2EMQBhDGMv279+fzczMLFk2Dzb581evXjVdV5zijIBT1CqktBJHkOoq
vqe8vZ18bvn9YXJyMhscHGxYLk4p3r9/P/0/Atz169crv992y4X4vuN7F8YAhDGEsXTqrhymysu2
ex5HgcqnI5sFnaLp6ens9OnT2bFjx7Lu7u6OQkK79zR7f/lnnb4/TnXm4+fu3bvXML4rjnLFshFA
y5OnF9fRbrkQ33ec0hXGAIQxhLGmR6XqhLGqo1rl98Yp0X379qVTdbdv386ePXu2uEyzMWZV7+kk
jNV5/+joaDY0NJT+f/z48ezy5ctLQl1+BO3UqVNtw1+z5YohVhgDEMYQxlZ8ZCwGqBdPYVZ9bow/
Ky7/5MmTypBQ9Z6qMFbn/S9evEjfyfPnz9NFCa9fv266TQ8ePKjchmbLhRhb58gYgDCGMJbE2KU4
HbfcMBZXWY6NjS0Ojo/nhw8fbgh7MZ7rzZs36XmcBsyvZMzHTlWFhKr3VIWxuu+PI2JHjx7NTp48
2fDzOLoWV0qG8kUCxXW0Wy7EGDRjxgCEMYSxJK7qiysilxvGwsjISDr6FDd4jasa4zRgLq6sjJ/n
N3+9e/duGuAfASVCSwx0rwoJVe+pCmN13z81NZV+Vp49IE49xniz/PYZeeAqr6PdciFOfbqaEkAY
QxhbDB7FI1lkKUzG0bTVcujQoRTYhDEAYQxhLImr/swh+b/iVGsc6Wt2FeS7EKdJ4/tea2UAQBiD
D9gRx7imGCPF/45xizvktxq4v1LxPZubEkAYQxhDGQBAGENHjDIAIIyhI0YZANBG+grQEaMMAAhj
6IhRBgCEMdARowwACGNsoI741q1b2ZEjR97LdjS7437ctf9D3e5BGQBAGOODd8RxE9LZ2dlV34an
T5+mu/2XtyU+u7+/3y9JGAMQxth4HfGff/6ZbnJaXnZ8fDxNCZTPrxg3hl2pwcHB7K+//mq6LbEN
sS0IYwDCGBuqI44Jq69evbpk2Th1ODc3l55HEItAVny92aOd0dHR7NKlSy235cqVKx9k8mxlAABh
jA/aEe/fvz/Nl1heNg9i76Ij//e//91w9K3ZumIbYlsQxgCEMTZURxxzMcbk2FXLLrcjn5+fT+PB
nj9/3nZdsQ2bN2/2ixLGAIQxNlZHHGPCOlm2+LM6pym/++677MaNGx1tS/FUKMIYgDDGhuiIV/vI
WKvgVl7fwsKCI2PCGIAwxsbriGOc1r1791YtjHW6Lffv3zdmTBgDEMbYeB1xXMH4yy+/fPAwdvny
ZVdTCmMAwhgbryOemppKN2L90A4dOpRNT0/7RQljAMIYG68jjjvwP3z48INtW9zWIrYBYQxAGGND
dsRxU9ejR49+sG2LzzY3pTAGIIyhI0YZABDGQEeMMgAgjKEjRhkAEMZAR4wyACCMoSNGGQAQxkBH
jDIAIIyhI0YZABDGQEeMMgAgjKEjRhkAEMZAR4wyACCMoSNGGQAQxkBHjDIAIIyhI0YZABDGQGeM
3z2AMIZOGb9zAGEMlnbOHhvnAUC1/wOYHdNR0i6IPwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-05-02 00:44:48 +1000" MODIFIED_BY="Heather Maxwell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVIAAAG9CAIAAADIpWnvAAATnElEQVR42u3dv64cRRaA8SshIQIH
BDwBz+AIWUQQ8U4QOkCCkLdAPMIKdkMgIkMs9mrtgMCGbHexeq+5EhrmzvT0n6qac6p+n24AF3Rc
nqmvz6nu6jo3NwAGZAIwDLQHaA+A9gBoD4D2AGgPgPYAaA+A9gBoD1PTRlLaY7BJueSXoD06mZGb
/ytoD4D2yJn2TVHaYzjnlfe0B+1Be9AetEdPU5PztAdAewC0R29T0/5c2mOceXn4D6Yo7TGc9syn
PfYWzLQ3H2jf/xe85JeRzTdFaY/V5mz4r6A9ANojZ9qP/3X/eeveAzzao4zzynvQnvagPWgfbWqq
8GmPPV9zLucv/ga0R58VCu1pj0HNN0Vpj73r5Mjf+M15fI+0x+q06W020H5Q7ZkP2tMetEfv5vu6
QXuA9kCoqelOPu2xobbP+DDMnKQ9Br1ggfZgPmiPrevkjAt7s5T22JU2feOmBO1pD9qja/OzfN0q
fNqj2Ao56QM8s5T2sDAB7UF70B6drVB8ILQHQHsAtMdMwRz8LL3JLj3ao4hIAO1pn2zMZint0a35
DsymPWqJ5DplSviIAdoDkRK+KUp77K3zcznPfNpjCIWqjtmdQtrTfqAK5WSoARWgPe1HyZzzwxvK
Atpb28ucinwgRuY8vEiVnaI6AtIeoS8rxbv06v9L+yHkqbpLr1LmpD3tISfTnvbYtw5PoVC9ZwSH
Aa3t0em3W63IlzlpjzTZPn7mtDmX9lCh3NRbPljbo/+En/RVnOKRa+wIoD3iKjRy5nQ/gva0j5s5
K+3Soz3tB10wx1eo9qPBw49FkQ/0rz1oj4iZk/a0R9B1cq6FiX47tFeKQ7YH7WVO2oP2EWr7Brv0
aI/O1/aJvu5KOwvt9qc9gl5QGmwxoj3tMZCc+u3QfqBUXO99+0pyFn+Ap5cu7SFzjp0PfBAIkjk1
saA9Cls6JWmAp/EG7VEmf+bapZf0oWOKMdOe9hiuQqE97d2YGO5+BO1HnOguguYD7REoc6bWPsu5
PbRHRIWa7dIbczFF++GW98H9abCzUI8g2o/lfLrM6XOmPWJNR/vbT34g8a9cvirax56ajtmgPfrO
Qg2KfO/b0x5BM2feZwQpSgnaD1HeV1Ir9WO24n9QoqaatB+ovJ//ZTSF0q3t3cnHoKX4yHOJ9nBB
Gd18RT6w/YJSKm1q6UF7KJiHv6T6IBAqczZooV3wfkS6OoL2GCXbOzCb9oOuk0c+J99igfYjZs6q
1xE38ydHaKJv7TNmzmb3I+J/PrRn/lgLk5YfMu0RyJ/4bSSTVihZWoPRHhHzWzM5x7zTQXsELWvr
vYHnNiTtR6zzM0Y2S2mPKDk53QrcW4O0p/1A2ttrQHvaF3apuKuO4qY9Iq7AMx7F3fhEIB1v0W0d
kelw+Oa7GHS8Be07vGswX0fQHleY4hmPo5zyHFBFeyBBHdH4Ikh7BMpCY2qf6DR72qNMWiuV3xq0
o26j/WS7DgbJ9ommZo0KP+PygfZAMfPHPK6L9oNW+8UjT8NvgKM9gia3XAVz2ZxcuxFoIvNpP5z2
U4bbY5Ui124Eam0P2setIwZ/jZ/2w5mf4pgNj9loj3GnZgrnNcNC3FQP0J75oZcPHXzIsj2u/R2n
2kI7pdoR4MBsjJjfUt/JT3G2P+1B+2KRbc5F/3X+VOGgy1wvzLTZWUh7dJuTWy6YU1xQrO3Rs/YN
9re3+UDs0gPtN5b3878E7dFPwTwlPEKzTbOQ4FrRHgMtTNocBBZ/sUN7DLQwmTTVpP2wRf7IJ+c2
GDPtEXE6JrpU1fgrZGwWQnsoa4vVER7ggfnbE6blA+0RemGf4uWT2g/wRj6ui/YYLidn3BFAe4Qu
JYYtxWmPoHJOSV44y/v6UHznaa9gDr22r/ESQdU7HVluc9Ke9nHNHzwn0x5Bs33eB3gjm0/7sdb2
ib7ujC/MZDn2k/ZIUKHo5EN7RMzJU55euukWU7RHmRV42b7OuQ66pD3tx6qZpzon6iXaS9fyCmtt
jxDOl10we60ldwHog6B93/ntKp8z7RGu+Bz2e6/aLIT2QNycrD0G7VFsrg+rvbU9rGaDluJ6BNEe
QbVPdwZOrh5BtEdE87XrpD2CFsyT03Ws7RE8IWc8ZqNB3z639ED7KNqnux9BewyhfUaLzHbaD7e2
r9r7qXZw5tMeQ1QoDS6CtY/QpD1wZe3bdPKZYj+DoP1wFqU4fHqqvyOgQeSwh+rRfsTMmXHrS8YL
Cu1B+yg5uXF/e9ojROaMn5PNSdojek4e+cgK2mNo7ackR1bY9kv7EYt8x1rXKCucpYfQE71Swk/X
i5r2oH3oCiW+9pMjNMH8yHKme0OB9gg0HWufeJe9ZqE9ui0iGrzJb5bSHp1rP1V+zFb2avJnsaPI
R8Q6f9KOWh1Bezk5bE5Op32iCwrtaZ/Az6p76YoHVOSD9qOU4rbrIOjaPv7tsbylOO0xVh1Ryfx0
pbhdeqD9WKW4tT3iVvgpXmL1mI32yJHu6l2kah9rTXswf6ARBn80SHtEnOsdZE7bdTDE2j5+Tm5Z
itMe6LwUb3kRpD2Y3/n9CGt7hC7yS83LjKU4aD9iTh68E9aU8K1B2qPnNWf2T0ORDxN9rE/DLT2E
rplHvqDQnvYYUaF0ryHTHrTPUVJFXvvQfqwif0qyC91tSNqjjELpztIb/DEb7TGc9qoq2iOo9uk2
Arm80n64LGQFPmkWQntE0772bGzQt4/2UEdskafBKz0j9wii/XDLzrwPwEfLybTHWBO96ggzHpJf
9sJNe9oj+tWq+DdIe9qPctfg3N89/lHctMf2rzmX88XlTNeXlvbIkZM1qExx4aY9IirkVZwWF2sf
BKJlzgZn6Q17NaE9xqqZ+7jBaW2PQHNxwNtjDeqIo6Fa2+MKuaKP8iTRnnx38tF/Hd74IjjgBYX2
tI+okDpiJrgiH9c0v/GOt3QvEUUfJzGs7UNpP505t2dP/Ly79GiPQEV++wOz46fQGp9w8UsV7Wkf
sazNqP3RByLbo2fzW15QSh3g06Yzt0O1EGhh77l9vWtipU+47NdHewRac6bWvt5fv/iYaY80RUoN
i8Y8fYD2IyqUInO2XPLs/Fga1D5lL1W0t5qNIk8b7bOXPB7goducPGV+pTf+X4H2tE+T5cLeNUi3
/4/21vaxFGp/ERywPKE9Ckz0RAdUme20R0ntp3KtL5vdFa93TYk8YNoPVNvrJ1d1YdLsfUTa45pZ
aMrWVHNK+z6iB3gIlIXyVigNBm9tD9qHq1BGX/1xY6hFfnw5MzaobPMNTjbnotc6Im+F0uCc/Mmr
OOh1+ZAxIZeVk/YoXNkOK+fknHzaj5mTfRpVFyZV22w5XQc9a590U40HeOjf/NT7Z4ethmg/4sI+
fua0qaZq7UN7xC2YU19YI+8spD2CZnuHfNMegUrEDgrmdDWFN/CwccYkOgwj78Kk7C49R2iijPZT
+DfwpuS3IeN/zrSnfaAsdJUlT/zLq/YY2Dsjfd0ur7RH6FSsjpjcyQc5awx+0K/PPO7ez6rZI2Mp
nvciS3ssneKHd8irzs6yl6osu/0PBxn/0QPtB9K+6oyvMcsTHTtfacznIrilh9XTsbjtDTo6R972
S3sMoX29mwUNsn2zz5n2kO1pb22PJtOxwWO24mv7SmOu+mkchQr+vhPtUdh/n0OafOCDAGgPgPYA
aA+A9gBoj2bfH7DmwSTt02svsshrI9Oe9iLTHrQXmfagvci0B+1Fpj1oLzLtEUf7F/978fjJ40ff
P3r772/f/O3mwTcPHn778JN/fvLLf38JG/nVqxcvXz5+/vzR06dv//zzzZMnD549e/jixSevXhlz
mTHTvmftv/j3F+/8453buXL/53YOff6vzwNG/u23L54+fefWnPs/t0b9+qsxFxgz7bvV/jYhnJwu
hz+3/0+oyLfp8aQ8hz+3/48x7xwz7fvU/jZLXJwxdz/nMkb7yLc586I/dz/n8qcx0z6Ek+fOqD93
UtL9//niLsuTq8FzleHJWvH5f55fPfLt2viwTv7665v33795663XPx99dPPdd8eV8++/G/OWMdO+
XR4+eV79Re2XnMp28vePnzxeOGNmCsXGkV++fHwoybvvvp6WX3118+WXr//hvfcWlc3GTPtYtfd8
X8QlXRNPfk0nf/no+0cnJscdpybNw28fXj3y8+ePTtbGP/74Ovabbx7//tkzY94yZtpf505bA+3v
nvQsnzQPvnlw9ch3z72Ofn744eaDD17H/uyz4//05Ikxbxkz7dtV+EdnqtbW/vR0OeTevLl65JNp
88MPX4f8+OPTN8mMecOYaX/lIn9+PS/b3/688cbrwD/9dMKfsNk++Jhp3632Pa3tz/1EXttHHjPt
r3knf8m/jnwn/+7njuUbYIyZ9iHMv9hb/uK/jvncfl6hmM/tU4yZ9j0/MrBLz5hpP5z2kz35xkz7
AbW/yxin7wn/URl++vTTgJH/eJvt7fNvsxlzgTHTvmftp/Nva59cDQaJfO7d9ZNrY2OmPe1FFpn2
tBdZZNrTXmSRaU97kWkP2otMe9BeZNojlvaAjreyvcgiy/a0F1lk2tNeZNrTnvYi0x60F5n2oL3I
tEca7TN2j9Wlt/aYad+z9hm7x+rS22DMtO9W+4ynvjgRqM2Yad+n9hnPeHP+X5sxd6j9xW2JG6It
/0yX/8/nDtVd+Mv5PzFjJ1ZdetuMuUPtlxwsX2rZvKI11eyZ2Qt7Y636EzN2YtWlt82Ye9P+YiOa
iy1ojjrVzfzrdKrL3bSma/0G7ZdffTJ2YtWlt82Y+9f+ZL49Z9dM88mFPSqXl+JrtV9b5GfsxKpL
b5sx96z9uSaz2zLthv+6UPtzl5v5/+HiV5uxE6suvW3GPFyRv0f7++8w79H+3Lrg/i+3re0zdmLV
pVe2D6f9zB+3uUFlkeDddGLVpdfavvCd/OXr+Zhr+5138lN0YtWl1538XeYvaTK7pJaeuVmw/E7+
fJHf5rl9ik6suvS2GXOf2o+GXXrXjWyXHgJpP9mT3yqyPfkIpP2Us3usLr0Nxkz7nrWfcnaP1aW3
9php37n2IotMe9qLLDLtaS8y7UF7kWkP2otMe9BeZNrjutoDOt7K9iKLLNvTXmSRaU97kWlPe9qL
THvQXmTag/Yi0x5ptNeX9pB6fWl1vEUU7fWlPaReX1odbxFFe2fg/CVnVjsDx+k6iKK9E++OsnGl
E++cpRdFg2gdb3cekrvh5Fzn2x6tuiv1pdXxNlzqC9LxdueR+NvOyXea/SH1+tLqeBux3I3Q8XZm
PGt/ufzqo3fNIfX60up4G/rm1tU73u7Ufm2Rr1PdIfX60up4G67CD9Xxds8YNnS81Zf2kHp9aXW8
TVDk79F+Z8fb/WNYpb1sfzEnF+lLq+Nt59qvrdjnx1Zbe2v7JSvw/X1pdbwNfSf/uh1vi9/edyc/
SF9aHW8DmR+q4+25Q448t28WuV5fWh1vEev5hV16h9ilR/shtJ/syT/Kn/bk034E7Sd9ae9l5kp9
aXW8RSDtJ31p763GK/Wl1fEWgbQXWWTa015kkWlPe5FpD9qLTHvQXmTag/Yi0x7X1R7Q8Va2F1lk
2Z72IotMe9qLTHva015k2oP2ItMetBeZ9kijfcYeryIfouMt1k2ajD1eRT5Ex1us+2oznicj8iFO
18G6rzbj6XEiH+V5Z+mtM2HhX+ri2dhrP5nl59suPCT34l7Lbnq8iny0nndy7kbxlveNnD/Kfqf2
8wd47zwSv5seryIf4pz8XdZtaHExLW53e78xxrkB7Nd+1Tn5GXu8inyIrjhl7m+t0n7a1JFyeROL
tdov/Hv9ScYeryIfogfe9gp/Q7urtZ2wpn098BZePtZqn7HHq8h/+aWOt+2L/Nran1sXnFssFMn2
wXu8iizb96/98ht1899ONz1eRba2L38n/2JdvV/7Smv7Ddpn7PEqsjv5e80/+ZeaaXS75AH+/C23
c3fy54v8hR1v12qfsceryId4bo8tDy/seMse2S49rNZ+sr89f2R78rH6q51y9ngV+Sjn63iLdZNm
ytnjVeSjdb6Ot1g3aUQWmfa0F1lk2tNeZNqD9iLTHrQXmfagvci0x3W1B3S8le1FFlm2p73IItOe
9iLTnva0F5n2oL3ItAftRaY90mifqxOrMbcZM+171j5dJ1ZjbjNm2nerfcZTX4y5zZhp36f2Gc94
M+Y2Y16q/fJNf2Wn8nxrylXjOXdGbZu/1J6Tc+e/wm46sRpzmzGv077Z7cd522c03pYVG1Q6+zve
Lj+B/46MnViNuc2Yi2m/6sj3hU3dl2T7VUPa37hivkfdfJZurH3GTqzG3GbMZbRf1TRm7S+3aX/x
D9qg/dq2OZsvLuf+eZX2GTuxGnObMZdZ2y93bHmzt4DaL68yVv0pSzrebtA+YydWY24z5o3Zfokn
q+r5+1eT/drPxIyg/bS44+3a8c9koeCdWI05YrZfqPraJL/wv27O9lXL7z3aL/985p81dNOJ1Zij
r+1XFflt1vbb1h1ry++rrO03XFAydmI1Znfy9z6333wnf77S3nAnP8Jz+xSdWI053HN7hMWON2PW
8Zb2BxnD/nZjpv1o2k8JO7Eac5sx075n7adsnViNuc2Yad+59iKLTHvaiywy7WkvMu1Be5FpD9qL
THvQXmTa47raAzreAliWLXwQAO0B0B4A7QHQHgDtAdAeQCDtAQzF/wG7YzI6+nXtpQAAAABJRU5E
rkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-05-02 00:45:28 +1000" MODIFIED_BY="Heather Maxwell">
<APPENDIX ID="APP-01" MODIFIED="2016-05-02 00:45:08 +1000" MODIFIED_BY="Heather Maxwell" NO="1">
<TITLE MODIFIED="2016-05-02 00:45:08 +1000" MODIFIED_BY="Heather Maxwell">MEDLINE</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-05 14:02:16 +1100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="23">
<TR>
<TD>
<P>
<B># &#9650;</B>
</P>
</TD>
<TD>
<P>
<B>Searches</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>randomised controlled trial.pt.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>randomized controlled trial.pt.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>controlled clinical trial.pt.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>randomized.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>randomised.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>placebo.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>randomly.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>trial.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>groups.ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>exp Breast Neoplasms/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>(milk or tender* or lactat* or feeding or fed).ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>exp Milk, Human/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>exp Breast Feeding/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>exp Lactation/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>12 or 13 or 14 or 15</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>11 not 16</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>exp Follow-Up Studies/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>(follow-up or follow-up care or follow-up stud* or centralised follow-up or decentralised follow-up or postoperative surveillance or routine).ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>18 and 19</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>10 and 17 and 20</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>limit 21 to humans</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-05-02 00:45:28 +1000" MODIFIED_BY="Heather Maxwell" NO="2">
<TITLE MODIFIED="2016-05-02 00:45:28 +1000" MODIFIED_BY="Heather Maxwell">Embase</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-05 14:05:43 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>#38</B>
</P>
<P>
<B>#37</B> AND [humans]/lim AND [embase]/lim</P>
<P>
<B>#37</B>
</P>
<P>
<B>#9</B> AND <B>#33</B> AND <B>#36</B>
</P>
<P>
<B>#36</B>
</P>
<P>
<B>#34</B> AND <B>#35</B>
</P>
<P>
<B>#35</B>
</P>
<P>
<B>'follow up'</B>/exp OR <B>'follow up'</B>
</P>
<P>
<B>#34</B>
</P>
<P>
<B>'follow up'</B>:ab,ti OR <B>'follow-up care'</B>:ab,ti OR <B>'follow-up study'</B>:ab,ti OR <B>'centralised follow-up'</B>:ab,ti OR <B>'decentralised follow-up'</B>:ab,ti OR <B>'postoperative surveillance'</B>:ab,ti OR <B>routine</B>:ab,ti</P>
<P>
<B>#33</B>
</P>
<P>
<B>#27</B> NOT <B>#32</B>
</P>
<P>
<B>#32</B>
</P>
<P>
<B>#28</B> OR <B>#29</B> OR <B>#30</B> OR <B>#31</B>
</P>
<P>
<B>#31</B>
</P>
<P>
<B>'lactation'</B>/exp OR <B>'lactation'</B>
</P>
<P>
<B>#30</B>
</P>
<P>
<B>'breast feeding'</B>/exp OR <B>'breast feeding'</B>
</P>
<P>
<B>#29</B>
</P>
<P>
<B>'breast milk'</B>/exp OR <B>'breast milk'</B>
</P>
<P>
<B>#28</B>
</P>
<P>
<B>milk</B>:ab,ti OR <B>tender*</B>:ab,ti OR <B>lactat*</B>:ab,ti OR <B>feeding</B>:ab,ti OR <B>fed</B>:ab,ti</P>
<P>
<B>#27</B>
</P>
<P>
<B>#15</B> AND <B>#26</B>
</P>
<P>
<B>#26</B>
</P>
<P>
<B>#16</B> OR <B>#17</B> OR <B>#18</B> OR <B>#19</B> OR <B>#20</B> OR <B>#21</B> OR <B>#22</B> OR <B>#23</B> OR <B>#24</B> OR <B>#25</B>
</P>
<P>
<B>#25</B>
</P>
<P>
<B>'locally advanced breast tumor'</B>
</P>
<P>
<B>#24</B>
</P>
<P>
<B>'locally advanced breast tumour'</B>
</P>
<P>
<B>#23</B>
</P>
<P>
<B>'locally advanced breast carcinoma'</B>
</P>
<P>
<B>#22</B>
</P>
<P>
<B>'locally advanced breast neoplasm'</B>
</P>
<P>
<B>#21</B>
</P>
<P>
<B>'locally advanced breast cancer'</B>
</P>
<P>
<B>#20</B>
</P>
<P>
<B>'early breast tumor'</B>
</P>
<P>
<B>#19</B>
</P>
<P>
<B>'early breast tumour'</B>
</P>
<P>
<B>#18</B>
</P>
<P>
<B>'early breast carcinoma'</B>
</P>
<P>
<B>#17</B>
</P>
<P>
<B>'early breast neoplasm'</B>
</P>
<P>
<B>#16</B>
</P>
<P>
<B>'early breast cancer'</B>
</P>
<P>
<B>#15</B>
</P>
<P>
<B>#10</B> OR <B>#11</B> OR <B>#12</B> OR <B>#13</B> OR <B>#14</B>
</P>
<P>
<B>'breast tumour'</B>
</P>
<P>
<B>#13</B>
</P>
<P>
<B>'breast carcinoma'</B>/exp</P>
<P>
<B>#12</B>
</P>
<P>
<B>'breast neoplasm'</B>
</P>
<P>
<B>#11</B>
</P>
<P>
<B>'breast cancer'</B>/exp</P>
<P>
<B>#10</B>
</P>
<P>
<B>'breast tumor'</B>/exp</P>
<P>
<B>#9</B>
</P>
<P>
<B>#1</B> OR <B>#2</B> OR <B>#3</B> OR <B>#4</B> OR <B>#5</B> OR <B>#6</B> OR <B>#7</B> OR <B>#8</B>
</P>
<P>
<B>#8</B>
</P>
<P>
<B>groups</B>:ab</P>
<P>
<B>#7</B>
</P>
<P>
<B>trial</B>:ab</P>
<P>
<B>#6</B>
</P>
<P>
<B>randomly</B>:ab</P>
<P>
<B>#5</B>
</P>
<P>
<B>placebo</B>:ab</P>
<P>
<B>#4</B>
</P>
<P>
<B>randomi*ed</B>:ab</P>
<P>
<B>#3</B>
</P>
<P>
<B>controlled</B> AND <B>clinical</B> AND <B>trial</B>
</P>
<P>
<B>#2</B>
</P>
<P>
<B>randomized</B> AND <B>controlled</B> AND <B>trial</B>
</P>
<P>
<B>#1</B>
</P>
<P>
<B>randomised</B> AND <B>controlled</B> AND <B>trial</B>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-04-27 11:34:00 +1000" MODIFIED_BY="Melina L Willson" NO="3">
<TITLE MODIFIED="2013-04-05 14:01:48 +1100" MODIFIED_BY="[Empty name]">CENTRAL</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-05 14:06:48 +1100" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor: [Breast Neoplasms] explode all trees</P>
<P>#2 early breast cancer* or early breast neoplas* or early breast tumour* or early breast tumor*:ti,ab,kw (Word variations have been searched)</P>
<P>#3 locally advanced breast cancer* or locally advanced breast neoplas* or locally advanced breast tumour* or locally advanced breast tumor*:ti,ab,kw (Word variations have been searched) </P>
<P>#4 #2 or #3</P>
<P>#5 #1 and #4</P>
<P>#6 MeSH descriptor: [Follow-Up Studies] explode all trees</P>
<P>#7 follow-up or follow-up care or follow-up stud* or centralised follow-up or decentralised follow-up or postoperative surveillance or routine:ti,ab,kw (Word variations have been searched)</P>
<P>#8 #6 and #7</P>
<P>#9 #5 and #8</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-04-27 11:34:00 +1000" MODIFIED_BY="Melina L Willson" NO="4">
<TITLE MODIFIED="2013-03-25 12:39:32 +1100" MODIFIED_BY="Melina L Willson">WHO ICTRP</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-05 14:06:08 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Basic Searches:</B>
</P>
<P>1. Follow-up strategies for women treated for early breast cancer</P>
<P>2. Breast cancer AND follow-up</P>
<P>3. Breast cancer AND centralised follow-up</P>
<P>4. Breast cancer AND decentralised follow-up</P>
<P>5. Breast cancer AND postoperative surveillance</P>
<P>6. Breast cancer AND routine</P>
<P>
<B>Advanced Searches:</B>
</P>
<P>1. <U>Title:</U> Follow-up strategies for women treated for early breast cancer</P>
<P>
<U>Recruitment: </U>All</P>
<P>2. <U>Condition:</U> breast cancer</P>
<P>
<U>Intervention:</U> follow-up OR follow-up care OR follow-up studies</P>
<P>
<U>Recruitment: </U>All</P>
<P>3. <U>Condition:</U> breast cancer</P>
<P>
<U>Intervention:</U> centralised follow-up OR decentralised follow-up OR postoperative surveillance OR routine</P>
<P>
<U>Recruitment: </U>All</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-04-27 11:33:58 +1000" MODIFIED_BY="Melina L Willson" NO="5">
<TITLE MODIFIED="2013-03-25 12:39:42 +1100" MODIFIED_BY="Melina L Willson">ClinicalTrials.gov</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-05 14:06:21 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>cancer</B>
</P>
<P>
<B>Basic Searches:</B>
</P>
<P>1. Follow-up strategies for women treated for early breast cancer</P>
<P>2. Breast cancer AND follow-up</P>
<P>3. Breast cancer AND centralised follow-up</P>
<P>4. Breast cancer AND decentralised follow-up</P>
<P>5. Breast cancer AND postoperative surveillance</P>
<P>6. Breast cancer AND routine</P>
<P>
<B>Advanced Searches:</B>
</P>
<P>1. <U>Title:</U> Follow-up strategies for women treated for early breast cancer</P>
<P>
<U>Recruitment:</U> All studies</P>
<P>
<U>Study Results:</U> All studies</P>
<P>
<U>Study Type:</U> All studies</P>
<P>
<U>Gender:</U> All studies</P>
<P>2. <U>Condition:</U> breast cancer</P>
<P>
<U>Intervention:</U> follow-up OR follow-up care OR follow-up studies</P>
<P>
<U>Recruitment:</U> All studies</P>
<P>
<U>Study Results:</U> All studies</P>
<P>
<U>Study Type:</U> All studies</P>
<P>
<U>Gender:</U> All studies</P>
<P>3. <U>Condition:</U> breast cancer</P>
<P>
<U>Intervention:</U> centralised follow-up OR decentralised follow-up OR postoperative surveillance OR routine</P>
<P>
<U>Recruitment:</U> All studies</P>
<P>
<U>Study Results:</U> All studies</P>
<P>
<U>Study Type:</U> All studies</P>
<P>
<U>Gender:</U> All studies</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_z1402170045571371561960244344501_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1402170045571371561960244344501">
<ADDRESS>
<DEPARTMENT>Department of Medical Oncology</DEPARTMENT>
<ORGANISATION>U.O. Oncologia Medica 2, IRCCS AOU San Martino &#8211; IST</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Genova</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included in quantitative synthesis (meta-analysis) (n= 4)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included in qualitative synthesis (n= 5)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Previous versions of this Cochrane Review:&lt;br&gt;-4 included studies&lt;/p&gt;" WIDTH="156"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 study for qualitative and quantitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Full-text articles assessed for eligibility (n = 15)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records screened (n = 2117)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records after duplicates removed (n = 45)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Review update: records identified through MEDLINE, EMBASE, CENTRAL, Specialised Register (n = 1493)&lt;/p&gt;" WIDTH="128"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Review update: additional records identified through other sources (ClinicalTrials.gov; WHO ICTRP) (n = 669)&lt;/p&gt;" WIDTH="151"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Records excluded on basis of title and abstract (n = 2102)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Full-text articles excluded, with reasons:&lt;br&gt;14 articles out of 15 were excluded after a full text evaluation because their PICOs did not match the review's eligibility criteria&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>